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Strong evidence supports the concept that mammalian target of rapamycin 
(mTOR) regulates essential cell processes and that dysregulation of mTOR signaling 
leads to the pathogenesis of several debilitating human conditions. Aberrant activation 
of mTORC1 signaling contributes to the malignant behavior of cancer cells by 
controlling proliferation, invasion, and metastasis. We identified a novel effector of the 
mTORC1 pathway and provisionally named the human ortholog, mammalian enhancer 
of akt1-7 (EAK-7) or (mEAK-7), due to its original identification in Caenorhabditis 
elegans. In nematodes, EAK-7 negatively affects longevity through regulation of FoxO 
transcription factors. While there is no functional characterization of mEAK-7 (also 
known as expressed sequence tag KIAA109 or TDLC1), there are examples in the 
literature that demonstrate upregulated mEAK-7 gene expression and copy number 
amplification in diverse cancer types. We discovered that some cancer cell lines derived 
from head and neck squamous cell carcinomas, non-small lung carcinomas, and breast 
carcinomas express mEAK-7 protein, while somatic cells we screened do not. 
Moreover, more than half of the cancer cell lines screened were mEAK-7 positive 
(mEAK-7+) cancers, but why these cells express mEAK-7 is unknown. When this is 
coupled with the fact that mTORC1 signaling is amplified in distinct human cancers, it 
suggests that mEAK-7 may, in part, be responsible for the pathogenesis of certain 
human cancers. With increasing interest in developing mTOR signaling inhibitors to 
xvi  
treat cancer patients, this thesis explores the mechanisms by which mEAK-7 regulates 
mTOR signaling and functions to support the progression of human cancer. As an 
aspiring dentist-scientist, I am primarily interested in tumorigenesis in relation to mEAK-
7 function under abnormal metabolism and DNA damage (X-ray irradiation). To this 
end, our central hypothesis is that mEAK-7 functions as a positive regulator of mTORC1 
signaling in human cancers.  
Canonical mTORC1 signaling utilizes nutrient rich conditions (insulin, amino 
acids, high energy levels) for activation of this evolutionarily conserved pathway. While 
stress conditions have been widely reported to inhibit mTOR signaling in non-cancerous 
cells, it has been shown that mTOR signaling can be sustained after DNA or oxidative 
stressors. We discovered that mTOR signaling increased after X-ray irradiation, and we 
provided evidence that mEAK-7 is required for sustained mTOR signaling after under 
DNA damage. Treatment options for cancer patients include 1) surgery and/or 2) 
chemo- or radio-therapy. However, patients who experience chemo- or radio- resistant 
cancers typically have poor clinical prognoses and there is a lack of well-defined 
biological markers indicative of this malignant process. Thus, the overarching goal of 
this thesis will be to elucidate the role of mEAK-7 in cancer, and to determine the extent 
to which mEAK-7 plays a role in tumorigenesis, and whether or not mEAK-7 is a cancer 
biomarker.  
In chapter 1, we outline key facets of knowledge gathered during the last 20 
years of mTOR signaling research, beginning with rapamycin’s illustrious discovery on 
Easter Island and leading to the identification of the molecular kinase, mTOR.  We also 
explore ideas of development and disease in craniofacial biology and cancer. In chapter 
xvii  
2, we rigorously outline the molecular mechanisms regarding mEAK-7 function. In 
chapter 3, we determined the role of mEAK-7 in human disease, specifically 
radioresistant cancers and metastatic cancers. Chapter 4, the final chapter, outlines the 
future goals of the mEAK-7 project and its potential to impact human medicine.  
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 Chapter 1 – Introduction 
 
Discovery of Rapamycin and mTOR signaling 
Rapamycin was identified during a Canadian expeditionary search for novel 
antibiotic compounds on Rapa Nui (Easter Island), and it was subsequently 
demonstrated to block yeast growth and to have strong immunosuppressive effects in 
mammals (1). Rapamycin is a macrolide that is a secondary metabolite of the 
bacterium, Streptomyces hygroscopicus (2). Several groups discovered that rapamycin 
forms a complex with FKBP12 resulting in a gain of function that inhibits signal 
transduction pathways required for cell growth and proliferation (3). It would take more 
than another decade before TOR/mTOR was identified as the target of the rapamycin-
FKBP12 inhibitory complex in yeast (4) and eukaryotes (5, 6). Subsequently, 
laboratories across the world have demonstrated the essential role of mTOR signaling 
in eukaryotic development and disease in response to nutrient sensing and metabolic 
regulation (1). 
TOR/mTOR is a member of the phosphatidylinositol-3 kinase-related kinase 
(PIKK) family (7). PIKKs are atypical Serine/Threonine protein kinases that also include 
ataxia-telangiectasia mutated (ATM), ataxia- and Rad3-related (ATR), DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs), transformation/transcription domain-
associated protein (TRRAP), and suppressor of morphogenesis in genitalia (SMG-1) 
(8). While these kinases share similar functional domains, they are responsible for 
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diverse actions, such as, regulating cell metabolism, DNA repair pathways, and genome 
surveillance. mTOR signaling is defined by its two best studied complexes: mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2) in mammals (1), and TOR1 
and TOR2 in yeast (9). mTORC1 is comprised of regulatory-associated protein of 
mTOR (raptor), mammalian lethal with SEC13 protein 8 (mLST8) or GβL, Proline-rich 
AKT1 substrate 1 (PRAS40), and DEPTOR (1). mTORC2 is comprised of mLST8, 
rapamycin-insensitive companion of mTOR (rictor), mammalian stress-activated protein 
kinase interacting protein 1 (mSIN1), Protor, DEPTOR, and Tti1 & Tel2 (1). Both 
complexes act at the lysosome, an essential cellular compartment for mTOR signaling, 
but govern different cellular processes (10, 11). The best known targets of mTORC1 are 
S6K1 and 4E-BP1, while the best known target of mTORC2 is Akt. Recently, we 
identified mammalian EAK-7 or mTOR associated, eak-7 homolog (mEAK-7) as a 
positive regulator of mTOR signaling through an S6K2/4E-BP1 axis, but not the 
canonical S6K1/4E-BP1 axis (12). This finding is striking, as we demonstrate that 
mEAK-7 possibly contributes to a novel, third mTOR complex (mTORC3) (Figure 1.1). 
Although many molecular and biochemical analyses have demonstrated that 
these mTOR and associated proteins are capable for forming complexes, little was 
known with regard to the actual binding and mechanics of mTOR complex formation. 
Advances in cryo-EM technology, electron detectors, super-computers, and advanced 
algorithms have paved the way for previously un-identifiable protein structures at the 
atomic level (13). Previously, the structure of mTOR was elusive to the scientific 
community due to nuanced issues related to crystallizing such a large multimeric 
complex. In a seminal paper, the structure of mTORC1 was resolved revealing that 
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mTOR formed a homodimer and that the FKBP-rapamycin complex limited access to 
architectural elements of mTORC1 at the recessed active site (14). Further work 
demonstrated rictor was insensitive to rapamycin treatment because crucial mTORC2 
protein partners blocked the structural site of rapamycin-FKBP12 binding (15, 16). While 
short-term rapamycin treatment does not disrupt rictor-mTOR binding (17), long-term 
rapamycin treatment is sufficient to block rictor-mTOR binding in vivo, though some 
animals still exhibit activated (Ser473) p-Akt levels (18). Much work has been completed 
to provide a viable structural model for mTORC1 and mTORC2. Since our evidence 
suggests the existence of a novel mTOR complex, it will be essential to understand how 
novel mTOR complexes form at the structural level. This will be especially important for 
proving that mEAK-7 can interact with mTOR and form a legitimate multimeric complex, 
as a central component of mTORC3.  
 
Upstream of mTOR signaling 
mTOR signaling is an essential metabolic pathway in eukaryotes. Many nutrient 
sensing networks function upstream of mTOR to coordinate this complex process. 
Upstream of mTORC1, the tuberous sclerosis complex (TSC) integrates diverse 
biologic inputs ranging from low energy levels to growth factor and hormonal activation 
(19). For instance, activation of the insulin receptor results in a cascade of events that 
activate Akt signaling which, in turn, phosphorylates TSC (comprised of TSC1, TSC2, 
and TBC1D7) proteins to allow mTOR activation (20). The TSC functions as a sensor 
for specific nutrient conditions and possesses Rheb-GAP activity (21). In response to 
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nutrients, the TSC is recruited away from the lysosome, allowing Rheb-GTPase to bind 
and activate mTOR signaling (22).  
In turn, multiple signaling modalities work in concert to ensure the activation of 
mTOR signaling. The lysosome is an essential hub for mTOR signaling and amino acids 
recruit mTOR to the lysosome through amino acid signaling via the Rag guanosine 
triphosphatase (GTPase) Rag A or B, which dimerizes with either Rag C or D (23). In 
the amino acid starved state, mTOR is diffuse within the cell, but amino acid stimulation 
allows the Ragulator-Rag complex to recruit mTOR directly to the lysosome (24). Thus, 
the culmination of these nutrient signals allows for Rheb GTPase to activate mTOR at 
the lysosome (11).  
Despite intensive research in this area, it is unclear how Rheb interacts with 
mTOR at the lysosome to activate mTOR signaling. Rheb is identified in the early and 
late forming endosomes, but not necessarily at the lysosome. Curiously, TOR signaling 
is essential for the formation of the endosome and the inhibition of endosomal 
degradation in Drosophila melanogaster (25). The endosome is a crucial compartment 
for cell growth and activation of mTOR signaling via amino acids and insulin (26). TOR 
also localizes to the endosome in yeast (27, 28) and human cells (23). However, with 
mTOR recruitment to the lysosome and Rheb existing at the late endosome, it is 
unclear how Rheb interacts with mTOR and how that activation occurs. It was recently 
determined that a substantial percentage of Rheb interacts with mTOR at the Golgi-
lysosome contact sites to activate mTORC1 signaling (29). This crucial evidence places 
mTOR at the lysosome, the cellular compartment for full activation by upstream 
signaling partners, though it is still unknown how Rheb activates mTOR. Ultimately, 
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there is much that is unknown, with regard to the specific players in the full activation of 
mTOR signaling. The molecular landscape of different types of tissues and cells allows 
for diverse combinations of mTOR complexes to form and upstream regulators to form 
and affect mTOR.  
 
Downstream of mTOR signaling 
As research groups gained interest on the role of mTOR signaling, it became 
apparent that mTOR was essential for many downstream events in metabolism, 
development, and disease. mTOR signaling exerts exquisite control over the production 
of organismal building blocks, namely, proteins, lipids, and nucleotides. In addition, 
mTOR signaling is essential for regulation of autophagy and whether or not cells 
undergo anabolism or catabolism. mTOR is a promiscuous protein that is capable of 
binding to diverse protein targets which result in a cascading effect to signal the cell to 
begin a specific and regimented program. There is still much that is unknown about the 
downstream targets of mTOR signaling. The comprehensive analysis of these pathways 
will unravel how dysregulation of mTOR signaling results in disease processes.  
The central dogma of molecular biology is the flow and preservation of genetic 
information within a biological system. As Francis Crick once stated, “DNA makes RNA 
and RNA makes protein”. With few exceptions, this fundamental truth has stood the test 
of time and accentuates the simplicity of nature at its core. As technology advances, 
there are likely many more discoveries to solve. mTOR signaling is best known for 
regulation of protein synthesis through downstream effectors S6 (cap-independent 
protein translation) and 4E-BP1 (cap-dependent protein translation). By regulating two 
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different processes for protein synthesis, mTOR and its affiliated complexes are crucial 
players in protein production. As a direct effect, mTORC1 targets S6K1/S6K2 and 4E-
BP1 to regulate cell size through its regulation of protein synthesis (30). Many of these 
findings were based upon the observation that rapamycin plays a crucial role in 
regulating cell growth and proliferation. Although it would be many years before mTOR 
would be identified as the protein kinase responsible for the effects of rapamycin, it is 
now clear that mTOR is an essential protein. Rapamycin is a potent inhibitor of cell 
growth processes (3, 31) and mTOR was shown to be the kinase targeted by rapamycin 
and responsible for S6K activity (32). mTORC1 directly phosphorylates S6K1/S6K2, at 
the hydrophobic motif at Thr389/Thr388 to allow for full activation and downstream 
targeting of S6 (33, 34). This coordinated effort to regulate downstream targets allows 
for specific control of cap independent protein translation. Additionally, it has only 
recently been appreciated that the regulation of S6K1 and S6K2 could have different 
target proteins. Much of the body of knowledge of mTOR signaling has been identified 
with S6K1, and much more work needs to be carried out to understand how S6K2 
regulates protein translation. The most immediate downstream target of the S6Ks is 
40S ribosomal protein S6, an essential regulator of a subclass of mRNA translation 
which contain a short oligopyrimidine sequence immediately after the transcriptional 
start site (35). Our work has demonstrated that there are certain cell specific scenarios 
where S6K2 plays a more important role than S6K1 in regulating S6 suggesting that 
there are specific adaptor proteins that are upregulated or downregulated, depending on 
the context.  
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mTOR signaling further regulates protein synthesis by modulating cap-dependent 
protein translation by phosphorylating the eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1). mTOR binds 4E-BP1 via raptor (mTORC1) at Thr37/46 
(36), which primes the 4E-BP1 phosphorylation site at Ser65 and Thr70, and allows 4E-
BP1 detachment from eukaryotic translation initiation factor 4E (eIF4E) (37). This 
elaborate sequence of events must occur for the full inhibition of 4E-BP1 by mTORC1. 
From an evolutionary perspective, intricate regulation of protein synthesis is required so 
that the organism can develop properly and respond quickly to beneficial or harmful 
stimuli. While mTOR inhibition modestly downregulates mRNA translation, it has been 
demonstrated that it significantly regulates mRNAs containing pyrimidine-rich 5′ TOP, 
mainly genes involved in protein synthesis (38). Thus, S6K and 4E-BP1 regulation by 
mTOR signaling is essential for proper production of proteins. 
As mTOR signaling is the master regulator of cellular metabolism, it also plays an 
essential role in blocking autophagy and protein catabolism. mTORC1 targets ULK1/2, 
which forms a complex with ATG13, FIP2000, and ATG101 to suppress the formation of 
the autophagosome (39). Suppression of mTOR signaling prevents the phosphorylation 
of ULK1/2, thereby allowing AMPK to activate the ULK and allow the autophagosome to 
proceed forward. Thus, when the cell is ready to divide, it must decrease the propensity 
of the cell to undergo energy saving regimens, where autophagy is activated. When the 
cell senses the reduction of nutrients, thereby inhibiting mTOR signaling, the cell will be 
able to recycle non-essential proteins to conserve energy and wait for its next energy 
bolus. Though we have a preliminary idea of how mTOR regulates autophagy under 
normal metabolic programs, understanding how this process is controlled in diseased 
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states will be important since autophagy is dysregulated in cancer. Primarily, cancer 
cells are capable of utilizing autophagy to survive microenvironmental stresses and to 
increase cell growth and aggressiveness (40). 
 
A third mTOR complex 
It has been theorized that additional mTOR complexes may complement 
mTORC1 and mTORC2 in mammals. Through ATP-competitive studies, Torin 1, a 
potent mTOR inhibitor, was shown to inhibit mTOR to a greater extent than rapamycin 
treatment alone. These results were similar to raptor knock-down, but there was no 
difference when rictor-/- cells were treated with Torin1 (41). These findings suggest that 
completely targeting mTOR kinase can strongly reduce downstream signaling, but 
blocking mTORC1 or mTORC2 specifically is not sufficient to yield potent effects. 
Additionally, though mTOR regulates TOP mRNA translational machinery through 
mTORC1 (raptor), cells lacking raptor or rictor can regulate TOP mRNA through an 
alternative mechanism, suggesting that there are other complexes that exist to regulate 
downstream mTOR targets (42). More recently, astrocytes provide one such example of 
how mTOR may function in a cell-type or tissue-type specific manner. GIT1 is an 
interacting partner of mTOR that does not associate with either raptor or rictor, though 
the molecular mechanism is unknown, is crucial for cell apoptosis (43). Thus, there may 
be cell-type specific mTOR complexes that remain to be discovered. In B cell cancers, 
ETV7 was identified as an interacting molecule of mTOR and was also resistant to 
rapamycin treatment, suggesting that other complex molecules are capable of 
sustaining mTORC1 activity, even in the presence of the potent mTORC1 inhibitor, 
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rapamycin (44). We provide evidence that mEAK-7 forms an alternative mTOR complex 
to regulate S6K2/4E-BP1 signaling in human cells, where mEAK-7 does not interact 
with canonical mTORC1 nor mTORC2 partners (12). Thus, though sparse, these 
findings demonstrate that cell-type specificity may dictate the molecular landscape that 
supports mTOR regulation and activation (Figure 1.2). 
 
mEAK-7 and the TLDc domain family of proteins 
EAK-7 (enhancer-of-akt1-7) integrates nematode insulin receptor signaling 
(IRS)to regulate DAF-16/FoxO (45), and through this network, functions in parallel with 
Akt to affect nematode dauer formation and lifespan. In humans, IRS also controls 
diverse signaling cascades related to cell growth, proliferation, and survival (46, 47). 
Downstream of IRS, PI3K signaling supports mTORC1 signaling through regulation of 
Akt signaling to regulate the tuberous sclerosis complex (Figure 1.1). Since nematode 
EAK-7 works in parallel to insulin receptor/Akt signaling, we hypothesized that mEAK-7 
is capable of regulating either Akt signaling or mTORC1 signaling, as both pathways are 
downstream of insulin receptor signaling. We demonstrate that mEAK-7 activates 
mTOR signaling through a novel S6K2/4E-BP1 axis (12). Though these findings were 
pivotal for describing the possibility of novel mTOR complexes in humans, the exact 
mechanism by which mEAK-7 regulates mTOR remains unclear.  
To describe mEAK-7 molecular function, we looked for clues that could 
potentially point us in the direction of how mEAK-7 works. To engage in that first step, 
we sought the molecular compartment where mEAK-7 resides. We discovered that 
mEAK-7 is an evolutionarily conserved, lysosomal protein that activates mTOR 
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signaling in human cells. mEAK-7 was determined to be a lysosomal protein due to its 
co-localization at the lysosome to a significant degree, in comparison to other cellular 
compartments. Another way to determine protein function is to understand which 
domains are conserved within the mEAK-7 protein. mEAK-7 contains an N-
myristoylation motif, a conserved TLDc domain, and a newly identified mTOR binding 
domain (MTB) (12). Unfortunately, little is known with regard to the role of these 
domains. The N-myristoylation motif is required for lipid-membrane tethering of proteins 
within the cell. We demonstrated that a glycine to alanine mutation was sufficient to 
untether mEAK-7 from the lysosome and the plasma membrane, suggesting that it 
played a crucial role in those cellular compartments (12). The TLDc domain is 
conserved in eukaryotes, but it is unclear what the role of this protein is. There are 
some instances which suggest that TLDc domain containing proteins confer 
neuroprotection against oxidative stress, but this appears to be dependent on the 
organism and cell type (48). Though evolutionarily conserved, the role of EAK-7 in 
nematodes versus mammalian cells are opposite of one another under stress 
conditions. eak-7 null nematodes treated with H2O2 demonstrate enhanced survivability 
(45), meaning that the loss of EAK-7 enables the organism to improve their ability to 
respond to noxious stimuli. Overexpression of mEAK-7 in mammalian neurons results in 
protection against oxidative stress and silencing mEAK-7 in combination with arsenite 
(oxidative stressor) results in enhanced apoptosis (49), demonstrating that mEAK-7 
evolved to combat toxic stimuli. Thus, understanding the context by which EAK-7 
functions across different eukaryotes will be essential to understand the mechanistic 
differences in species. 
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Finally, we demonstrate that mEAK-7 directly binds to mTOR, and that binding is 
dependent on a newly discovered domain on mEAK-7, known as the MTB domain. The 
finding that mEAK-7 directly binds to mTOR suggests that it either acts as an adapter 
protein or an essential protein resulting in post-translational modification of mTOR. 
mEAK-7 recruits mTOR to the lysosome and is crucial for the function of mTOR 
signaling. mEAK-7 is an essential interacting protein of mTOR and mLST8, but not of 
other mTORC1 or mTORC2 components, suggesting that a third mTOR complex exists. 
From here onwards, we will use the term mTORC3 to describe this mEAK-7/mTOR 
complex because of its specificity in regulating S6K2/4E-BP1. In our second chapter, 
we demonstrated the molecular mechanism governing mTORC3 regulation in response 
to serum-, amino acid-, and insulin-mediated mTOR signaling. mEAK-7 is necessary for 
S6K2-mTOR interaction, S6K2 activity, and 4E-BP1-eIF4E interaction, it supports cell 
proliferation and cell migration. In the third chapter, we demonstrate a novel binding 
partner of mTORC3, namely, DNA-PK—which has a well-known role in non-
homologous end joining after DNA damage. Thus, the culmination of these interacting 
molecules suggest that a third mTOR complex exists. 
Prior to the discovery that mEAK-7 was a crucial regulator of mTOR signaling 
through S6K2/4E-BP1 axis, many reports demonstrated MEAK7 overexpression in 
human cancer patients. MEAK7 is 50-fold higher in metastatic hepatocellular carcinoma 
cell lines compared to normal hepatocellular cell lines and about 3-fold higher in liver 
cancer patients compared to healthy individuals (50). Microarray analysis of 76 primary 
tumors revealed that lymph node-positive breast cancers have a 1.66-fold increase in 
MEAK7 expression over healthy controls (51). MEAK7 expression is upregulated in 
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patients with metastatic renal clear-cell carcinoma and they are identified as a potential 
cancer immunotherapy targets (52). MEAK7 is also the third most overexpressed target 
in non-tumor infiltrating lymphocytes in human ovarian cancers, suggesting that it could 
be a target for immunotherapy as well (53). These independent reports on the 
overexpression of MEAK7 demonstrate the many different patient scenarios where 
mEAK-7 could be playing a role in tumorigenesis, since mEAK-7 activates mTOR 
signaling and mTOR signaling is implicated in cancer (54). 
The mTOR signaling community may be on the verge of discovering new mTOR 
complexes in human cells. mEAK-7 supports the interaction of S6K2 and mTOR, but 
does not bind to raptor or rictor endogenously or exogenously (12). These findings were 
quite surprising because of the evolutionary differences that arose between mammalian 
EAK-7 and nematode EAK-7. Nematode EAK-7 functions in parallel to Akt signaling to 
control DAF-16 nuclear localization (human FoxO) during development and lifespan 
(45). mEAK-7 is essential for alternative mTOR signaling to regulate S6K2 and 4E-BP1, 
but nematodes only possess one S6 kinase, RSKS-1, making it unclear how or if, EAK-
7 regulates TOR signaling in nematodes. Thus, understanding mEAK-7/mTORC3 in 
humans will further our understanding of this growth complex and human development 
and disease. 
In concert with these findings, DNA-PK has been identified to interact with 
mEAK-7 to regulate mTOR and S6K2 signaling (Figure 3.5). DNA-PK is an essential 
conductor of non-homologous end joining DNA repair (8), but also has unexplored roles 
in regulation of cell metabolism (55). In human cancer, mEAK-7 protein is detectable at 
higher levels, compared to normal lung tissue and lymph nodes, suggesting a role in the 
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disease progression of human cancer patients with mEAK-7 (Figure 3.2). Thus, 
understanding how DNA damage responses and metabolism intersect will be essential 
to understanding the role of disease processes where cancer cells can hijack DNA 
damage responses to improve survival after DNA damage, resulting in chemoresistant 
or radioresistant cancers.  
For the future, it will be important to elucidate the structure of mTORC3, to shed 
insight on how mEAK-7 interacts with other components to bind mTOR to affect 
downstream signaling. Understanding the structure of mTORC3 will allow for the 
development of mEAK-7-specific inhibitors for the treatment of human cancer and other 
aberrant mTOR activation and related diseases.  
 
mTOR signaling through S6K1 versus S6K2 
Studying mTOR in mammalian systems is challenging because gene knockout 
strategies pertaining to mTORC1 or mTORC2 components often result in embryonic 
lethality (56). This makes sense since the developing eukaryote requires a precise 
metabolic sensor that is capable of signaling to other cells when to grow and when to 
divide. Because S6K1 was the isoform first identified as the primary mTOR target in 
eukaryotes, it is the best-studied molecular target. S6K1 is an essential regulator of 
eukaryotic cell size and a common mTOR signaling marker (30). In transgenic S6K1 
knockout mice with high-fat diets (HFD), loss of S6K1 leads to weight loss and 
increases insulin sensitivity (57) while mice with standard diets (SD) are glucose-
intolerant, hypoinsulinaemic, and have reduced β cell size (58). This evidence suggests 
that loss of mTORC1 signaling via S6K1 alone may be detrimental to organismal 
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metabolism. Intriguingly, loss of both S6K1 and S6K2 reverses the deleterious effects of 
S6K1 knockout in mice, restores glucose tolerance under a SD, and enhances glucose 
tolerance with a HFD, suggesting that S6K2 plays a crucial role in the metabolism of 
mammals (59). Because mEAK-7 is the key regulator of an mTORC3/S6K2/4E-BP1 
axis, mEAK-7 knockout mice may result in improved metabolic function and reduction of 
a type II diabetic state.  
Much less is known about S6K2 in development, metabolism, and disease, but 
there has been a steadily growing interest in understanding the specific molecular role 
of S6K2 (12). For instance, S6K1 is a potent regulator of cell size, and postnatal 
delivery of S6K1 null mice are smaller than wild-type mice and S6K2 null mice are 
slightly larger, which suggests that S6K2 null mice may regulate another metabolic 
phenomenon unrelated to cell size. However, it is clear that S6K1 and S6K2 have some 
redundant targets because double knockout mice results in perinatal lethality (60). 
Intriguingly, S6K1 knockout mice express higher levels of S6K2 in the liver, muscles, 
thymus, and brain, and S6K2 remains responsive to rapamycin-mediated inhibition of 
S6 phosphorylation (61). Thus, S6K2 is not simply redundant to S6K1 and tissue-
specific functions of S6K2 are increasingly being identified. Linking mEAK-7 to S6K2 
activity demonstrates that there is specificity in the ability of mTOR to choose its 
complex, pending the cell context.   
 Adult S6K2 null mice tend to have higher basal levels of insulin in plasma, 2.5x 
more β cell mass with a SD, and improved glucose tolerance, as well as enhanced 
insulin sensitivity with a HFD (62). Additionally, single S6K2 knockout enhances ketone 
body production and increases peroxisome proliferator-activated receptor alpha activity 
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in the liver, and S6K1 knockout mice are capable of maintaining (Ser240/244) p-S6 levels, 
while S6K2 knockout mice are not (63). Hence, elucidating the role of mEAK-
7/mTORC3 signaling in mammals will further our understanding of diseases activated 
by mTOR signaling through aberrant S6K2 activity.  
Therefore, ongoing research challenges the canon that S6K1 phosphorylation is 
a bona fide readout of mTORC1 activity. Because mTOR is capable of targeting S6K2, 
it has proven to be a crucial kinase that regulates diverse metabolic targets (64).  
Further study of mTORC3 will yield novel insights to human metabolism and disease, 
and will perhaps allow this pathway to be a specific therapeutic target. In these next 
sections, we will focus on development and disease states of the craniofacial region due 
to our interest as dentist-scientists. 
 
mTOR signaling in head and neck squamous cell carcinoma 
Aberrant or hyperactive mTORC1 and mTORC2 signaling has been implicated in 
human cancer progression and pathogenesis (1). Recently, a prostate cancer 
transgenic mouse model of mTOR-mediated tumor formation demonstrated that the 4E-
BP1 axis controlled cancer initiation and genes associated with metastasis (38). In 
2018, there was an estimated 51,540 new cases of head and neck squamous cell 
carcinoma, comprising 3% of all new cancers (65). Of those new cases of head and 
neck cancers, 10,030 patient deaths were recorded, comprising 1.6% of all cancer-
related deaths in the United States (65). The Gutkind group demonstrated that 5 day 
treatment with rapamycin in HNSCC xenografts resulted in a regression of tumor size 
(66). Due to extensive interest in HNSCC, much work has been accomplished to 
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demonstrate that mTOR signaling is a viable molecular target against HNSCC (66) 
(Figure 1.3). However, the standard therapy for aggressive HNSCC patients includes 
tumor resection and several courses of chemotherapy and/or radiotherapy. 
Unfortunately, this treatment regimen results in populations of patients who still exhibit 
residual cancerous lesions. In a mouse model of minimal residual disease of HNSCC, 
rapamycin treatment could prevented HNSCC recurrence, and the cancers that did 
regrow were significantly smaller than their control counterparts. These data suggest 
that rapamycin could serve as adjuvant therapy given concurrently with standard 
surgery and chemo/radiotherapy (67). mTOR inhibition by rapamycin treatment is 
capable of preventing oral-tumor progression in a chemical carcinogenesis model (68). 
Though many clinicians and scientists had high hopes for rapalogs to help treat cancers 
with high mTOR activity, blocking mTOR signaling in a non-specific manner results in 
toxicities and ultimately requires a higher precision target within the mTOR signaling 
pathway (1). Decades of clinical trials using previous and current mTOR inhibitors 
demonstrate that a cancer specific target of mTOR signaling is required to reduce 
widespread toxicities in humans. 
 
mTOR signaling in epithelial stem cell biology and mucositis 
While the mTOR signaling community touts the benefits of mTOR inhibition for 
the treatment of hyperactivated mTOR cancers, there are still many challenges and side 
effects that occur with inhibition of this important metabolic sensor. mTOR inhibitors in 
the clinic have resulted in many different types of toxicities in humans. Up to 31% of 
patients taking mTORC1 inhibitors (temsirolimus) for the treatment of advanced renal 
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cell carcinoma reported mucositis (69, 70). Mucositis is defined as the painful 
inflammation and ulceration of the mucous membranes and is one of the most widely 
reported toxicities with mTOR signaling inhibitors. These findings in humans are 
intriguing because they are counter to the results described in mouse models treated 
with radiation. Mice treated with rapamycin after radiation damage improves the 
survivability of the salivary gland, suppresses epithelial stem cell senescence, and 
mucositis (71). Thus, while mice may benefit from rapamycin treatment with limited 
toxicities, humans with prolonged rapamycin treatment or mTOR inhibitors result in 
unintended mucositis. Interestingly, patients who undergo mTOR inhibitor treatment, 
such as rapalogs, experience a high incidence of painful mTOR inhibitor associated 
stomatitis (72, 73). Thus, evolutionary differences between mice and humans may 
confound the pronounced benefit of rapamycin treatment to reduce radiation-mediated 
toxicities. These findings suggest that a more specific mTOR inhibitor, perhaps targeting 
mTORC3 would be beneficial to patients who take rapalogs for the treatment of cancer. 
Creating mEAK-7 specific inhibitors would potentially reduce the toxicities that 
accompany rapalog treatment, prove more effective in targeting cancers versus normal 
tissue, and improve the quality-of-life for patients. 
 
mTOR signaling in cranial neural crest cells and craniofacial development 
Since mTOR is expressed in nearly every tissue during development and 
adulthood, it is likely that mTOR plays an important role in craniofacial development, an 
area of oral biology of immense interest to dentist-scientists. mTORC1 activity is high in 
prehypertrophic and early hypertrophic chondrocytes, indicative of a role in mammalian 
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endochondral bone formation. Further, p-S6, which serves as a readout of mTORC1 
signaling, is highly expressed in prehypertrophic and early hypertrophic chondrocytes. 
While the deletion of raptor resulted in impaired chondrogenesis, ablation of raptor had 
minor effects on later chondrocyte proliferation and survival. These studies suggests 
that mTORC1 has an important role in early mammalian endochondral bone formation. 
Compared to mTORC1, mTORC2 plays a secondary role in endochondral skeletal 
development. Ablation of rictor does not significantly affect bone formation. 
During development, the craniofacial skull is formed by migrating cranial neural 
crest cells (NCCs) and the reorganization of facial prominences and pharyngeal arches, 
thus making it highly susceptible to a large number of birth defects, known as 
neurocristopathies (74). Understanding the molecular pathways that regulate NCCs 
during development is essential to understand the development of craniofacial bones 
since NCCs form the bulk of the frontal, nasal, and zygomatic bone (75). 
Hyperactivation of mTORC1 via TSC1 deletion results in sclerotic craniofacial bone 
lesions where neural crest-derived (NCD) cells resulted in overpopulation of the NCD 
bone and thicker frontal bone due to an increase in NCD osteoblasts and 
osteoprogenitor cells (76). Additionally, it was demonstrated that Akt signaling, a 
prominent mTORC2 target, was required for NCC migration in vivo in Xenopus laevis 
(77). Still, very few studies on mTOR signaling have been conducted on craniofacial 




mTOR signaling in the tongue, taste buds, and salivary glands 
In line with notion that mTOR inhibitors cause nonspecific toxicities, there are 
instances where mTOR inhibitors could benefit patients treated for different diseases. 
Mammals that receive irradiation treatment demonstrate a protective benefit from 
rapamycin treatment (71). The tongue is an important organ responsible for essential 
human behaviors, such as speech and eating. mTOR signaling is essential for a 
properly stratified epithelium and mTOR knockout or rictor knockout mice resulted in a 
hypoplastic epithelium of the tongue (78). mTOR inhibition has also been shown to 
reduce the malignancy of chemically-induced tongue cancer formation (79). While 
limited, many studies are now focusing on the role of mTOR signaling during tongue 
development or squamous cell carcinoma in the tongue. mTORC3 may also play a vital 
role in the development of the tongue, taste buds, and the malignancies associated with 
the tongue. 
mTOR signaling plays a crucial role in salivary gland development. For humans, 
saliva production occurs so food can be digested in the gastrointestinal tracts. Thus, 
salivary glands play an important role in the digestion of food. Furthermore, rapamycin 
treatment prior to X-ray irradiation resulted in a protective effect in salivary glands (80). 
Intriguingly, radiation-induced salivary gland dysfunction was rescued after the 
administration of IGF-1, a potent activator of Akt signaling, suggesting that upregulation 
of mTORC2 signaling is beneficial for cell survival in salivary glands (81). IGF-1 
treatment of salivary gland spheroids resulted in an enhanced ability for self-renewal 
after radiation treatment (81).  
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mTOR signaling in the dental pulp development and disease 
mTORC1 and mTORC2 were identified as crucial regulators of self-renewal, 
pluripotency, and fate determination in human embryonic stem cells (82). Our initial 
interest to study mEAK-7 was to study its potential role in stem cell self-renewal. In lieu 
with our interests and due to growing interest, many groups are starting to study the role 
of mTOR in teeth, which house multipotent cells capable of giving rise to this important 
mammalian organ for food consumption. Most recently, groups have demonstrated, 
using a mouse-incisor model, that an FAK-YAP-mTOR axis regulates stem cell self-
renewal and proliferation (83). For instance, it was demonstrated that mTOR signaling 
plays a crucial role in odontoblast differentiation and function (84). IGF-1 stimulation in 
dental pulp stem cells promote proliferation and osteogenic differentiation due to 
activated mTOR signaling and the subsequent upregulation of RUNX2, OSX, and OCN. 
During mTOR signaling inhibition, this inductive effect of IGF-1 is reversed suggesting 
IGF-1 plays an important role during osteogenic differentiation and may have clinical 
implications for osteoporosis (85).   
 
mTOR signaling in osteoarthritis of the temporomandibular joint  
Osteoarthritis (OA) is a chronic degenerative disease defined by gradual 
cartilage loss, synovial inflammation, and subchondral bone restructuring which results 
in debilitating severe pain and dysfunction. OA of the temporomandibular joint (TMJ) or 
TMJOA is an important subset classification of temporomandibular disorders, but the 
exact pathogenesis and process of TMJOA remain to be understood (86). In an injury-
induced human and chondrocyte-specific mTOR KO mouse model of OA, mTOR gene 
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and protein were demonstrated to be upregulated in OA and suppression of mTOR via 
rapamycin or genetic knockout rescued the disease state of OA (87). mTOR signaling is 
up-regulated in the mechanically induced OA articular knee joints and rapamycin 
treatment was demonstrated to reduce the severity of OA and maintain cartilage 
cellularity (88). However, in a rat model of biomechanical stimulated chondrocyte 
autophagy, mTOR signaling is suppressed during the early response in the 
degenerative cartilage (89). This provides a striking contrast to evidence found in 
skeletal articular joints versus temporomandibular joints, possibly due to their 
embryological origins and differing mechanisms of action. Thus, understanding the 
molecular mechanisms governing the pathogenesis and pathobiology of TMJOA will 
spearhead novel therapeutics that specifically modulate mTOR signaling in diseased 
tissues, but not normal tissues. It is also possible that an mTORC3 axis governs the 
pathobiology of TMJOA. 
 
Summary 
The mammalian/mechanistic target of rapamycin (mTOR) is an essential nutrient 
sensor that regulates diverse biologic processes, such as lifespan, metabolism, protein 
synthesis, and autophagy. Since the discovery of mTOR more than two decades ago, 
scientific groups from around the world have demonstrated the importance of mTOR 
signaling in diverse cell and tissue types and that dysregulation of mTOR results in 
diseases or conditions as diverse as cancer, diabetes, neurological diseases, and 
craniofacial developmental anomalies. mTOR signaling is an essential metabolic 
regulator of pluripotency, self-renewal, and differentiation. Many diseases, such as 
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osteoarthritis of the temporomandibular joint, oral mucositis, head and neck squamous 
cell carcinoma, and irradiation-induced salivary gland dysfunction are, in part, caused by 
hyperactivated mTOR signaling. Suppression via rapamycin analogs, or rapalogs, or 
mTOR kinase specific ATP-catalytic site inhibitors has been demonstrated to reduce 
these detrimental effects. The characterization of the mTOR complexes, mTORC1 and 
mTORC2, have added tremendous insight to the nuances of mTOR signaling, but the 
notion of novel mTOR complexes is enticing. However, furthering our understanding of 
mEAK-7/mTORC3 from a developmental biology perspective and a disease processes 
standpoint will inform the approach for drug discovery and treatment of mTOR related 
diseases.  
The focus of my thesis is to investigate the role of a novel protein, 
mammalian EAK-7, in the context of metabolism and disease. We have tested the 
hypothesis that mEAK-7 is essential for mTOR signaling through an alternative mTOR 
complex. Additionally, we demonstrate a role for mEAK-7 in human cancer cells and 
describe a working molecular model for mEAK-7 within mTORC3 signaling. All of the work 
done in this thesis has been done in the context of non-cancerous and cancer cell lines, 
as well as analysis of human cancer patient samples. The following chapter will elucidate 









Figure 1.1. Summary of mTOR signaling and mTOR complexes. Insulin, amino acids, and 
nutrient signals are capable of activating mTOR signaling. Insulin binds to the insulin receptor, a 
receptor tyrosine kinase that ultimately activates PI3K to activate Akt signaling. PI3K activates 
PDK1 by inducing PIP3 from PIP2, where PDK1 phosphorylates T308. Activated Akt will 
phosphorylate and inhibit the Tuberous Sclerosis complex (TSC1/2), which inhibits Rheb 
GTPase in the absence of nutrients. Inhibition of TSC through nutrient stimulation allows for 
Rheb GTPase to activate mTORC1, and allows mTOR to phosphorylate and activate S6K1 and 
phosphorylate and inhibit 4E-BP1. mTORC2 also regulates Akt signaling, by phosphorylating 
S473, in response to nutrients. mTORC3 is formed by mEAK-7 and is necessary for S6K2 




Figure 1.2. mTOR complex 1, 2, and 3. mTORC1 is comprised of regulatory-associated protein 
of mTOR (raptor), mammalian lethal with SEC13 protein 8 (mLST8) or GβL, Proline-rich AKT1 
substrate 1 (PRAS40), and DEPTOR and is essential for cell growth and cell proliferation. 
mTORC2 is comprised of mLST8, rapamycin-insensitive companion of mTOR (rictor), 
mammalian stress-activated protein kinase interacting protein 1 (mSIN1), Protor, DEPTOR, and 
Tti1 & Tel2 to regulate cytoskeletal rearrangement. mTORC3 is comprised of mTOR, mEAK-7, 
mLST8, DNA-PK, and unknown proteins to regulate cell proliferation and migration in mEAK-7 
positive cells like malignant cancer cells. All complexes act at the lysosome, an essential 








Figure 1.3. mTOR signaling is significantly enhanced in later stages of mTOR signaling. In 
2018, 51,540 new cases of head and neck squamous cell carcinoma were discovered, 
comprising 3% of all new cancers. An estimated 10,030 new patient deaths are a direct result of 
patients with head and neck cancer, comprising of 1.6% of all cancer-related deaths in the US. 
As tissues of the oral cavity go from dysplasia to overgrowth to carcinoma stages, it’s been 
demonstrated that mTOR signaling is upregulated. mTOR signaling is a viable molecular target 
against HNSCC. However, the standard therapy for cancer patients is to have tumor resection 
and undergo several courses of chemotherapy and/or radiotherapy. It was demonstrated that 
even with this treatment regimen, there are still populations of patients who exhibit residual 
cancer disease, even with pathology-graded clean tumor margins and that rapamycin was 
suitable for treatment of these patient populations. mTOR inhibition by rapamycin treatment is 
capable of preventing oral-tumor progression by chemical carcinogenesis model. Though many 
clinicians and scientists had high hopes for rapalogs to help treat cancers with high mTOR 
activity, blocking mTOR signaling in a non-specific manner results in toxicities and ultimately 
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 Chapter 2 – Mammalian EAK-7 activates alternative mTOR signaling to regulate 
cell proliferation and migration 
 
Summary 
Nematode EAK-7 regulates dauer formation and controls lifespan, but the 
function of the human ortholog, mammalian EAK-7 (mEAK-7), is unknown. We report 
that mEAK-7 activates an alternative mTOR signaling pathway in human cells, in which 
mEAK-7 interacts with mTOR at the lysosome to facilitate S6K2 activation and 4E-BP1 
repression. Despite interacting with mTOR and mLST8, mEAK-7 does not interact with 
other mTORC1 or mTORC2 components, yet is essential for mTOR signaling at the 
lysosome. This phenomenon is distinguished by S6 and 4E-BP1 activity in response to 
nutrient stimulation. Conventional S6K1 phosphorylation is uncoupled from S6 activity in 
response to mEAK-7 knockdown. mEAK-7 recruits mTOR to the lysosome, a crucial 
compartment for mTOR activation. Loss of mEAK-7 results in a marked decrease in 
lysosomal localization of mTOR, while overexpression of mEAK-7 results in enhanced 
lysosomal localization of mTOR. Deletion of the C-terminus of mEAK-7 significantly 
decreases mTOR interaction. mEAK-7 knockdown decreases cell proliferation and 
migration, while overexpression of mEAK-7 enhances these cellular effects. 
Constitutively activated S6K rescues mTOR signaling in mEAK-7 knocked-down cells. 
Thus, mEAK-7 activates an alternative mTOR signaling pathway through S6K2 and 4E-




In the first chapter, we focus on a broad overview of mTOR signaling in 
development and disease. In the second chapter, we focus on the role of a novel 
protein that we discovered in the lab. Evolution demonstrates that fundamental signaling 
pathways in eukaryotes are conserved through orthologous and paralogous genes. In 
C. elegans, EAK-7 (enhancer-of-akt1-7) integrates insulin receptor signaling (IRS) to 
regulate DAF-16/FoxO, and through this network, functions in parallel with Akt to affect 
nematode dauer formation and lifespan (43). However, how EAK-7 imparts these 
effects in mammals is unknown. In humans, IRS also controls diverse signaling 
cascades related to cell growth, proliferation, and survival (45). One of these crucial 
metabolic signaling cascades is the mechanistic or mammalian target of rapamycin 
(mTOR) signaling pathway. On an expeditionary search for novel antibiotic compounds 
in the South Pacific, rapamycin was discovered on Rapa Nui and was found to block 
yeast growth and to have strong immunosuppressive effects in mammals (1). 
Rapamycin was subsequently shown to form a complex with FKBP12, which resulted in 
a gain of function that inhibited signal transduction pathways required for cell growth 
and proliferation (3). mTOR was identified as the target of the rapamycin-FKBP12 
inhibitory complex responsible for repressing protein production and cell metabolism in 
eukaryotes (5). Decades later, laboratories across the world have demonstrated the 
essential role of mTOR signaling in eukaryotic development and disease in response to 
nutrient sensing (1). 
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mTOR is a member of the phosphatidylinositol-3 kinase-related kinases family. 
mTOR signaling diverges into two known complexes: mTOR complex 1 (mTORC1) and 
mTOR complex 2 (mTORC2) (1). Both complexes act at the lysosome, an essential 
cellular compartment for mTOR signaling, but govern different cellular processes. 
Upstream of mTORC1, the tuberous sclerosis complex (TSC) integrates biologic inputs 
such as low energy levels and growth factor activation (19). However, for mTORC1 to 
be fully activated, it must be recruited to the lysosome through amino acid signaling via 
the Rag GTPases Rag A or B, which dimerizes with either Rag C or D (23). In the 
amino acid starved state, mTOR is diffuse within the cell, but amino acid stimulation is 
sufficient to allow the Ragulator-Rag complex to recruit mTOR to the lysosome (24). 
Thus, the culmination of these nutrient signals allows for Rheb GTPase to activate 
mTOR at the lysosome (11).  
We focused on mTORC1 signaling because it integrates metabolic processes to 
affect macromolecular biosynthesis, growth, and protein synthesis (1). Dysregulation of 
the aforementioned mechanisms promotes cancer formation and progression, and 
aberrant mTORC1 signaling is implicated in the pathogenesis of human disease (1). 
Independent reports also reveal human EAK-7 mRNA is overexpressed in diseases 
such as hepatocellular carcinoma (48) and lymph-node positive breast cancers (49), 
suggesting that it may play a role in human disease. Because mTOR is an essential 
effector for many of these important cellular contexts and functions within the IRS 
pathway, we hypothesized the human ortholog of EAK-7, termed mammalian EAK-7 





mEAK-7 is an evolutionarily conserved protein  
Bioinformatics databases were analyzed to gain insight to the molecular 
functions of mEAK-7, also known through genomic and proteomic studies as KIAA1609 
(87), LOC57707 (88), or TLDC1 (TBC/LysM-Associated Domain Containing 1) (89). 
Algorithmic analysis demonstrated that the amino acid identity of mEAK-7 and EAK-7 is 
89% similar across eukaryotes (Figure 2.1.A and Figure 2.7.A) (90), suggesting mEAK-
7 may be important to mammalian evolution. 
mEAK-7 contains two known domains: the TLD (TBC-containing and LysM 
associated Domain) and the N-myristoylation motif (Figure 2.1.B). TLD domain-
containing proteins confer neuroprotection against oxidative stress through unknown 
mechanisms (47). Computational analysis predicts mEAK-7 is an enzyme that folds into 
α/β+β sheets (91). The crystal structure of the TLDc domain of oxidation resistance 
protein 2 from zebrafish reveals that two antiparallel ß-sheets form a central ß-sandwich 
surrounded by two helices and two one-turn helices (92). The N-myristoylation motif 
irreversibly attaches myristate to anchor proteins to lipid bilayers or endomembrane 
compartments. Despite this information, the functional relevance of these domains is 
not known for mEAK-7. 
To investigate the molecular function of mEAK-7, we verified an antibody that 
detects endogenous mEAK-7 in human cells (Figure 2.7.B) and identified cells that 
express endogenous mEAK-7 protein (Figure 2.1.C and Figure 2.7.C). mEAK-7 protein 
was detected in UM-SCC-1, H1975, MDA-MB-231, H1299, HCC1937, MDA-MB-436, 
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SUM149, MDA-MB-468, UM-SCC-10A, -11A, -17B, and -81B (Figure 2.1.C and Figure 
2.7.C). Through this limited human cell screen, we detected mEAK-7 in many human 
cell lines.  
 
mEAK-7 is anchored at the lysosomal membrane 
mEAK-7 has been identified in membrane-bound/organelle fractions (93) and 
lysosomal fractions (88), but definitive evidence of the precise cellular compartment 
where mEAK-7 resides has not yet been demonstrated. By generating H1299 cell lines 
with stably expressed C-terminal HA-tagged mEAK-7 (HA-mEAK-7WT) and co-staining 
with compartment-specific proteins, we determined HA-mEAK-7WT strongly co-localizes 
with lysosomal-associated membrane protein-2 (LAMP2, lysosome; Figure 2.1.D), 
LAMP1 (lysosome; Figure 2.1.E), and, to a lesser extent, the plasma membrane. GFP-
tagged EAK-7 in nematodes exhibited fluorescence in the plasma membrane of the 
pharynx, nervous system, intestine, body wall muscle, hypodermis, vulva, and a group 
of cells near the anus (43). However, subcellular localization at the lysosome has not 
been demonstrated in nematodes. 
 We observed little-to-no co-localization of HA-mEAK-7WT in the endosome 
(Figure 2.7.A), mitochondria (Figure 2.7.B), endoplasmic reticulum (Figure 2.7.C), and 
Golgi complex (Figure 2.7.D). However, overexpression of exogenous protein can 
sometimes result in non-specific targeting to random cell compartments. Thus, we 
validated an antibody that targets endogenous mEAK-7 to determine the physiological 
localization within cells (Figure 2.8, A and B). We demonstrated that endogenous 
mEAK-7 strongly co-localizes with endogenous LAMP1 and LAMP2 (Figure 2.8.C). 
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These data illustrate that mEAK-7 is principally a lysosomal protein, an essential cellular 
compartment for mTORC1 signaling (94).  
 
mEAK-7 supports mTORC1 signaling in response to nutrients 
mTORC1 localizes to the lysosome in response to nutrient stimulation and this 
process is required for mTOR function (11). Further insights guiding our hypothesis that 
mEAK-7 may be an effector of mTORC1 signaling include the observations that 
nematode EAK-7 functions within the IRS pathway (43), mEAK-7 is primarily a 
lysosomal protein (Figure 2.1, D and E, and Figure 2.8), and mTORC1 is the core 
complex for this signaling pathway at the lysosome (94). 
To test the extent to which mEAK-7 functions in mTORC1 signaling, H1975 cells 
were treated with three unique mEAK-7 siRNAs for 48 hours in 10% serum-containing 
medium (DMEM+serum). mEAK-7 knockdown substantially decreased (Ser240/244) p-S6 
levels, an indicator of activated mTORC1 signaling (95), revealing mEAK-7 functions in 
mTORC1 signaling under DMEM+serum conditions (Figure 2.1.F). To determine if this 
was a universal phenomenon, H1975, MDA-MB-231, and H1299 cells treated with two 
unique mEAK-7 siRNAs which resulted in acutely diminished (Ser240/244) p-S6 levels 
(Figure 2.1.G). Finally, H1299 cells were treated with mEAK-7 siRNA, starved of serum 
for 2 hours in DMEM+AAs, and reintroduced to serum for 24 hours. mEAK-7 knocked-
down H1299 cells failed to activate and sustain (Ser240/244) p-S6 levels in response to 
serum stimulation (Figure 2.9.A). Together, these data indicate that mEAK-7 is 
important for basal-level and serum-mediated mTORC1 signaling in mEAK-7+ cells. 
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mTORC1 regulates cap-dependent protein translation by phosphorylating 
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) at Thr37/46, which 
primes the 4E-BP1 phosphorylation site at Ser65 and Thr70, and allows 4E-BP1 
detachment from eukaryotic translation initiation factor 4E (eIF4E) (96). Because 
mEAK-7 supports S6 phosphorylation through mTOR, we sought to assess the 
functional status of 4E-BP1, a major target of mTOR.  To test the effects of mEAK-7 on 
4E-BP1 phosphorylation, H1975, MDA-MB-231, H1299, and HEK-293T cells were 
treated with control or mEAK-7 siRNA for 48 hours in DMEM+serum. mEAK-7 knockdown 
appreciably decreased (Ser65) p-4E-BP1, (Thr37/46) p-4E-BP1, and (Thr70) p-4E-BP1 
levels (Figure 2.1.H). mEAK-7 knocked-down H1299 cells also failed to activate and 
sustain (Ser65) p-4E-BP1 levels in response to serum stimulation (Figure 2.9.A). Thus, 
data suggest mEAK-7 is capable of regulating both S6 and 4E-BP1, two primary 
markers for mTORC1 signaling.  
mTORC1 signaling is activated through amino acids and/or insulin stimulation at 
the lysosome (11). To address the possibility that mEAK-7 regulates mTORC1 signaling 
in response to specific nutrients, cells were starved for 2 hours in custom manufactured 
DMEM lacking amino acids (AAs) (DMEM-AAs). Subsequently, cells were collected as a 
starved control or collected after reintroduction of AAs, insulin, or both. Control siRNA-
treated H1975, MDA-MB-231, H1299, and HEK-293T cells increased mEAK-7 protein 
levels that correlated with increased (Ser240/244) p-S6 levels in response to all nutrient 
conditions (Figure 2.1.I and Figure 2.11). mEAK-7 protein levels also increased after 
serum reintroduction at different time points following serum starvation in H1299 cells 
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(Figure 2.10.A). Thus, serum, AAs, and insulin facilitate the regulation of mEAK-7 
protein levels. 
H1975, MDA-MB-231, H1299, and HEK-293T cells treated with mEAK-7 siRNA 
demonstrated reduced (Ser240/244) p-S6 levels under all conditions (Figure 2.1.I and 
Figure 2.11). In addition, mEAK-7 knocked-down H1299 cells displayed an impaired 
ability to activate and sustain (Ser65) p-4E-BP1 levels in response to amino acid and 
insulin stimulation over time (Figure 2.10.B). Taken together, these data suggest that 
mEAK-7 can regulate mTORC1 signaling in response to serum, AAs, and insulin, and 
that mEAK-7 protein is influenced by nutrient stimulation. While HEK-293T cells, a 
widely used cell line to study mTOR signaling, exhibits comparatively low mEAK-7 
protein levels (Figure 2.10.C), mEAK-7 knockdown still led to a significant reduction in 
mTOR signaling, as demonstrated by S6 and 4E-BP1 phosphorylation.  
 
mEAK-7 functions through S6K2 rather than S6K1  
Upon further examination of mEAK-7 function in mTORC1 signaling, we obtained 
evidence that was unexpectedly contrary to our initial hypothesis. After knocking down 
mEAK-7, we discovered that while (Ser240/244) p-S6 levels were decreased, (Thr389) p-
S6K1 levels were increased (Figure 2.1.I, Figure 2.10, A and D, and Figure 2.11). Since 
(Thr389) p-S6K1 is a reliable indicator of mTORC1 signaling, these findings appear to 
uncouple S6K1 activity from (Ser240/244) p-S6 levels in certain contexts. HEK-293T cells 
demonstrated typical (Thr389) p-S6K1 regulation in response to amino acid and/or insulin 
stimulation, while H1975, MDA-MB-231, and H1299 cells exhibited aberrantly 
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functioning S6K1 (Figure 2.1.I and Figure 2.11). Thus, an alternative kinase may exist to 
compensate for dysregulated S6K1 activity in H1975, MDA-MB-231, and H1299 cells. 
To investigate this perceived molecular anomaly, we examined S6K2, an 
understudied target of mTORC1. S6K1 is a prominent target of mTOR, but mTOR also 
targets S6K2, a closely related homolog of S6K1 (97). It is believed that the role of 
S6K2 is redundant to S6K1, but emerging evidence suggests these kinases also have 
distinct functions. S6K1-/- cells are capable of regulating (Ser240/244) p-S6 levels, while 
S6K2-/- cells fail to regulate (Ser240/244) p-S6 levels, demonstrating that S6K1 may not 
always be the primary kinase linked to (Ser240/244) p-S6 levels (57). Furthermore, S6K2 
knockout mice and S6K2 siRNA-treated cells exhibit increased S6K1 function, 
demonstrated by a stark increase in (Thr389) p-S6K1 levels (61). These data suggest 
S6K2 may play a vital role in mTOR signaling. Therefore, we investigated the extent to 
which S6K1 and S6K2 may be linked to (Ser240/244) p-S6 levels in mEAK-7+ cells. 
To elucidate the roles of S6K1 and S6K2, we analyzed (Ser240/244) p-S6 levels in 
response to insulin stimulation after knockdown of mEAK-7, S6K1, or S6K2. Cells were 
starved for 2 hours in DMEM+AAs without serum and subsequently introduced to insulin 
at 1 μM or 10 μM for 30 minutes. In H1975 and MDA-MB-231 cells, mEAK-7 or S6K2 
knockdown markedly reduced (Ser240/244) p-S6 levels, but S6K1 knockdown had a 
lesser effect (Figure 2.1.J and Figure 2.12, A and B). We observed mEAK-7 or S6K2 
knockdown dramatically increased (Thr389) p-S6K1 levels, which suggests the 
uncoupling of S6K1 on (Ser240/244) p-S6 levels in some cell contexts (Figure. 2.1.J and 
Figure 2.12, A and B). 
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In contrast, S6K1 affects (Ser240/244) p-S6 levels to a greater degree in H1299 
and HEK-293T cells, although mEAK-7 or S6K2 knockdown substantially abrogated 
(Ser240/244) p-S6 levels (Figure 2.1.J and Figure 2.12, C and D). These findings suggest 
that most mEAK-7+ cell lines function primarily through S6K2, rather than S6K1, to 
activate mTOR signaling. Additionally, differential levels of mEAK-7 protein (Figure 
2.10.C) were not predictive of whether cell lines will favor S6K2 over S6K1 in mTORC1-
mediated signaling. These findings are consistent with reports that S6K1 and S6 
phosphorylation are not exclusively linked, and that S6K2 has additional biological roles 
in eukaryotes (61). 
 
Molecular analysis of mEAK-7 protein 
To rule out the possibility that siRNA-mediated knockdown of mEAK-7 non-
specifically influences mTORC1 signaling, we transduced H1975, MDA-MB-231, 
H1299, and HEK-293T cells with pLenti-III-HA-Control or pLenti-III-HA(C-terminus)-
mEAK-7WT lentivirus and selected these cells with 1μg/mL puromycin for 2 weeks. We 
demonstrate that overexpression of HA-mEAK-7 activated mTORC1 signaling in H1975, 
MDA-MB-231, H1299, and HEK-293T cells (Figure 2.2.A). Thus, both knockdown and 
overexpression studies demonstrated that mEAK-7 is an essential component of 
mTORC1 signaling in mEAK-7+ cells. 
Next, we investigated the molecular domains necessary for mEAK-7 function. To 
assess the mEAK-7 domains essential for mTOR signaling, several mutants were 
generated and transduced with lentivirus into cells that expressed endogenous mEAK-7 
(Figure 2.2.B).  We compared HA-mEAK-7WT with HA-mEAK-7 mutants for LAMP2 co-
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localization at the lysosome (Figure 2.2, C-H). We also investigated differential 
overexpression effects of wild type (WT) and mutants on mTOR signaling under AAs 
and insulin stimulation (Figure 2.2, I and J). HA-mEAK-7WT co-localized with LAMP2 
(Figure 2.2.C) and AAs and insulin stimulation successfully induced (Ser240/244) p-S6 in 
WT overexpressing H1299 cells (Figure 2.2.I).  
HA-mEAK-7G2A, a mutant with a point mutation that replaces the first glycine 
residue with alanine within the N-myristoylation motif, failed to anchor to the lysosome 
(Figure 2.2.D). However, AAs and insulin stimulation induced (Ser240/244) p-S6, possibly 
due to endogenous mEAK-7 function (Figure 2.2.I). Deletion of amino acids 1-139 (HA-
mEAK-7ΔNDEL1) also led to a lysosomal anchorage (Figure 2.2.E), due to the loss of the 
N-myristoylation motif, but did not significantly alter endogenous mTORC1 signaling 
(Figure 2.2.I). HA-mEAK-7ΔNDEL2 co-localized with LAMP2 (Figure 2.2.F) and also did 
not significantly alter endogenous mTORC1 signaling (Figure 2.2.I). 
While both HA-mEAK-7ΔTLD and HA-mEAK-7ΔCDEL localize at the lysosome 
(Figure 2.2, G and H), stable expression of either HA-mEAK-7ΔTLD or HA-mEAK-7ΔCDEL 
inhibited the induction of (Ser240/244) p-S6 levels by AAs and insulin (Figure 2.2, I and J), 
and resulted in increased (Thr389) p-S6K1 levels (Figure 2.2.J). Although it is unclear 
how these mutants affect endogenous mEAK-7 function to impair mTOR signaling, 
these results demonstrate that the TLD domain and C-terminus are necessary for 
mEAK-7-mediated mTOR function.  
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mEAK-7 recruits mTOR to the lysosome in nutrient-deprived and nutrient-rich 
conditions 
mTOR signaling components are translocated to the lysosome in response to 
nutrient stimulation and this shuttling is necessary to activate mTORC1 signaling (1). 
Because mEAK-7 is predominantly lysosomal, we posited a role for mEAK-7 in targeting 
mTOR to the lysosome. To determine the role of mEAK-7 in lysosomal localization of 
mTOR, H1299 cells were treated with control or mEAK-7 siRNA for 48 hours. 
Subsequently, cells were starved in DMEM-AAs for 1 hour and AAs and insulin were 
reintroduced for 30 min. We found that mEAK-7 knockdown impaired mTOR localization 
to the lysosome (Figure 2.3.A), confirming that mEAK-7 is important for mTOR 
localization. While low levels of mTOR remained capable of migrating to the lysosome 
after mEAK-7 knockdown, this may be due to residual mEAK-7 still expressed since 
siRNA treatment is not 100% effective and because other major regulators of mTOR, 
such as the Rag GTPases, have been shown to recruit mTOR to the lysosome (24). 
Further analysis demonstrated that the expression of mTORC1/2 components 
was not altered after mEAK-7 siRNA treatment (Figure 2.3.B). H1299 cells treated with 
mEAK-7 siRNA demonstrated a statistically significant decrease in mTOR/LAMP2 co-
localization in the starved condition (Figure 2.3.C). In the nutrient replenished condition, 
H1299 cells treated with mEAK-7 siRNA also exhibited a statistically significant 
decrease in mTOR/LAMP2 co-localization (Figure 2.3.C). To substantiate this finding, 
we performed the reciprocal experiment by overexpressing HA-mEAK-7. HA-mEAK-7 
overexpression in H1299 cells resulted in a statistically significant increase in 
mTOR/LAMP2 co-localization in the absence of nutrients (Figure 2.3, D and E). 
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Additionally, reintroduction of nutrients in control cells resulted in a significant 
enhancement of the co-localization of mTOR/LAMP2, and HA-mEAK-7 overexpression 
increased mTOR/LAMP2 co-localization in the presence of nutrients (Figure 2.3, D and 
E). Further analysis demonstrated nutrient reintroduction did not result in a statistically 
significant change of HA-mEAK-7/LAMP2 co-localization (Figure 2.3.F). We then 
hypothesized that endogenous mEAK-7 would co-localize with endogenous mTOR in 
response to nutrient stimulation because amino acids recruit mTOR to the lysosome. 
H1299 cells were nutrient starved for 1 hour and stimulated with AAs, insulin, or both for 
1 hour. Endogenous mEAK-7 and endogenous mTOR strongly co-localized in response 
to nutrient stimulation (Figure 2.13, A-E). 
We hypothesized that mEAK-7 could directly affect mTOR kinase function, 
possibly as an adaptor protein. mTOR interaction with its complex components is known 
to be sensitive under different buffer conditions (98). To rule out the possibility of non-
specific or artificial interactions due to an abundance of exogenously produced protein 
and buffer-dependent conditions, we harvested either H1299, or HA-mEAK-7 
expressing H1299 cells, in either NP40 or CHAPs buffer. Thus, we assessed the 
potential for interaction between these two proteins using a co-immunoprecipitation 
assay. Co-immunoprecipitation of exogenous HA-mEAK-7WT confirmed significant 
interaction with endogenous mTOR, compared to an IgG control under serum-
containing conditions (Figure 2.4.A). In addition, endogenous mEAK-7 interacted with 
endogenous mTOR (Figure 2.4.B). Finally, knockdown of mEAK-7 diminished the 
interaction of endogenous mEAK-7 with endogenous mTOR and mLST8 (Figure 2.4.C 
and Figure 2.14.A). However, mEAK-7 failed to interact with raptor or rictor, key 
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components of mTORC1 and mTORC2, respectively. Intriguingly, exogenous HA-
mEAK-7WT also interacted with mTOR and mLST8, but did not interact with rictor, Sin1, 
raptor, PRAS40, or DEPTOR (Figure 2.4.D). These findings suggest the possibility of an 
alternative mTOR complex that is yet to be identified in mammalian cells. 
To assess the nutrient dependency of this interaction, HA-mEAK-7WT cells were 
starved for 2 hours and AAs, insulin, or both were reintroduced for 30 min. All lysates for 
immunoprecipitation were collected in NP40 lysis buffer, unless noted otherwise. Under 
these conditions, exogenous HA-mEAK-7WT and endogenous mTOR interacted in the 
starved condition and this interaction was increased by nutrient stimulation (Figure 2.4.E 
and Figure 2.14.B). To further demonstrate the validity of these nutrient-dependent 
interactions, data support that endogenous mEAK-7 also strongly interacts with 
endogenous mTOR under the AAs and insulin or AAs and serum conditions (Figure 
2.4.F and Figure 2.14.C). Additionally, co-immunoprecipitation of endogenous mTOR to 
detect exogenous HA-mEAK-7WT also confirmed this interaction increased under 
nutrient stimulation (Figure 2.4.G and Figure 2.14.D). Therefore, data suggest that both 
exogenous and endogenous mEAK-7 are capable of interacting with mTOR. 
To determine the molecular domain necessary for mEAK-7 interaction with 
mTOR, co-immunoprecipitation was performed in cells stably expressing HA-mEAK-
7WT, HA-mEAK-7ΔTLD, and HA-mEAK-7ΔCDEL, because these domains are necessary for 
the activation of mTORC1 signaling in mEAK-7+ cells (Figure 2.2, I and J). We found 
that the C-terminus protein region is necessary for the interaction of exogenous HA-
mEAK-7WT and endogenous mTOR (Figure 2.4.H and Figure 2.14.E), so this region of 
the C-terminus was termed the mTOR-binding (MTB) domain. Other mEAK-7 mutants 
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were also capable of interacting with endogenous mTOR, suggesting that maintaining 
an intact MTB domain is sufficient for mTOR binding (Figure 2.13, F and G). 
Additionally, overexpression of HA-mEAK-7ΔTLD and HA-mEAK-7ΔCDEL increased 
(Thr389) p-S6K1 levels (Figure 2.4.H). These findings suggest that the interaction of 
mEAK-7 and mTOR diverts mTOR targeting from S6K1 to S6K2, while loss of mEAK-7 
diverts mTOR targeting from S6K2 to S6K1, resulting in increased (Thr389) p-S6K1 
levels.  
We hypothesized that mEAK-7 regulates mTORC1 signaling through S6K2 
because (Thr389) p-S6K1 levels were not linked to its downstream target, (Ser240/244) p-
S6 (Figure 2.1, I and J, Figure 2.2.J, and Figure 2.10, A and D). To assess this 
possibility, H1299 cells were transiently transfected with pcDNA3-HA-S6K2-WT and 
either control or mEAK-7 siRNA, and HA-S6K2 was immunoprecipitated. mEAK-7 
knockdown considerably decreased the interaction between endogenous mTOR and 
HA-S6K2 (Figure 2.4.I and Figure 2.14.F). To ensure mEAK-7 specificity in this 
interaction, two mEAK-7 siRNAs were employed and both demonstrated a substantial 
decrease in HA-S6K2 interaction with mTOR (Figure 2.4.J and Figure 2.14.G). These 
outcomes suggest that mEAK-7 supports the interaction of S6K2 and mTOR. 
Next, we hypothesized mEAK-7 may also influence S6K1 and mTOR interaction. 
To test this, H1299 cells were transiently transfected with pRK7-HA-S6K1-WT and 
control or mEAK-7 siRNA, and HA-S6K1 was immunoprecipitated. mEAK-7 knockdown 
increased the interaction of exogenous HA-S6K1 with endogenous mTOR (Figure 2.4.K 
and Figure 2.14.H). Subsequently, two different mEAK-7 siRNAs confirmed these 
enhanced interactions were the result of mEAK-7 knockdown (Figure 2.4.L and Figure 
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2.14.I). Thus, we demonstrate that mEAK-7 intricately controls mTOR interaction with 
both S6K2 and S6K1.  
While these data support the necessity of mEAK-7 for the interaction of mTOR 
with S6K2, they do not provide direct evidence of S6K2 function. To our knowledge, an 
antibody specific to (Thr388) p-S6K2 does not exist. However, the amino acid sequences 
of the hydrophobic motifs of the S6Ks (Figure 2.4.M) are nearly identical. Given this 
similarity, we predicted the monoclonal antibody against (Thr389) p-S6K1 (Cell Signaling 
Technology: clone 108D2) would reveal the relative phosphorylation status of S6K2, 
since it was designed to target the mTOR-targeting hydrophobic motif, and this is a 
strategy utilized by other groups (60). Because (Thr389) p-S6K1 levels are a common 
readout of S6K1 kinase activity and mTORC1 functionality, we expected that (Thr388) p-
S6K2 levels would also indicate S6K2 kinase activity in this context. Additionally, the 
molecular weights of S6K1 and S6K2 are different in that S6K1 is 65-70 kDa and S6K2 
is 60 kDa; therefore, immunoprecipitation would yield detectable phosphorylation 
differences of the concentrated kinase. To determine the phosphorylation status of 
S6K2 by mEAK-7, H1299 cells were transiently transfected with pcDNA3-HA-S6K2-WT 
and either control or mEAK-7 siRNA, starved of nutrients, and DMEM+serum was 
reintroduced for 30 min. HA-S6K2 was then immunoprecipitated and probed with the 
108D2 antibody. Data suggest that mEAK-7 is required for the interaction of mTOR with 
S6K2 in response to serum and regulates (Thr388) p-S6K2 levels, as demonstrated by a 
loss of S6K2 phosphorylation in response to mEAK-7 knockdown (Figure 2.4.M). 
Furthermore, loss of mEAK-7 diminished S6K2-mediated phosphorylation of S6 in 
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response to serum stimulation (Figure 2.4.M). Therefore, mEAK-7 is required for S6K2 
activity in these cells. 
Finally, to demonstrate the extent to which mEAK-7 regulates 4E-BP1 and eIF4E 
interaction, we treated H1299 cells with either control or mEAK-7 siRNA and 
immunoprecipitated eIF4E. We discovered that mEAK-7 knockdown enhanced binding 
of 4E-BP1 to eIF4E (Figure 2.4.N and Figure 2.14.J). Thus, these data establish mEAK-
7 as a novel effector of mTOR signaling that regulates both S6K2 activity and 4E-BP1 
activity. 
 
mEAK-7 supports cell proliferation and migration  
After demonstrating that mEAK-7 supports mTOR signaling, we hypothesized 
that mEAK-7 was essential for critical cellular functions governed by mTOR. mTOR 
signaling is important for regulation of cell number (1). To elucidate the influence of 
mEAK-7 on proliferation, cells were treated with either control or mEAK-7 siRNA, and 
counted after 3 and 5 days. In H1975 (Figure 2.5.A), MDA-MB-231 (Figure 2.5.B), 
H1299 (Figure 2.5.C), and HEK-293T cells (Figure 2.5.D), treatment with mEAK-7 
siRNA resulted in a significant reduction in cell proliferation. Further, annexin V staining 
or acridine orange-propridium iodide (AO-PI) staining demonstrated no difference in cell 
death after mEAK-7 knockdown (Figure 2.15, A-C). Previous reports corroborate the 
finding that the loss of TLD domain-containing proteins (47) or single knockdown of 
S6K2 without an apoptotic stimulator (99) does not result in significant levels of cell 
death. Due to the low expression of mEAK-7 in some human cells, we hypothesized 
that mEAK-7 overexpression would promote cell proliferation. Thus, to test the effect of 
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mEAK-7 overexpression on cell proliferation, we transduced H1975, MDA-MB-231, 
H1299, and HEK-293T cells with pLenti-GIII-CMV-Control-HA and pLenti-GIII-CMV-
mEAK-7-HA. Overexpression of HA-mEAK-7 in H1975 (Figure 2.5.E), MDA-MB-231 
(Figure 2.5.F), H1299 (Figure 2.5.G), and HEK-293T (Figure 2.5.H) significantly 
enhanced cell proliferation at day 3 and day 5.  Thus, we concluded that mEAK-7 is vital 
for cell proliferation in mEAK-7+ cells. 
mTORC1 signaling has substantial control over cell migration and metastasis, 
with the 4E-BP1-eIF4E axis regulating mTOR-sensitive migration and invasion genes 
(38). Given the role of mEAK-7 in mTOR signaling, we investigated the impact of 
mEAK-7 on cell migration. H1975, MDA-MB-231, and H1299 cells were treated with 
either control or mEAK-7 siRNA and seeded into CIM-plates, which use xCELLigence 
technology to quantify cell migration in real-time, collecting hundreds of data points 
through a dimensionless cell-index parameter. Cells must pass through a pore 
embedded in a gold-plated electric grid, creating electrical impedance and registering a 
signal for real-time, quantifiable cell migration. We proceeded to conduct statistical 
analyses at select time points of 12, 24, 36, and 48 hours. Treatment of H1975 (Figure 
2.5.I), MDA-MB-231 (Figure 2.5.J), H1299 (Figure 2.5.K), and HEK-293T (Figure 2.5.L) 
cells with mEAK-7 siRNA resulted in statistically significant reductions of real-time cell 
migration at 24, 36, and 48 hours. In addition, scratch wound assay analysis of H1975 
(Figure 2.5.M), MDA-MB-231 (Figure 2.5.N), H1299 (Figure 2.5.O), and HEK-293T 
(Figure 2.5.P) cells treated with mEAK-7 siRNA resulted in a dramatic defect of wound 




The S6 Kinases have differential functions mediated through mEAK-7 
Data from several sources suggest that S6 kinases play redundant roles due to 
their high homology, but recent evidence reveals that independent role of S6K2 remains 
undetermined (61). Genome-wide assessment of S6K1 and S6K2 in human tumors and 
in vitro silencing of these kinases demonstrate that their targets are different from each 
other, and that S6K2 more closely mirrors eIF4E function (100). S6K2 has also been 
shown to be an essential regulator of cell proliferation, due to its involvement with 
Heterogeneous Ribonucleoprotein F (101). Previous reports demonstrate that S6 is 
essential for mammalian cell proliferation and that S6K1 controls eukaryotic size (102). 
Given that mEAK-7 regulates S6K2 function, we hypothesized that mEAK-7 also 
regulates S6K2-mediated cell proliferation. 
To determine the extent to which S6K2 regulates cell proliferation and to 
compare its functional role in other mTOR targets, H1975 cells were treated with 
control, S6K1, S6K2, or eIF4E siRNA for 48 hours in DMEM+serum (Figure 2.6.A). Cells 
were then seeded into new tissue culture plates and were counted after 3 and 5 days. 
Treatment with S6K1, S6K2, and eIF4E siRNA resulted in a significant reduction of cell 
proliferation at day 3 and day 5 (Figure 2.6.B). Importantly, treatment with S6K2 or 
eIF4E siRNAs significantly reduced cell proliferation at day 5, compared to S6K1 siRNA. 
However, H1975 cells treated with S6K2 siRNA, compared to eIF4E siRNA, did not 
result in a statistically significant reduction, suggesting that S6K2 functions similarly to 
eIF4E with regards to cell proliferation, as the literature reports (100). These results 
demonstrate S6K2 is essential for cell proliferation under these conditions. 
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mTOR signaling also controls cell size in eukaryotes (30). Because we found that 
mEAK-7 is a positive activator of mTOR signaling, we sought to determine the role of 
mEAK-7 in regulating cell size. H1975, MDA-MB-231, and H1299 cells were treated 
with control or mEAK-7 siRNA for 48 h, seeded onto new tissue culture plates, and 
processed at day 3. Cells were analyzed on a Beckman-Coulter CyAn 5 flow cytometer 
for forward scatter. Interestingly, H1975 (Figure 2.15.D), MDA-MB-231 (Figure 2.15.E), 
and H1299 (Figure 2.15.F) cells treated with mEAK-7 siRNA resulted in an increase in 
cell size, suggesting that dysfunctional S6K1 activity results in aberrant cell size 
regulation after mEAK-7 knockdown. Under the same conditions, cell size was also 
assessed using the Logos Biosystems Luna Cell Counter. H1975 (Figure 2.6.C), MDA-
MB-231 (Figure 2.6.D), and H1299 (Figure 2.6.E) cells treated with mEAK-7 siRNA 
resulted in a significant increase in cell size. These data demonstrate that while loss of 
mEAK-7 resulted in decreased downstream mTOR signaling, aberrant activation of 
S6K1 leads to dysregulation of cell size. Additionally, H1975 cells were treated with 
control, S6K1, or S6K2 siRNA and then analyzed via forward scatter in flow cytometry. 
S6K1 knockdown reduced cell size, while S6K2 knockdown demonstrated limited 
change in cell size (Figure 2.6.F). 
Because overexpression of pcDNA3-HA-S6K2-WT or pRK7-HA-S6K1-WT was 
not sufficient to rescue mTOR signaling in H1299 cells treated with mEAK-7 siRNA 
(Figure 2.4, I-M), we posited that this obstacle could be overcome by transfecting cells 
with constitutively activated forms of S6K1 or S6K2. To determine whether this could 
rescue mEAK-7 knockdown effects, cells were treated with control siRNA, mEAK-7 
siRNA, mEAK-7 siRNA + pRK7-HA-S6K1-F5A-E389-deltaCT (50 kDa – deletion that 
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results in a truncated kinase) (cS6K1) plasmid, or mEAK-7 siRNA + pcDNA3-HA-S6K2-
E388-D3E (60 kDa) (cS6K2) plasmid. Concomitant knockdown of mEAK-7 and 
overexpression of cS6K1 and cS6K2 in H1299, H1975, and MDA-MB-231 cells resulted 
in rescue of (Ser240/244) p-S6 levels (Figure 2.6.G). Knockdown of mEAK-7 and 
overexpression of cS6K1 or cS6K2 resulted in partial rescue of cell proliferation defects 
(Figure 2.6.H). Thus, we demonstrate that mEAK-7 functions upstream of S6K2 and 
promotes S6K2-mediated signaling and proliferation.  
 
Discussion 
In this study, we determined mEAK-7 is an important, evolutionarily-conserved, 
lysosomal protein that activates mTOR signaling in response to nutrient stimulation in 
many cell types (Figure 2.6.I). We provide mechanistic insight for a novel protein that is 
required for serum-, amino acid-, and insulin-mediated mTOR signaling in human cells. 
We also demonstrate mEAK-7 is necessary for S6K2 function by regulating S6K2-
mTOR interaction, 4E-BP1-eIF4E interaction, and supporting cell proliferation and cell 
migration in mEAK-7+ cells. We identified mEAK-7 as an essential interacting protein of 
mTOR and mLST8, but not other mTORC1 components, raptor, DEPTOR, or PRAS40, 
and mTORC2 components, rictor, DEPTOR, or Sin1. mEAK-7 interacts with mTOR 
through the MTB domain (Figure 2.6.J). mEAK-7 regulates mTORC1 signaling at the 
lysosome and is a key player for mTOR recruitment to the lysosome. Thus, we 
determined that mEAK-7 functions as an essential component of mTOR signaling to 
regulate S6K2 and 4E-BP1, through a potentially alternative pathway to the canonical 
mTORC1 or mTORC2 models.  
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Since the discovery of rapamycin, decades of research have contributed to 
understanding the mechanism by which mTOR is regulated in response to nutrients and 
stress (1). The two best-known complexes that contain mTOR are mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2). mTORC1 is comprised of regulatory-
associated protein of mTOR (raptor), mammalian lethal with SEC13 protein 8 (mLST8) 
or GβL, Proline-rich AKT1 substrate 1 (PRAS40), and DEPTOR (1). mTORC2 is 
comprised of mLST8, rapamycin-insensitive companion of mTOR (rictor), mammalian 
stress-activated protein kinase interacting protein 1 (mSIN1), Protor, DEPTOR, and Tti1 
& Tel2 (1). 
With the finding that mEAK-7 is an interacting and functioning partner of mTOR 
and mLST8, we posited that mEAK-7 may form a novel complex to regulate the 
specificity of S6K2 interaction with mTOR. 4E-BP1 binding to eIF4E is also affected by 
the loss of mEAK-7, and data suggest a potential new complex may, in certain contexts, 
regulate this mTOR-mediated function as well. Our evidence suggests that mEAK-7 
functions at the level of mTOR as a coordinator for S6K2 and 4E-BP1, but the 
downstream partners that mediate this process remain unknown.  
It has been theorized that additional mTOR complexes may complement 
mTORC1 and mTORC2 in mammalians. Astrocytes of the central nervous system 
provide one such example of how mTOR may function in a cell-type dependent manner. 
In this context, GIT1 functions as an interacting partner of mTOR that does not 
associate with either raptor or rictor (42). This finding is intriguing because it 
demonstrates that cell-type specificity may dictate the molecular landscape that allows 
for full mTOR regulation and activation. mEAK-7 may have eluded previous mTOR 
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immunoprecipitation and mass spectrometry analyses because it is found to a limited 
extent in human cells (Figure 2.1.C, Figure 2.7.C, and Figure 2.10.C). It is also unknown 
where mEAK-7 is expressed during development. The interaction between mEAK-7 and 
mTOR, as well as the associated influence on S6K2 and 4E-BP1 functions, suggests 
there are more mTOR components yet to be identified that may interact in a cell-type, or 
context-dependent manner (Figure 2.6.I). 
Because we did not screen mEAK-7 in all human cell types, further investigation 
of mEAK-7 in other physiological contexts is essential for understanding how mEAK-7 
functions in human development or disease. We provide molecular insight 
demonstrating that mEAK-7 supports the interaction of S6K2 and mTOR, but the full 
complement of interacting partners is yet to be determined. In addition, evolutionary 
differences arose between mammalian EAK-7 and nematode EAK-7. Nematode EAK-7 
functions in parallel to Akt signaling to regulate DAF-16 (human FoxO) during 
development and lifespan (43). We demonstrate that mEAK-7 is essential for mTOR 
signaling to regulate S6K2 and 4E-BP1, but nematodes only possess one S6 kinase, 
RSKS-1. Thus, it is unclear how, or if, EAK-7 regulates TOR signaling in nematodes. 
One of the challenges in studying mTOR in mammalian systems is the difficulty 
in discerning tissue or organ-specific functions, as knockout of major components of 
mTORC1 or mTORC2 results in embryonic lethality (53). S6K1 is the best-studied 
target of mTOR in eukaryotes. In mice, loss of S6K1 reduces weight and improves 
insulin sensitivity with high-fat diets (HFD) (54), while mice with a standard diet (SD) are 
glucose-intolerant, hypoinsulinaemic, and have reduced β cell size (55). Intriguingly, 
loss of both S6K1 and S6K2 reverses the deleterious effects of S6K1 knockout mice, 
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restores glucose tolerance under a SD, and further improves glucose tolerance with a 
HFD (56).  
Because S6K2 has been studied to a lesser extent in the scientific community, 
much less is known about the importance of S6K2 in development, metabolism, and 
disease. Compared to wild-type mice, S6K1 null mice are much smaller, S6K2 null mice 
are slightly larger, and double knockout animals result in perinatal lethality (57). Recent 
data suggest that S6K2 may not be a purely redundant kinase to S6K1 because S6K1 
null mice demonstrate higher S6K2 expression in the liver, muscles, thymus, and brain, 
and because S6K2 remains responsive to rapamycin-mediated inhibition of S6 
phosphorylation in S6K1 null mice (58). Thus, S6K2 was largely neglected and tissue-
specific functions of S6K2 are now beginning to be understood. The loss of S6K2 
resulted in higher basal levels of insulin in plasma, 2.5x more β cell mass with a SD, 
and improved glucose tolerance, as well as enhanced insulin sensitivity with a HFD 
(59). Additionally, single S6K2 knockout enhances ketone body production and 
increases peroxisome proliferator-activated receptor alpha activity in the liver, and S6K1 
knockout mice are capable of maintaining (Ser240/244) p-S6 levels, while S6K2 knockout 
mice are not, as we have demonstrated (60). Thus, elucidating the role of mEAK-7-
mediated regulation of S6K2 and mTOR signaling in mammals will further our 
understanding of diseases where hyper-activation of mTOR signaling occurs through 




Materials and Methods 
 
Cell lines 
H1299, H1975, MDA-MB-231, and HEK-293T cell lines were obtained from 
ATCC. Other cell lysates were donations and used as part of the initial cell screen. 
Figure 2.1.C and Figure 2.7.C lysates: the donor labs verified the cell lysates and hold 
the validation paperwork. Cell lysates derived from our lab: human embryonic stem cell 
line H1 undifferentiated, H1 endoderm (differentiated to pancreatic progenitors), H1 
mesoderm (cardiac progenitors), H1 ectoderm (neuronal progenitors), H1 embryoid 
body, Human gingival fibroblasts (2 different patients). Dr. Tom Carey: UM-SCC-1, UM-
SCC-10A, UM-SCC-11A, UM-SCC-14A, UM-SCC-17A, UM-SCC-17B, UM-SCC-74A, 
UM-SCC-74B, and UM-SCC-81B. Dr. Mark Cohen: H1975 and H1299. Dr. Shuichi 
Takayama: MDA-MB-231. Dr. Max S. Wicha: BT474, HCC1937, MDA-MB-436, SK-BR-
3, SUM149, SUM159, T4D7, MDA-MB-468. 
 
Cell culture 
Cell culture: Cell lines were grown in Dulbecco’s minimal essential medium 
(DMEM, Thermo Fisher Scientific (TFS): cat# 11995-073), without 
antibiotics/antimycotics and supplemented with a concentration of 10% fetal bovine 
serum (FBS, TFS: cat# 10437-036, Lot # 1399413) at 37°C in 5.0% CO2 incubator. 
Cells were grown in Falcon™ Tissue Culture Treated Flasks T-75 (Fisher Scientific 
(FS): cat# 13-680-65) until 75% confluent, split with Trypsin-EDTA 0.25% (TFS: cat# 
25200-056) for 5 min in the 37°C cell incubator. Cells were washed 1x with PBS and 
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resuspended in 10% FBS containing DMEM. Cells were counted with the LUNA™ 
Automated Cell Counter (Logos Biosystems (LB): cat# L10001) utilizing LUNA™ Cell 
Counting Slides (LB: cat# L12003) and AO-PI dye (LB: cat# F23001). 
Starvation protocol: Cells were starved in DMEM lacking amino acids (DMEM-AAs: TFS, 
cat# ME120086L1) for 50 minutes (min) or 2 hours, then stimulated with amino acids 
(normal DMEM), insulin (1 μM or 10 μM: Sigma-Aldrich; cat# I9278-5ML), or both for 30 
or 60 min.  
 
Small interfering RNA or plasmid transfection 
Cells were seeded at a density of 500,000 cells per 60 mm TCP and grown for 
24 hours. For siRNA transfection, we incubated Lipofectamine® RNAiMAX Transfection 
Reagent (TFS: cat# 13778-150) within Opti-MEM® I Reduced Serum Medium (TFS: 
cat# 31985-070) and 100 nM siRNA was incorporated before being introduced into cells 
at 100 nM concentration. For plasmid transfection, we utilized FuGENE® 6 Transfection 
Reagent (Promega: cat# E2691) into Opti-MEM I Reduced Serum Medium and 2 μg 
plasmid was incorporated before being introduced into cells. For dual transfection, we 
added both solutions. Mammalian EAK-7 (mEAK-7) siRNAs are identified as KIAA1609 
or TLDC1: for siRNA mEAK-7 #1 (TFS: ID# s33640), #2 (TFS: ID# HSS126697), #3 
(TFS: ID# HSS126699). We also utilized these siRNAs; mEAK-7 (TFS: ID# s33641, ID# 
s33642, and ID# HSS126698), S6K1 (TFS: ID# 1 - s12282, 2- s12283), S6K2 siRNA 
(TFS: ID# 1- s12286, 2-s12287), eIF4E (TFS: ID# s4578), control siRNA (TFS: cat# 
4390843). Plasmids were purchased from Addgene. pRK7-HA-S6K1-WT was a gift 
from John Blenis (Addgene, # 8984). pcDNA3-S6K2-WT was a gift from John Blenis 
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(Addgene, # 17729). pRK7-HA-S6K1-F5A-E389-deltaCT was a gift from John Blenis 




Cells were collected with a cell scraper and lysed in cold NP40 lysis buffer (50 
mM Tris, 150 mM NaCl, and 1.0% NP-40 at pH 8.0).  50 μg of protein lysate was 
separated in Novex™ WedgeWell™ 4-20% Tris-Glycine Gels (TFS; cat# XP04205BOX) 
or 10% Tris-Glycine Gels (TFS; cat# XP00105BOX). Proteins were transferred to PVDF 
membranes, incubated with primary antibodies overnight at 4°C, and then incubated 
with secondary antibodies at room temperature for 1 hour. Membranes were incubated 
with SuperSignal™ West Pico Chemiluminescent Substrate (TFS; cat# 34078) or Femto 
(TFS; cat# 34095). Primary antibodies were as follows: mouse monoclonal antibody 
against mEAK-7 (KIAA1609) was obtained from Origene Technologies (clone OTI12B1, 
formerly 12B1: cat# TA501037). All antibodies from Cell Signaling Technologies (CST) 
were as follows: glyceraldehyde-3-phosphate dehydrogenase (cat# 2118S), 
(Ser240/244) phospho (p)-S6 ribosomal protein (2215S), S6 ribosomal protein (2217S), 
(Thr389) p-p70 S6 kinase (9234S), S6K1 (2708S), S6K2 (14130S), mTOR (2983S), 
HA-tag mouse (2367S), HA-tag rabbit (3724S), (Ser65) p-4E-BP1 (9451S), (Thr37/46) 
p-4E-BP1 (9459S), (Thr70) p-4E-BP1 (13396S), mLST8 (3274S), raptor (2280S), 
PRAS40 (2691S), DEPTOR/DEPDC6 (11816S), rictor (2114S), Sin1 (12860S), 4E-BP1 
(9452S), and eIF4E (2067S). Antibodies p-S6, S6, and 4E-BP1 were used at 1:3,000 
dilution and the remainder at 1:1,000 dilution in 5% BSA in 1X TBST buffer with 0.04% 
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sodium azide. Secondary antibodies for immunoblot analysis: 1:4,000 dilution for α-
mouse IgG HRP Conjugate (Promega; cat# W4021) and 1:7,500 dilution for α-rabbit 
IgG HRP Conjugate (Promega; cat# W4011).  
 
Molecular cloning of HA-mEAK-7WT into mutants 
Gibson Assembly Reaction (GAR) (New England Biolabs; cat# E2611S) was 
used to generate mutant constructs in accordance to manufacturer’s instructions. In 
table S1 we outline the list of primers used to produce the different mutant plasmids 
and extended materials and methods. pLenti-GIII-CMV-mEAK-7-HA (abm inc., cat# 
LV198982) was used as backbone. All mutants were confirmed by DNA sequencing. 
10X lentiviral supernatant for wild type and mutant constructs was prepared by the 
Vector Core at the University of Michigan. H1299 cells were infected with 1X virus and 
selected with 1 μg/mL puromycin in 10% serum-containing DMEM medium. After two 
weeks, cells were used for immunoblot analysis and confocal microscopy. 
 
Immunoprecipitation (IP) analysis  
After siRNA and/or plasmid transfection, cells were harvested in 1% NP40 lysis 
buffer or CHAPs lysis buffer (FIVEphoton Biochemicals (FB): cat# CIB-1) supplemented 
with protease inhibitors (FB: cat# PI-1) and phosphatase inhibitors (FB: cat# PIC1). 250 
μg proteins were used for immunoprecipitation reactions and 25 μg proteins were used 
for whole cell lysate (WCL) analysis. 2 μg antibodies and 40 μL of ImmunoCruz™ 
IP/WB Optima C agarose beads (Santa Crus Biotechnologies (SCB): Cat# sc-45040) 
were incubated in 1 mL PBS for 1 hour at 4°C. Separately, 250 μg proteins were 
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incubated with 50 μL Preclearing Matrix C (SCB: cat# sc-45054) in CHAPs buffer for 1 
hour. After washing, the antibody-bead conjugate was incubated with pre-cleared 
protein lysate for 1.5 hours at 4°C and precipitated beads were washed 3 times with 
PBS. Antibodies for immunoprecipitation were as follows: Goat anti-HA epitope tag 
(Novus Biologicals: cat# NB600-362), goat IgG (SCB: cat# sc-2028), mTOR (CST: cat# 
2983S), mEAK-7 (SCB: cat# sc-247321), and eIF4E (SCB: cat# sc-271480). 
 
Cell immunofluorescence analysis  
250,000 cells were seeded into Nunc™ Lab-Tek™ II Chamber Slide™ System 2-
well (FS: cat# 12-565-5) for 24 hours. Cells were starved for 50 min in DMEM-AAs and 
stimulated with amino acids or 1 μM insulin for 30 min. Then, cells were fixed with Z-Fix 
solution (Anatech LTD: cat# 170) for 10 min at RT, washed 3 times in PBS, incubated 
with the following: unmasking solution (PBS, 2N HCL, 0.5% TritonX) for 10 min, 
quenching solution (TBS, 0.1% Sodium Borohydride) for 10 min, permeabilization 
solution (PBS, 0.02% TritonX) for 10 min, and 5% BSA for 1 hour. Cells were incubated 
overnight at 4˚C with primary antibody. Next, slides were washed with PBS and 
incubated in secondary antibodies for 1 hour at room temperature. We used Nikon Ti 
Eclipse Confocal Microscope (100x magnification) to capture images. We captured 
images with or without 3x digital zoom, 1/32 frames per second, 1024x1024 image 
capture, 1.2 Airy Units, 2x line averaging, appropriate voltage and power settings 
optimized per antibody. No modification was done, except image sizing reduction for 
figure preparation. Quantitative analyses were completed via Imaris software for 
confocal images with calculation of co-localization as percentages. Identical threshold 
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settings captured images across three to five individual fields (10 to 15 cells) per 
condition, with the data representing at least three independent experiments. Primary 
antibodies for immunofluorescence were as follows: mouse HA-tag (CST: cat# 2367S), 
rabbit HA-tag (CST: cat# 3724S), LAMP1 (CST: cat# 9091S), LAMP2 (SCB: cat# sc-
18822), mEAK-7 (SCB: cat# sc-247321), EEA1 endosome (CST: cat# 3288S), AIF 
mitochondria (CST: cat# 5318S), PDI endoplasmic reticulum (CST: cat# 3501S), RCAS-
1 Golgi complex (CST: cat# 12290S), and mTOR [1:1,000] (CST: cat# 2983S). All 
antibodies were used at 1:1,500 with a working volume of 1.5 mL in 5% BSA in PBS, 
unless noted otherwise. Secondary antibodies for immunofluorescence were as follows: 
Donkey anti-Mouse IgG Alexa Fluor® 488 (TFS: cat# R37114). Donkey anti-Rabbit IgG 
Alexa Fluor® 594 (TFS: cat# A-21207). All antibodies were used at a concentration of 
1:1,500 with a working volume of 1.5 mL in 5% BSA in PBS. DAPI stain was used for 
DNA. 
 
Cell proliferation, size, migration, apoptosis, and scratch wound assay analysis 
For cell proliferation and size assay, cells were processed with the LUNA™ 
Automated Cell Counter (Logos Biosystems (LB): cat# L10001) utilizing LUNA™ Cell 
Counting Slides (LB: cat# L12003) and AO-PI dye (LB: cat# F23001). After 
siRNA/plasmid transfection or lentiviral transduction, 200,000 cells were seeded in 100 
mm TCPs for 3 and 5 day analysis. All cell size data was processed at day 3. Cell size 
was consistent across multiple platforms for analysis. For cell migration assay, cells 
were seeded at a density of 50,000 cells/well in CIM-plate 16 (ACEA BIO: cat# 
05665817001). Real-time capture of cell migration was performed over 48 hours on the 
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xCELLigence System, RTCA DP Instrument (ACEA BIO: cat# 00380601050) and 
processed by RTCA Software 2.0. This technology is a widely utilized and validated 
tool, with over 1,200 publications (https://aceabio.com/publications/). Cells must pass 
through a pore embedded in a gold-plated electric grid, creating electrical impedance 
and registering a signal for real-time, quantifiable cell migration. As cells migrate 
through a small pore, they pass over a gold grid, which causes electrical impedance 
that is registered in real-time as cellular migration. In order to prepare the data, we 
plotted the Cell Index every 12 hours. . We can distribute all data points upon request. 
For scratch wound assays, cells were seeded at a density of 1,500,000 cells in 35 mm 
TCPs. After 24 hours, cell plates were linearly scratched with a pipet tip, and images 
representative of wound healing were captured after 48 hours. For cell size and death 
analysis via flow cytometry, cells were analyzed for forward scatter with the Beckman-
Coulter CyAn flow cytometer at the University of Michigan Flow Cytometry Core. Cells 
were analyzed by Annexin V/PI staining with Annexin V (TFS: cat# A13199) and PI 
(Sigma-Aldrich: cat# 25535-16-4), according to manufacturer’s protocols. 
 
Statistical analysis and reproducibility  
Cell proliferation, migration, and size were analyzed via paired student’s t-test. 
Immunoblot and immunoprecipitation assays were repeated at least three times in all 
cell lines. All data needed to evaluate the conclusions in the paper are present in the 
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Figure 2.1. mEAK-7 is a lysosomal protein, conserved across eukaryotes, and is required for 
mTOR signaling in human cells. (A) Comparison of eukaryotic mEAK-7 orthologs. (B) Diagram 
depicting the mEAK-7 N-myristoylation motif and the TLD (TBC/LysM associated) domain. (C) 
Immunoblot screen of human cell lines to detect mEAK-7 protein. (D, E) Confocal microscopy 
analysis of H1299 cells stably expressing HA-mEAK-7WT for HA and LAMP2 (D) or LAMP1 (E). 
White bar denotes 10 μm. (F) H1975 cells were treated with control or 3 unique mEAK-7 
siRNAs to assess S6 phosphorylation. (G) H1975, MDA-MB-231, and H1299 cells were treated 
with control or 2 unique mEAK-7 siRNAs to assess S6 phosphorylation. (H) Cells were treated 
with control or mEAK-7 #1 siRNA to assess 4E-BP1 phosphorylation. (I) Cells were treated with 
control or 2 unique mEAK-7 siRNAs. Next, cells were starved in DMEM-AAs for 2 hours and 
AAs, insulin, or both were reintroduced for 30 min. (J) Cells were treated with control, mEAK-7 
#1, S6K1, and S6K2 siRNA. Next, cells were starved in DMEM+AAs for 2 hours and insulin 
(1μM and 10 μM) were reintroduced for 30 min. All experiments were repeated at least 3 times. 























Figure 2.2. Overexpression of mEAK-7 activates mTOR signaling and the TBC/LysM-
Associated Domain and mTOR-binding (MTB) domain are necessary for mEAK-7 function. (A) 
H1975, MDA-MB-231, H1299, and HEK-293T cells were transduced with pLenti-III-HA-Control 
vector or pLenti-III-HA-mEAK-7-WT and selected with puromycin for 2 weeks. 1,000,000 cells 
were grown for 48 hours in 60 mm TCPs and collected for immunoblot analysis. (B) Design of 
the deletion mutants from HA-mEAK-7WT (wild-type); HA-mEAK-7G2A (G2A mutation), HA-
mEAK-7ΔNDEL1 (Δ1-139 AAs), HA-mEAK-7ΔNDEL2 (Δ135-267 AAs), HA-mEAK-7ΔTLD 
(Δ243-412 AAs), and HA-mEAK-7ΔCDEL (Δ413-456 AAs). H1299 cells were transduced to 
stably express these mutant proteins. (C—H) Confocal microscopy analysis of H1299 cells 
stably expressing (C) HA-mEAK-7WT, (D) HA-mEAK-7G2A, (E) HA-mEAK-7ΔNDEL1, (F) HA-
mEAK-7ΔNDEL2, (G) HA-mEAK-7ΔTLD, and (H) HA-mEAK-7ΔCDEL to stain for HA and 
LAMP2. White bar denotes 10 μm. (I) H1299 cells stably expressing HA-mEAK-7WT and 
mutants were starved in DMEM-AAs for 2 hours. Subsequently, amino acids and insulin were 
reintroduced for 30 min. (J) Under the same conditions in (I), HA-mEAK-7ΔTLD and HA-mEAK-
7ΔCDEL cells were assessed for (Thr389) p-S6K1 levels. All experiments were replicated at 




















Figure 2.3. mEAK-7 is required for lysosomal localization of mTOR. (A) H1299 cells were 
treated with control or mEAK-7 siRNA for 48 hours in 10% serum-containing DMEM medium. 
Subsequently, 200,000 cells were transferred to 2-well glass chamber slides and allowed to 
settle for 24 hours. H1299 cells were then starved in DMEM-AAs for 1 hour and AAs and insulin 
were reintroduced for 30 min. (B) Immunoblot analysis of H1299 cells treated with control or 
mEAK-7 siRNA to assess the expression of mEAK-7 and mTOR complex proteins after mEAK-7 
knockdown. (C) Statistical analysis of co-localization of mTOR and LAMP2 for Figure 2.3.A. (D) 
200,000 normal H1299 cells or H1299 cells stably expressing HA-mEAK-7 were seeded to 2-
well glass chamber slides and allowed to settle for 24 hours. Cells were then starved in DMEM-
AAs for 1 hour and AAs and insulin were reintroduced for 30 min. (E, F) Statistical analysis of 
co-localization of mTOR and LAMP2 or HA-mEAK-7 and LAMP2 for Figure 2.3.D. 100x oil 
magnification. Cells were processed to detect DAPI (DNA), LAMP2 (lysosomal marker), mTOR, 
and HA (mEAK-7). *P<0.01, **P<0.001, ***P<0.0001, ‡P<0.00001, §P<0.000001, 






















Figure 2.4. mEAK-7 interacts with mTOR through the MTB domain and is required for S6K2 
activity. (A) HA-mEAK-7WT cells immunoprecipitated with goat IgG or goat anti-HA. (B) H1299 
cells, in CHAPs, immunoprecipitated with anti-mEAK-7. (C) H1299 cells transfected with control 
or mEAK-7 siRNA, in CHAPs, immunoprecipitated with anti-mEAK-7. (D) Normal H1299 or HA-
mEAK-7WT cells, in CHAPs, immunoprecipitated with anti-HA. (E) HA-mEAK-7WT cells starved in 
DMEM-AAs for 2 hours, nutrient stimulated for 30 min, immunoprecipitated with anti-HA. (F) 
H1299 cells starved in DMEM-AAs for 2 hours, nutrient stimulated for 60 min, immunoprecipitated 
with anti-mEAK-7. (G) Conditions mimicked in (E), immunoprecipitated with anti-mTOR 
antibody. (H) HA-mEAK-7WT, HA-mEAK-7ΔTLD, and HA-mEAK-7ΔCDEL cells immunoprecipitated 
with anti-HA. (I, J) H1299 cells transfected with pcDNA3-HA-S6K2-WT and control, mEAK-7 #1, 
or mEAK-7 #2 siRNA, immunoprecipitated with anti-HA. (K, L) H1299 cells transfected with 
pRK7-HA-S6K1-WT and control, mEAK-7 #1, or mEAK-7 #2 siRNA, immunoprecipitated with 
anti-HA. (M) mTOR targeting hydrophobic motif. H1299 cells transfected with pcDNA3-HA-
S6K2-WT and control or mEAK-7 #1 siRNA. Cells starved in DMEM-AAs for 2 hours, 10% serum 
stimulated, immunoprecipitated with anti-HA. (N) H1299 cells transfected with control or mEAK-























Figure 2.5. mEAK-7 is essential for cell proliferation and cell migration. (A—D) (A) H1975 
(n=13), (B) MDA-MB-231 (n=9), (C) H1299 (n=8), and (D) HEK-293T (n=6) cells treated with 
control or mEAK-7 #1 siRNA. 200,000 cells transferred to 100 mm TCPs and counted at day 3 
and 5. (E—H) (E) H1975 (n=6), (F) MDA-MB-231 (n=6), (G) H1299 (n=6), and (H) HEK-293T 
(n=6) cells were transduced with pLenti-III-HA-Control vector or pLenti-III-HA-mEAK-7-WT. 
200,000 cells were transferred to 100 mm TCPs and counted at day 3 and 5. (I—L) (I) H1975 
(n=6), (J) MDA-MB-231 (n=5), (K) H1299 (n=5), and (L) HEK-293T (n=6) cells were treated with 
control or mEAK-7 #1 siRNA. 50,000 cells were transferred to CIM 16-well plates and real-time 
analysis was performed for 48 hours using ACEA Bioscience’s RCTA DP instrument. (M—P) 
(M) H1975, (N) MDA-MB-231, (O) H1299, (P) HEK-293T cells were treated with control or 
mEAK-7 siRNA. 1,500,000 cells were transferred into 35 mm TCPs. The following day, a 
scratch is created down the middle and pictures were taken at 0 and 48 hours. White bar 
denotes 125 μm. Data are represented as mean ± SEM. Statistical significance denoted: 























Figure 2.6. Overexpression of constitutively activated S6K2 or S6K1 is capable of rescuing cell 
defects due to mEAK-7 knockdown. (A) H1975 cells were treated with control, S6K1, S6K2, or 
eIF4E siRNA. (B) From (A), 500,000 cells were transferred to 100 mm TCPs and counted at day 
3 and 5. (C—E) (C) H1975 (n=13), (D) MDA-MB-231 (n=9), and (E) H1299 (n=8) cells were 
treated with control or mEAK-7 siRNA. 500,000 cells were transferred to 100 mm TCPs and cell 
size was analyzed at day 3 with AO-PI staining via Logos Biosystems. (F) H1975 cells were 
treated with control, S6K1, or S6K2 siRNA and analyzed for forward scatter via flow cytometry. 
(G) H1299, H1975, and MDA-MB-231 cells were transiently transfected with control siRNA, 
mEAK-7 siRNA, mEAK-7 siRNA + pRK7-HA-S6K1-F5A-E389-deltaCT plasmid, or mEAK-7 
siRNA + pcDNA3-HA-S6K2-E388-DE plasmid. (H) 500,000 H1299 cells treated as described in 
(G) were transferred to 100 mm TCPs and counted at day 3 and 5 via Logos Biosystems. (I) 
Diagram depicting mEAK-7 function on mTOR complex formation for S6K2. (J) Summary of 
mEAK-7 domains: N-myristoylation motif, TLD domain, and mTOR-binding (MTB) domain. Data 
are represented as mean ± SEM. Statistical significance denoted: *P<0.01, **P<0.001, 






















Figure 2.7. T-coffee analysis of mEAK-7 in eukaryotes, validation of human mEAK-7 antibody, 
and an expanded cell screen for mEAK-7 protein. (A) T-Coffee analysis of mEAK-7 primary 
protein structure across human, mouse, frog, zebrafish, nematode, and fruit fly. (B) Analysis of 
mouse monoclonal antibody clone 12B1 targeting mEAK-7. Normal HEK-293T or HEK-293T 
cells stably expressing exogenous mEAK-7 protein were probed with anti-mEAK-7 antibody. 
H1299 cells were treated with control or mEAK-7 siRNA and probed with anti-mEAK-7 antibody. 
(C) Cell screen of breast carcinoma and head & neck squamous cell carcinoma cell lines. (1) 
BT474, (2) HCC1937, (3) MDA-MB-436, (4) SK-BR-3, (5) SUM149, (6) SUM159, (7) T4D7, (8) 
MDA-MB-468, (9) UM-SCC-1, (10) UM-SCC-10A, (11) UM-SCC-11A, (12) UM-SCC-14A, (13) 
UM-SCC-17A, (14) UM-SCC-17B, (15) UM-SCC-74A, (16) UM-SCC-74B, and (17) UM-SCC-


























Figure 2.8. Extended immunofluorescence analysis of HA-mEAK-7WT in other cellular 
compartments. (A) H1299 cells stably expressing HA-mEAK-7WT were stained with HA 
antibody and early endosome antigen-1 (EEA1, endosome) antibody. (B) H1299 cells stably 
expressing HA-mEAK-7WT were stained with HA antibody and apoptosis inducing factor (AIF, 
mitochondria) antibody. (C) H1299 cells stably expressing HA-mEAK-7WT were stained with HA 
antibody and protein disulfide isomerase (PDI, endoplasmic reticulum) antibody. (D) H1299 cells 
stably expressing HA-mEAK-7WT were stained with HA antibody and receptor-binding cancer 
antigen expressed on SiSo cells (RCAS1, Golgi complex) antibody. Experiments were 























Figure 2.9. Validation of mEAK-7 antibody for immunofluorescence analysis of endogenous 
mEAK-7 at the lysosome. Polyclonal goat antibody SCB cat# sc-247321 was utilized for anti-
mEAK-7 immunofluorescence analysis. (A) H1299 cells stably expressing HA-mEAK-7WT were 
grown under 10% serum DMEM+AAs, fixed, and stained with (left panel) anti-mEAK-7, anti-HA 
mouse, and anti-LAMP1 or (right panel) anti-mEAK-7, anti-HA rabbit, and anti-LAMP2. (B) 
H1299 cells were treated with control or mEAK-7 siRNA for 48 hours under 10% serum 
DMEM+AAs and stained with anti-mEAK-7. (C) H1299 cells were cultured under 10% serum 
DMEM+AAs and stained with (left panel) anti-mEAK-7 and anti-LAMP1, (middle panel) anti-
mEAK-7 and anti-LAMP2, or (right panel) anti-LAMP1 and anti-LAMP2. Experiments were 
replicated at least three times. Images were captured with 100x oil confocal microscopy. White 





















Figure 2.10. mEAK-7 regulates serum-mediated activation of mTORC1 signaling and 
knockdown of mEAK-7 results in increased (Thr389) p-S6K1 levels. (A) H1299 cells were 
treated with control or mEAK-7 siRNA for 48 hours in 10% serum-containing DMEM medium. 
Subsequently, cells were starved in DMEM+AAs for 2 hours and 20% serum-containing DMEM 
medium was reintroduced for up to 24 hours to assess S6 and 4E-BP1 activation status. (B) 
H1299 cells were treated with control or mEAK-7 #1 siRNA for 48 hours in 10% serum-
containing DMEM medium. Subsequently, cells were starved in DMEM+AAs for 2 hours and 
AAs and insulin were reintroduced for the course of 8 hours to assess 4E-BP1 activation status. 
(C) H1975, MDA-MB-231, H1299, and HEK-293T cells were analyzed via immunoblot analysis 
for comparing relative protein levels of mEAK-7. (D) H1975 cells were treated with control or 
one of six unique mEAK-7 siRNAs for 48 hours in 10% serum-containing DMEM medium. 
Experiments were replicated at least three times. ImageStudioLite and Microsoft Excel software 







Figure 2.11. Densitometry analysis of Figure 2.1 (I). Densitometry analysis of Figure 2.1.I for 
(A) H1975 cells, (B) MDA-MB-231 cells, (C) H1299 cells, and (D) HEK-293T cells. A.U. 





Figure 2.12. Densitometry analysis of Figure 2.1 (J). Densitometry analysis of Figure 2.1.wJ for 
(A) H1975 cells, (B) MDA-MB-231 cells. (C) H1299 cells, and (D) for HEK-293T cells. A.U. 














Figure 2.13. Immunofluorescence analysis of endogenous mEAK-7 co-localizing with 
endogenous mTOR in response to nutrients and immunoprecipitation analysis of HA-mEAK-7 
mutants for mTOR interaction. (A) H1299 cells were starved in DMEM-AAs for 1 hour and 
stained with anti-mEAK-7 and anti-mTOR. (B) H1299 cells were starved in DMEM-AAs for 1 
hour. After reintroducing AAs for 1 hour, cells were stained with anti-mEAK-7 and anti-mTOR. 
(C) H1299 cells were starved in DMEM-AAs for 1 hour. After reintroducing insulin for 1 hour, 
cells were stained with anti-mEAK-7 and anti-mTOR. (D) H1299 cells were starved in DMEM-
AAs for 1 hour. After reintroducing AAs and insulin for 1 hour, cells were stained with anti-
mEAK-7 and anti-mTOR. (E) Statistical analyses of A-D. Experiments were replicated at least 
three times. Images were captured with 100x oil confocal microscopy. Images were analyzed 
with Imaris Software. *P<0.01, **P<0.001, ***P<0.0001, ‡P<0.00001, §P<0.000001. White bar 
denotes 25 μm. (F) H1299 cells stably expressing HA-mEAK-7 WT or mutants were starved in 
DMEM-AAs. After reintroducing AAs and insulin for 1 hour, cells were immunoprecipitated with 
goat anti-HA antibody. (G) Densitometry analysis of Figure S 2.7.F. A.U. represents arbitrary 























Figure 2.14. Densitometry analysis of Figure 4. Densitometry analysis of (A) Figure 2.4.C, (B) 
Figure 2.4.E, (C) Figure 2.4.F, (D) Figure 2.4.G, (E) Figure 2.4.H, (F) Figure 2.4.I, (G) Figure 
2.4.J, (H) Figure 2.4.K, (I) Figure 2.4.L, and (J) Figure 2.4.N. A.U. represents arbitrary units. 

























Figure 2.15. Knockdown of mEAK-7 does not result in enhanced cell apoptosis, but increases 
cell size. (A) 500,000 H1975 cells were seeded into 60 mm tissue culture plates (TCPs) and 
treated with 100 nM control or mEAK-7 siRNA for 48 hours. Subsequently, 500,000 siRNA 
treated cells were seeded into 100 mm TCPs and grown for 5 days. Next, 1,000,000 cells were 
processed for flow cytometric analysis and stained for PI and AnnexinV. (B) Percentages were 
mapped out according to PI-/AnxV-, PI-/AnxV+, PI+/AnxV+, and PI+/AnxV-. n=3 for H1975. (C) 
Cell viability assay of H1975, MDA-MB-231, and H1299 cells by AO/PI staining on the 
automated cell counter Logos Biosystems. Student’s t-test was used for statistical analysis. 
(D—F) (D) H1975, (E) MDA-MB-231, and (F) H1299 cells were treated with control or mEAK-7 
siRNA #1 for 48 hours in 10% serum-containing DMEM medium. Subsequently, 500,000 cells 
were transferred to 100 mm tissue culture plates and cell size was analyzed at day 3 via the 












PCR 1: NMYRF1 (Forward), Insert Reverse 1 (Reverse) 
NMYRF1: 
atatcaacaagtttgtacaaaaaagttggcatgGCAaacagcagaagccgtgtggggcgg 
Insert Reverse 1: 
ccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatactttctcggcag 
PCR 2: Vector Forward 1 (Forward), NMYRF1 (Reverse) 







PCR 3: NDEL1bF (Forward), Insert Reverse 1 (Reverse) 
NDEL1bF: 
tcaacaagtttgtacaaaaaagttggcatggtgctaagccacagacaggagctgagaggc 
Insert Reverse 1: 
ccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatactttctcggcag 
PCR 4: Vector Forward 1 (Forward), NDEL1bR (Reverse) 








PCR 5: NDEL2F (Forward), Insert Reverse 1 (Reverse) 
NDEL2F: 
gaagtccaaaagtttacagaggatctggttctgctcttttcgtctgagctccatggacac 
Insert Reverse 1: 
ccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatactttctcggcag 
PCR 6: Vector Forward 1 (Forward), NDEL2R (Reverse) 







PCR 7: TLDF1 (Forward), Insert Reverse 1 (Reverse primer) 
TLDF1: 
ctgcctcgggagcagcggcaccgctggcgcgacccctcagaggagcagttggccaagggc 
Insert Reverse 1: 
ccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatactttctcggcag 
PCR 8: Vector Forward 1 (Forward), NDEL2R (Reverse) 








PCR 9: CDEL1F: (Forward), Insert Reverse 1 (Reverse) 
CDEL1F: 
tttgataagatggaggtgtgggcggttggatgcccaactttcttgtacaaagtggttgat 
Insert Reverse 1: 
ccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatactttctcggcag 
PCR 10: Vector Forward 1 (Forward), CDEL1R (Reverse) 





Full Sequence of HA-mEAK-7WT Plasmid Based off of NCBI Accession # BC060844. 
 
Extended materials and methods for cloning: 
Primers are 60 mers and have a melting temperature optimized for 72°C. All 
primers were purchased from Thermo Fisher Scientific. PCR. Q5® Hot Start High-
Fidelity DNA Polymerase was used (NEB; cat# E0555L) in accordance to manufacturer 
specifications. Gibson assembly reaction (GAR). The PCR products were quantified to 
have the correct picomolar concentration and ratio necessary for an optimized GAR 
protocol. Please visit the New England Biolabs website to see their recommendation for 
concentration ratios. Optimized cloning efficiency is 50–100 ng of vectors (larger 6 kb 
PCR fragments) with 2–3 fold molar of excess inserts (smaller 4 kb PCR fragments). 
We incubated samples in a thermocycler at 50°C for 60 min and stored at -20°C to be 
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used for downstream bacterial transformation. Bacterial transformation. We utilized One 
Shot® MAX Efficiency® DH5α™-T1R Competent Cells (TFS; cat # 12297-016), 
following their protocol for transformation. Thawing DH5α cells on ice, we placed 50 μL 
of bacteria, added 2 μL of diluted GAR product (diluted 1:4) in a 1.5 mL microfuge tube 
and placed the mixture on ice for 30 min. Next, we heat shocked the bacteria at 42°C 
for 30 seconds, placed the sample on ice for 2 min and added 950 μL Super Optimized 
Conditioned medium in a 37°C incubator, rotating at 250 rpm for 45 min. Next, we 
spread 50 μL of transformed bacteria onto LB plates with 50 μM kanamycin (FS: cat# 
50-990-246); that was grown for 16 hours at 37°C. Afterwards, 5-7 clones were selected 
and grown in LB medium with 50 μM kanamycin grown overnight at 37°C and 
miniprepped (Qiagen) for DNA sequencing at the DNA Sequencing Core at the 
University of Michigan and lentiviral supernatant production. Lentiviral production and 
stable transduction of cells. We sent HA-mEAK-7 mutant constructs to the Vector Core 
at the University of Michigan to create 1X lentiviral supernatants to treat H1299 cells for 
stable expression. We infected 500,000 H1299 cells with 1X or 10X lentiviral 
supernatant for (HA-mEAK-7WT, HA-mEAK-7ΔG2A, HA-mEAK-7ΔNDEL1, HA-mEAK-
7ΔNDEL2, HA-mEAK-7ΔTLD, and HA-mEAK-7ΔCDEL) in a 60 mm TCP in 10% serum-
containing DMEM medium. After 24 h, we split cells and placed all cells in a T-75 tissue 
culture flask with 1 μg/mL puromycin in 10% serum-containing DMEM medium. We 
replenished with puromycin containing medium every 24 hours. After two weeks, we 
confirmed mutants via immunoblot and confocal microscopy. HA-mEAK-7 plasmid is the 
KIAA1609 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) and was 
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 Chapter 3 – mEAK-7 forms an alternative mTOR complex with DNA-PK to 
promote radiation resistance in human cancer 
 
Summary  
Mammalian EAK-7, or MTOR associated protein, eak-7 homolog (mEAK-7), 
activates mTOR signaling in human cells. mEAK-7 forms an alternative mTOR complex 
to regulate S6K2 and 4E-BP1. However, the molecular roles of mEAK-7 in human 
cancer has not yet been identified. We demonstrate mEAK-7 and mTOR signaling were 
strongly elevated in lung tumor and metastatic lymph nodes of NSCLC patients 
compared to normal lung or lymph tissue. CD44+/CD90+ cancer stem cells showed 
more mEAK-7 and activated mTOR signaling. mEAK-7 was required for 2D clonogenic 
potential and 3D spheroid formation. mEAK-7 associated with DNA-PK and this 
interaction was increased in response to X-ray irradiation to regulate S6K2 signaling. 
DNA-PK inhibition reduced S6K2, mEAK-7, and mTOR binding with DNA-PK, resulting 
in loss of S6K2 activity and mTOR signaling. mEAK-7 is required for clonogenic 
potential, spheroid formation, and radiation resistance through an alternative mTOR 
signaling pathway involving DNA-PK and S6K2 in human cancer cells. 
 
Introduction  
In chapter 2, we describe the molecular determinants and mechanisms of mEAK-
7 activity, but we did not demonstrate the extent to which it played a role in human 
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development or human disease. In chapter 3, we will begin to investigate the role for 
mEAK-7 in human disease. Aberrant mTOR signaling has been observed in many types 
of human cancer (1). Recently, mEAK-7 (Mammalian EAK-7 or MTOR associated 
protein, eak-7 homolog) was identified as a novel molecular activator of mTOR signaling 
in human cells (12). Interestingly, mEAK-7 exhibits a preferential expression pattern in 
human cancer cell lines (12). While EAK-7 regulates dauer formation and lifespan in C. 
elegans (43), it is unknown the extent to which EAK-7 functions similarly in nematodes 
and mammals in order to regulate TOR/mTOR function.  
mEAK-7 uses the S6K2/4E-BP1 axis to regulate mTOR signaling (12). However, 
S6K2 signaling has not been adequately delineated from that of S6K1 signaling due to 
their assumed functional redundancies (61). Yet, in breast cancer cells, loss-of-function 
studies demonstrate that S6K1 and S6K2 have several different protein targets (100). 
Additionally, canonical models of mTOR complex 1 (mTORC1), the traditional S6K 
regulators, and mTORC2 may not exist similarly in all cell types. As examples of this 
phenomena, a novel mTOR complex that involves GIT1, which is distinct from mTORC1 
and mTORC2 has been identified in astrocytes (42), and ETS Variant 7 is capable of 
binding to mTOR and sustaining mTOR signaling in the presence of rapamycin (103). 
These pivotal findings disrupt conventional ideas regarding the existence of only two 
mTOR complexes, and therefore suggest the possibility of unidentified mTOR 
complexes. 
While it is largely believed that mTOR signaling is suppressed under genotoxic 
stress via AMPK regulation of TSC2 (104), studies have demonstrated aberrant 
activation of mTOR signaling in response to DNA damage. For example, mTORC1 
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signaling inhibits DNA damage response mechanisms in vitro and in vivo through 
RNF168 (105). S6K2 may also function in the DNA damage response, as S6K2 
knockdown results in the strong reduction of mTOR signaling (105). Adding to the 
complexity of the role of mTOR signaling in DNA damage is the observation that CHK1 
function requires mTORC1 signaling in response to DNA damage repair processes, 
suggesting that mTOR signaling supports DNA damage responses (106). Similarly, 
sustained radiation treatment to mice activates mTOR signaling and oxidative stress in 
the intestine (107) and normal tissues undergoing long-term radiation stress exhibited 
activated mTOR signaling in mini pigs (85). Thus, there is a rationale to treat patients 
with a combination of chemotherapeutics and rapamycin due to additive cytotoxic 
effects in breast carcinoma cell lines (108). These studies suggest that mTOR signaling 
and DNA damage repair processes may function synergistically in some biologic 
contexts. The proposed pathways include the downregulation of p53 via S6K-mediated 
activation of MDM2 (109), or 4E-BP1 phosphorylation in response to DNA damage 
(110). Thus, we posit a novel mechanism supporting sustained mTOR signaling after 
genotoxic stress, which may allow enhanced cell survival through radiation resistance. 
Cancer stem cells (CSCs) are known to be radiation resistant and thrive under 
genotoxic stress, but the molecular mechanisms responsible for these observations 
remain unknown (111, 112). CSCs are a self-renewing population of cells within a tumor 
mass (113) and mTOR signaling has been implicated in regulating pancreatic CSC 
viability and self-renewal (114). This suggests that a population of cancer cells utilize 
mTOR signaling to contribute to the survival and pathogenicity of human cancers. Data 
from a medulloblastoma in vivo model of CSCs suggest that PI3K signaling is activated 
 111 
in response to DNA damage, as indicated by S6 regulation, a crucial readout of mTOR 
signaling (115). This substantive evidence suggests that mTOR signaling plays an 
important role in CSC DNA damage response and self-renewal.  
In light of reports that genotoxic stresses are capable of activating mTOR 
signaling, select CSCs were found to demonstrate radiation resistance, and because 
CSCs require mTOR signaling, we sought to determine the extent to which mEAK-7 
contributes to radiation resistance and self-renewal in cancer cells through an 




mEAK-7 protein levels are elevated in metastatic human NSCLC lymph nodes  
Although mEAK-7 protein levels appear to be disproportionately high in human 
cancer cell lines (12), this limited observation does not exclude the possibility that 
mEAK-7 is present in healthy human tissues, since mTOR expression is found in many 
tissue types (98). To gain a better understanding of the expression pattern of mEAK-7 in 
healthy human tissues, we accessed the GTEx database and identified basal-level 
expression of MEAK7 in many human tissues (Figure 3.1.A). The BioGPS database 
also confirmed that MEAK7 is expressed in diverse tissue types (Figure 3.7.A) (116-
118). Thus, future mEAK-7 analyses in healthy tissues are essential during mammalian 
development to understand its role in metabolism. 
To identify MEAK7 genomic alterations in human cancer patients, we accessed 
the cBioPortal database. Genetic modifications in MEAK7 were found to be cancer type-
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dependent and included deletions, copy number amplifications, and mutations (Figure 
3.1.B and 3.1.C). For example, many prostate cancers exhibit MEAK7 deletions, 
whereas breast cancers often sustain substantial MEAK7 gene copy number 
amplification (Figure 3.1.B). Because of these different gene profiles, the search 
parameters were narrowed to include only gain-of-expression and copy number 
amplification. The percentage of patients who demonstrated either of these anomalies 
ranged between 5 and 50% (Figure 3.1.C) (119, 120), demonstrating that MEAK7 
genetic modifications are cancer-type specific and can be observed in several diverse 
human cancers.  
The TCGA cBioPortal revealed high expression of MEAK7 in NSCLC cell lines 
(12) and patients with NSCLC. The Oncomine database was accessed to analyze 
MEAK7 expression patterns in lung carcinomas and were compared to healthy lung 
tissue. Through two different lung cancer studies, MEAK7 was found to be highly 
expressed in many non-small cell lung carcinomas (NSCLC) and small cell lung 
carcinomas, compared to normal lung tissue, suggesting that MEAK7 may play a role in 
lung tumorigenesis (Figure 3.1.D and 3.1.E) (121). Additionally, there was an 
association between MEAK7 expression and cancer patient outcomes. Patients who 
had died from ductal breast carcinoma (P=2.72x10-6, Fold Change: 2.136) and acute 
myeloid leukemia (P=7.99x10-5, Fold Change: 2.655) had enhanced MEAK7 expression 
(Figure 3.7.B and 3.7.C) (24). Thus, the MEAK7 expression profile in cancer patients 
may provide insight into predicting patient prognosis and survival. 
In a screen of human squamous cell carcinomas, the UM-SCC-17A cell line 
(122), derived from the primary laryngeal cancer site of a 48-year-old female patient, did 
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not express detectable levels of mEAK-7 protein. Interestingly, the UM-SCC-17B cell 
line, derived from a metastatic site from the same patient, did express mEAK-7 (12). 
These findings suggest that increased expression of mEAK-7 may be associated with 
tumor metastasis. To test the hypothesis that elevated mEAK-7 protein levels are 
associated with metastasis, lymph nodes of cancer patients were compared to healthy 
lung tissues, healthy lymph tissues, or primary tumors of patients. A NSCLC tissue 
microarray containing thirty individual pathologist-graded, patient-matched sections of 
primary tumors, as well as their normal adjacent tissue, and metastatic lymph nodes 
were stained and analyzed. mEAK-7 and (Ser240/244) p-S6 protein levels were 
significantly increased in the primary human tumor as opposed to normal adjacent 
tissue (Figure 3.2.A-3.2.C). Further, mEAK-7 and (Ser240/244) p-S6 protein levels were 
significantly greater in the metastatic lymph nodes as compared to both primary tumor 
and normal adjacent tissue (Figure 3.2.A-3.2.C). In contrast, comparatively healthy adult 
lymph tissue did not yield substantial mEAK-7 or (Ser240/244) p-S6 protein levels (Figure 
3.8.A).  
While Oncomine databases demonstrate that higher MEAK7 expression is 
associated with poor patient prognoses (Figure 3.7.B and 3.7.C), direct evidence has 
not yet been procured. Therefore, to investigate the association of higher mEAK-7 
protein levels with poor patient prognoses, a lung adenocarcinoma tissue microarray 
detailing patient survival data was stained with antibodies targeting endogenous mEAK-
7 and (Ser240/244) p-S6. A Kaplan-Meier Survival Curve analysis illustrated that mEAK-7 
protein levels were strongly associated with poor patient prognosis, specifically in 
patients with relapse following surgical intervention (Figure 3.2.D).  
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Because mEAK-7 protein levels were highly expressed in metastasized lymph 
nodes, we tested the extent to which mEAK-7 is required for cell invasion in vitro. To 
test this, H1975 cells were treated with control or mEAK-7 siRNA for 48 hours and 
50,000 cells were seeded into invasion chambers for 24 hours. Results showed a 
statistically significant reduction in cell invasion after 24 hours (Figure 3.2.E). Thus, 
mEAK-7 may be a clinically actionable biomarker for patients with metastatic NSCLC.  
 
Cancer stem cells exhibit high protein levels of mEAK-7 and mTOR signaling
 mEAK-7 is a strong, positive regulator of mTOR signaling (12) and several 
groups have demonstrated that mTOR signaling is essential for CSC self-renewal (114) 
and radiation resistance (123). Therefore, we hypothesized that mEAK-7 is differentially 
expressed in the CSC versus non-CSC populations. Because the majority of information 
on human mEAK-7 has been demonstrated in NSCLC cell lines H1975 and H1299, we 
sought to determine the expression profile of mEAK-7 and mTOR signaling in NSCLC 
CSCs. These cells are best identified as being CD44+ (124) and CD90+ (125); as a 
result, H1299 cells were subjected to fluorescence-activated cell sorting (FACS) for the 
aforementioned markers. CD44+/CD90+ cells, representing 1% of all cells sorted, were 
analyzed for mEAK-7 and mTOR signaling (Figure 3.3.A). Immunoblot analysis 
demonstrated that CD44+/CD90+ cells, when compared to CD44-/CD90-, yielded 
greater protein levels of mEAK-7 and S6K2, as well as mTOR signaling activation via p-
S6 and p-4E-BP1 (Figure 3.3.B). The CD44+/CD90+ cell population expressed n-
cadherin (Figure 3.3.B), which is known as an essential component of the epithelial-
mesenchymal transition (EMT) state in CSCs (126). These results demonstrate that 
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there is a selective expression profile of mEAK-7 and S6K2 in human cancer, but more 
specifically in the self-renewing cancer cell population that display a CD44+/CD90+ 
phenotype. 
 
mEAK-7 is necessary for clonogenic potential and spheroid formation in human 
cancer cells 
To test the hypothesis that mEAK-7 impacts the survival of cells after X-ray 
irradiation damage, a 2D clonogenicity assay was used to assess the surviving fraction 
of cancer cells after radiation damage (127, 128). H1299 and H1975 cells were treated 
with control or mEAK-7 siRNA for 48 hours, then subjected to no treatment or X-
irradiated with 2 gy or 6 gy, reseeded into new 60 mm tissue culture plates and allowed 
to grow for 10 days. Clonogenic potential was significantly decreased after mEAK-7 
knockdown, and was further exacerbated after 2 gy and 6 gy X-ray irradiation in both 
H1299 and H1975 cells (Figure 3.3.C-3.3.H). Similar results were observed at higher 
cell seeding densities (Figure 3.8.B) demonstrating that mEAK-7 enhances the 
clonogenic potential of human cancer cells in response to DNA damage.  
While 2D assays measuring clonogenic potential demonstrate the essential role 
of mEAK-7 in the DNA damage response, 3D assays better simulate in vivo conditions. 
The spheroid forming assay is a widely accepted experimental strategy to identify stem 
cell self-renewal in mammalian cell systems in vitro and in vivo (129). Specifically, 
CSCs are the principal cancer cell population responsible for spheroid formation (130). 
Thus, to test the effect of mEAK-7 on spheroid size and formation, H1975 cells were 
treated with control or mEAK-7 siRNA for 48 hours, subjected to no treatment or 2 gy 
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and 6 gy X-ray irradiation, and then seeded in ultra-low attachment dishes for 1 week. 
mEAK-7 knockdown resulted in a dramatic reduction of spheroid size with no treatment, 
2 gy, and 6 gy treatment (Figure 3.4.A). Additionally, the gross number of spheroids 
formed was significantly reduced after mEAK-7 knockdown, and even further reduced 
following 2 gy or 6 gy X-ray irradiation treatment (Figure 3.4.B). Similar results were 
observed when H1975 cells were seeded at a lower density (Figure 3.9). These results 
collectively indicate that mEAK-7 plays a significant role in cancer cell spheroid 
formation.  
 
mEAK-7 is necessary for chemo-resistance, radiation-resistance, and sustained 
DNA damage-mediated mTOR signaling in human cancer cells 
While X-ray irradiation is a potent inducer of the DNA damage response 
pathway, we hypothesized that other forms of genotoxic stress may be capable of 
regulating mEAK-7. Cisplatin, a chemotherapeutic drug that which forms DNA adducts, 
is often used to treat patients with solid tumors. However, following initial tumor 
regression, a fraction of solid tumors become chemoresistant (131). mTOR signaling 
can be activated during cisplatin treatment of ovarian cancer cells over time, as 
measured by enhanced (Thr389) p-S6K1 levels (132). Since mEAK-7 is required for 
mTOR signaling, we tested the hypothesis that mEAK-7 responds to cisplatin treatment 
as an essential modulator of mTOR signaling after genotoxic stress. To test the extent 
to which genotoxic stress modifies mEAK-7 activity, H1299 cells were treated with 
mEAK-7 siRNA for 48 hours. Next, these cells were treated with either DMSO or 10 μM 
cisplatin for 4 or 8 hours. Under these conditions, mEAK-7 protein levels were increased 
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in response DNA damage by cisplatin treatment and that mEAK-7 was required for 
regulation of (Ser65) p-4E-BP1, an indicator of mTOR signaling (Figure 3.4.C). 
Therefore, cisplatin is capable of regulating mEAK-7-mediated mTOR signaling. 
 
mEAK-7 knockdown impairs the DNA damage response and enhances noxa 
levels after X-ray irradiation  
CSCs utilize many mechanisms to promote radioresistance in response to 
cancer therapies (133). To determine the role of X-ray irradiation on mEAK-7 and the 
DNA damage response, H1975 cells were treated with control or mEAK-7 siRNA, and 
X-irradiated with 20 gy for up to 2 hours. Subsequently, immunoblot analyses was 
performed. H1975 cells treated with mEAK-7 siRNA exhibited in a dramatic increase in 
noxa levels (Figure 3.4.D). Noxa is upregulated in response to DNA damage, which 
ultimately leads to cellular apoptosis (134) suggesting that mEAK-7 plays a role in the 
DNA damage response and cancer cell survival. 
The comet assay is used to quantify intracellular DNA damage resulting from an 
insufficient DNA damage repair response in eukaryotic cells (135). H1299 and H1975 
cells were independently embedded in an agarose gel and lysed, thereby releasing 
intracellular DNA. During gel electrophoresis, DNA fragments migrate towards the 
anode, resulting in a “comet” pattern with a trail of DNA fragments, such that a longer 
trail signifies more DNA damage (136). Due to the dramatic results from radiation 
treatment with mEAK-7 knockdown in the clonogenicity (Figure 3.3.C-3.3.H) and 
spheroid assays (Figure 3.4.A and 3.4.B), we hypothesized that mEAK-7 plays a crucial 
role in the DNA damage repair pathways. The visualization of DNA strand migration, 
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and subsequent quantification of that migration, allowed us to predict the relative levels 
of the DNA repair response. H1299 and H1975 cells were treated with control or mEAK-
7 siRNA and subjected to no treatment, 2 gy, and 6 gy X-ray irradiation for 30 minutes. 
Comet pattern formations, quantified as tail DNA %, were enhanced in H1299 and 
H1975 cells treated with mEAK-7 siRNA and X-ray irradiation (Figure 3.4.E-H) 
suggesting mEAK-7 is necessary for the DNA repair response in these cancer cells.  
 
mEAK-7 interacts with DNA-PK in response to X-ray irradiation damage 
To determine the extent to which mEAK-7 regulates genotoxic activation of 
mTOR signaling, we sought to identify novel interacting partners of mEAK-7 by 
transducing H1299 cells with a lentivirus expressing pLenti-GIII-HA(c-term)mEAK-7. 
Through HA-mEAK-7 immunoprecipitation and mass spectrometry analysis, a list of 
proteins that potentially interact with exogenously expressed mEAK-7 was generated 
(Table S 3.1). DNA-dependent protein kinase catalytic subunit isoform 1 (DNA-PKcs) 
scored highest with 241 exclusive spectral counts and 36% protein coverage (Figure 
3.5.A). Thus, we posited that mEAK-7 regulates mTOR signaling, in part, through the 
interaction with DNA-PK.  
Protein lysates were harvested from H1299 cells stably transduced with HA-
mEAK-7 and immunopreciptation experiments confirmed the IP-mass spectrometry 
results to demonstrate that exogenous mEAK-7 interacts with endogenous DNA-PK 
(w3.5.B). Under ultraviolet B irradiation, DNA-PK has been shown to interact with 
mTOR kinase and SIN1 to affect mTORC2 signaling in epithelial skin keratinocytes, but 
the molecular rationale for this interaction remains elusive (137). Furthermore, nuclear 
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DNA-PK transverses to the cytosol in response to DNA damage (137). This ability to 
travel to the cytoplasm and evidence that DNA-PK can activate metabolism-related 
genes, suggest a novel role for DNA-PK in metabolic signaling. Thus, knowing that 
DNA-PK is capable of interacting with mTOR after DNA damage and that mEAK-7 
interacts with mTOR (12), we sought to determine if mEAK-7 forms a complex with 
DNA-PK. H1299 cells stably expressing HA-mEAK-7 were subjected to no treatment or 
X-irradiated with 10 gy for 30 and 60 minutes, and results revealed that mEAK-7 
increasingly interacted with DNA-PK over time in response to DNA damage (Figure 
3.5.C). These data suggest that mEAK-7 associates with DNA-PK in response to DNA 
damage.  
Since mEAK-7 is required for the mTOR-S6K2 axis (12), potential interaction 
between DNA-PK and S6K2 was tested to determine if both mEAK-7 and DNA-PK are 
part of a complex that regulates mTOR signaling. H1299 cells were transiently 
transfected with pcDNA3-HA-S6K2-WT, then X-irradiated at 10 gy for 1 hour, and HA-
S6K2 was immunoprecipitated. X-ray irradiation considerably increased the interaction 
between DNA-PK and HA-S6K2, but had little-to-no influence on mTOR and HA-S6K2 
interaction (Figure 3.5.D). Thus, DNA-PK is capable of interacting with S6K2 to regulate 
its function in response to DNA damage. To determine if S6K2 is required for mTOR 
signaling under X-ray irradiation, H1975 cells were treated with controls or two unique 
S6K1, or S6K2 siRNAs. Under these conditions, (Ser240/244) p-S6 levels were abrogated 
after S6K2 knockdown (Figure 3.10) suggesting that S6K2 is necessary for sustained 
S6 phosphorylation in response to DNA damage.  
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To determine if mTOR is required for mEAK-7-mediated DNA-PK function and 
interaction, mTOR was knocked down with two different mTOR siRNAs, which resulted 
in a dramatic reduction of DNA-PK interaction with endogenous mEAK-7 (Figure 3.5.E). 
This collective evidence links mEAK-7 to the major metabolic sensor, mTOR, and the 
crucial DNA-damage repair regulator, DNA-PK. 
While we established the function of mEAK-7 in mTOR signaling under nutrient 
conditions (12), the role of mEAK-7 in mTOR signaling under genotoxic stresses is 
unknown. To test the hypothesis that mEAK-7 is required for mTOR activation after 
DNA damage, H1299 and H1975 cells were treated with control or mEAK-7 siRNA for 
48 hours in DMEM with 10% FBS. Two different conditions were compared: 1 hour 
nutrient starvation with 30 minute nutrient replenishment was compared to X-ray 
irradiation at 10 gy for 30 minutes. Under these conditions, mEAK-7 was also capable of 
regulating X-ray irradiation induced activation of mTOR signaling in NSCLC (Figure 
3.5.F). Next, we posited that mEAK-7 was required for S6K2 phosphorylation and 
activation after X-ray irradiation. H1975 cells were treated with control or mEAK-7 
siRNA for 48 hours and treated with 10 gy X-ray irradiation for 1 hour. IP of endogenous 
S6K2 demonstrated that mEAK-7 knockdown resulted in a dramatic decrease in X-ray 
irradiation-mediated S6K2 phosphorylation (Figure 3.5.G).  
Finally, to test the extent to which DNA-PK activity is required for S6K2 function, 
H1299 and H1975 cells were treated with either DMSO or NU7441, a highly specific 
chemical inhibitor of DNA-PK, at 5 µM for 2 hours under freshly stimulated 10% FBS 
medium. NU7441 is 1000x more specific for DNA-PK than PI3K and 200x more specific 
for DNA-PK than mTOR. DNA-PK inhibition resulted in a substantial decrease in 
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S6K2/mTOR/DNA-PK binding, S6K2 functional activity, and a reduced ability to 
phosphorylate (Ser240/244) p-S6 (Figure 3.5.H). These results suggest that mEAK-7 
physically links DNA-PK and S6K2 to mTOR signaling. 
 
mEAK-7 is required for sustained IR-mediated mTOR signaling in human cancer 
cells and loss of mEAK-7 results in enhanced PARP cleavage  
There are some examples that describe sustained mTOR signaling through DNA 
damage as a modulator of self-renewal and radiation resistance (138). To test the 
hypothesis that mEAK-7 is necessary for sustained X-ray irradiation-mediated mTOR 
signaling, H1299 and H1975 cells were treated with control or mEAK-7 siRNA for 48 
hours in DMEM with 10% FBS, then X-irradiated at 10 gy for 30 minutes, 2 hours, and 8 
hours. H1299 and H1975 cells treated with mEAK-7 siRNA exhibited abrogated mTOR 
signaling over time (Figure 3.6.A). These results were also confirmed in MDA-MB-231 
cells, a triple-negative breast carcinoma cell line (Figure 3.11). Additionally, H1299 cells 
treated with mEAK-7 siRNA demonstrated enhanced cleavage of PARP (139), an 
important regulator of cell death (Figure 3.6.B). These results provide further evidence 
that mEAK-7 is required for radiation resistance, and that the loss of mEAK-7 results in 
severe reduction of mTOR signaling and enhanced PARP cleavage.  
Both S6K1 and S6K2 are essential components of mTOR signaling that are 
described to have similar, but distinct cellular roles in human development and disease 
(61). To elucidate the roles of S6K1 and S6K2 under X-ray irradiation damage, 
(Ser240/244) p-S6 levels were measured in response to siRNA-mediated knockdown of 
mEAK-7, S6K1, or S6K2 and subsequent X-ray irradiation at 10 gy. H1975 cells were 
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treated with control, mEAK-7, S6K1, or S6K2 siRNA for 48 hours in DMEM with 10% 
FBS, then X-irradiated at 10 gy for 30 minutes and 1 hour. mEAK-7 and S6K2 
knockdown each markedly reduced (Ser240/244) p-S6 levels, but S6K1 knockdown did 
not have a substantial effect on (Ser240/244) p-S6 levels (Figure 3.6.C). These results 
mirrored the nutrient conditions, as previously published (12). Furthermore, mEAK-7 or 
S6K2 knockdown dramatically increased (Thr389) p-S6K1 levels after X-ray irradiation-
induced damage, suggesting a specific role for S6K2 and mEAK-7 during X-ray 
irradiation-mediated mTOR signaling (Figure 3.6.C).   
While some reports suggest a possible intersection of DNA-PK and mTOR 
signaling, these ideas have not been fully validated. In an effort to test the hypothesis 
that DNA-PK and mTOR signaling depend on mEAK-7 to carry out a shared function, 
we treated H1299 and H1975 cells with NU7441. NU7441 treatment significantly 
reduced IR-mediated mTOR signaling in a dose-dependent manner, but had little effect 
on (Ser2448) p-mTOR levels (Figure 3.12.A). To determine whether NU7441 significantly 
inhibits IR-induced activation of mTOR signaling compared to other mTOR inhibitors, 
we used specific inhibitors of DNA-PK (NU7441), mTOR (Rapamycin), and PI3K 
(LY249002). Inhibition of DNA-PK, mTOR, or PI3K significantly decreased mTOR 
signaling in H1975 cells (Figure 3.6.D). These results were also consistent in H1299 
cells (Figure 3.12.B).  
 
Discussion 
Surgical intervention and radiation therapy are common treatment modalities for 
patients with solid tumors. However, many patients relapse as tumors acquire 
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resistance through intratumoral evolution (140). CD44+/CD90+ cells have been 
identified as a unique population of cancer cells that may be required for the regulation 
of chemo- and radio-resistance through PI3K and mTOR signaling (141). Furthermore, 
the literature demonstrates that S6K2 inhibits apoptosis in lung cancer (142), and that 
S6K2 amplification is associated with more aggressive forms of breast cancer (143). 
Similarly, a retrospective study conducted on breast cancer patients demonstrated that 
4E-BP1 and S6K2 were correlated with poor prognosis and endocrine resistance (144). 
This evidence, combined with our findings that mTOR signaling, mEAK-7, and S6K2 are 
upregulated in CD44+/CD90+ cancer cell populations, suggests that mEAK-7 is 
involved in radiation resistance.  
Although CD44+/CD90+ cells demonstrate radiation resistance and self-renewal 
capacity in association with mEAK-7 protein levels, loss of mEAK-7 alone does not 
result in enhanced cell apoptosis in human cancer cells (12). However, this is likely due 
to the fact that the mechanisms that support cell survival and self-renewal are different. 
PI3K and mTOR signaling are crucial regulators of radiation resistance and self-renewal 
in many epithelial-based cancers, including cervical cancer (145), head and neck 
squamous cell carcinoma (146), and breast carcinoma (147). Specifically, CSCs have 
been identified as a cell population that modulates radiation resistance and self-renewal 
in solid tumors (148). 
Alternative mTOR signaling appears to be upregulated in human cancer patients, 
specifically in patients with metastatic disease (Figure 3.2.A-3.2.C). Here, DNA-PK was 
identified as a new interacting partner of mEAK-7 (Figure 3.5.A-3.5.H) and may 
participate in the regulation of this alternative mTOR signaling. DNA-PK is a member of 
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the phosphatidylinositol 3-kinase-related kinases (PIKKs) family that includes 
mechanistic target of rapamycin (mTOR), ataxia-telangiectasia mutated (ATM), ataxia- 
and Rad3- related (ATR), suppressor of morphogenesis in genitalia (SMG1), and 
transformation/transcription domain-associated protein (TRRAP) (149). DNA-PK has 
been extensively studied in the context of non-homologous end joining and homologous 
recombination, both of which are DNA damage repair pathways (150). PIKKs typically 
have redundant cellular roles, depending on their cellular localization and biologic 
context. For example, DNA-PK, ATM, and ATR all have similar cellular targets in 
response to DNA damage (151). Intriguingly, DNA-PK was found to play a critical role in 
metabolic gene regulation in response to insulin (52). However, DNA-PK predominantly 
resides in the nucleus, so it was initially unclear how DNA-PK could exit the nucleus to 
affect nutrient metabolism. The literature supports the observation that pockets of DNA-
PK exists in lipid rafts outside of the nucleus, suggesting the existence of a novel role 
for DNA-PK in cytoplasmic cellular signaling (152). In support of these diverse findings, 
we demonstrate that DNA-PK interacts with mEAK-7 to regulate mTOR signaling, 
predominantly through S6K2. 
In mini pigs, mTOR signaling is enhanced in salivary glands after 5 days of X-ray 
irradiation (85). In addition, PI3K and mTOR are essential regulators of radiation 
resistance in prostate cancer cells (153) as dual PI3K-mTOR inhibitors re-sensitize 
cancer cells to radiation treatment (154). Here, we demonstrate that mEAK-7 is required 
for the sustained activity of mTOR signaling under X-ray irradiation damage. Continued 
investigation of mEAK-7 and other molecular machinery that regulates IR damage-
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mediated activation of mTOR signaling will allow for the creation of novel inhibitors 
promoting radiation re-sensitization.  
As the role of mEAK-7 is further studied in the context of human disease, its 
unique role in nutrient-sensing mechanisms and the DNA damage response (Figure 
3.6.E) will likely expand. S6K2 is a crucial component of mTOR signaling that has been 
widely overlooked (61). Many studies demonstrate that S6K2 is associated with a 
human diseases, including non-small cell lung cancer (142) and late stage breast 
cancer (100). We determined that there are high mEAK-7 protein levels in the tumors 
and lymph nodes of metastatic cancer patients, mEAK-7high patients have poor 
prognoses, and that mEAK-7 is essential for self-renewal and radio-resistance. To 
determine the evolutionary benefit that cancer cells gain from upregulating mEAK-7, 
future research should be focused on elucidating the mechanisms allowing 
tumorigenesis in a broader range of cancers. Likewise, development of mEAK-7 
inhibitors may benefit patients with metastatic cancers that demonstrate aberrant mTOR 
signaling associated with high levels of mEAK-7.  
 
Limitations of the Study 
Here, we report the novel binding partners of the mEAK-7-mTOR complex, 
namely DNA-PK. Some pitfalls of these studies are namely that we lack animal models 
that could recapitulate human disease. Since most of our work is to identify novel 
binding partners and the detailed mechanism by which they interact, future studies will 
be required to examine the role of mEAK-7 in vivo. Also, our inhibitor studies against 
DNA-PK, though several fold more specific to DNA-PK versus mTOR, could still yield 
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some off-target effects, suggesting genetic approaches are required to understand the 
role of DNA-PK binding to mTOR. Thus, the role of this alternative complex to canonical 
mTOR signaling requires further study in animal models where mTOR signaling is 
required for eukaryotic development and disease progression. 
 
Methods and Materials  
 
Cell lines 
H1299 and H1975 are non-small cell lung carcinoma cell lines obtained from 
ATCC. MDA-MB-231 is a triple negative breast carcinoma cell line obtained from ATCC. 
 
Cell culture 
Cell culture: Cell lines were grown in Dulbecco’s minimal essential medium 
(DMEM, Thermo Fisher Scientific (TFS): cat# 11995-073), without 
antibiotics/antimycotics and supplemented with a concentration of 10% fetal bovine 
serum (FBS, TFS: cat# 10437-036, Lot # 1399413) at 37°C in 5.0% CO2 incubator. 
Cells were grown in Falcon™ Tissue Culture Treated Flasks T-75 (Fisher Scientific 
(FS): cat# 13-680-65) until 75% confluent and split with Trypsin-EDTA 0.25% (TFS: cat# 
25200-056) for 5 min in the 37°C cell incubator. Cells were washed 1x with PBS and 
resuspended in 10% FBS containing DMEM. Cells were counted with the LUNA™ 
Automated Cell Counter (Logos Biosystems (LB): cat# L10001) utilizing LUNA™ Cell 
Counting Slides (LB: cat# L12003) and AO-PI dye (LB: cat# F23001).  
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Small interfering RNA or plasmid transfection 
Cells were seeded at a density of 500,000 cells per 60 mm TCP and grown for 
24 hours. For siRNA transfection, Lipofectamine® RNAiMAX Transfection Reagent 
(TFS: cat# 13778-150) was incubated with Opti-MEM® I Reduced Serum Medium (TFS: 
cat# 31985-070) and 100 nM siRNA was incorporated before introduction to cells at 100 
nM concentration. For plasmid transfection, FuGENE® 6 Transfection Reagent 
(Promega: cat# E2691) was incubated with Opti-MEM I Reduced Serum Medium and 2 
μg plasmids were incorporated before introduction into cells. For dual transfection, we 
added both solutions. siRNAs used were as follows: siRNA mEAK-7 #1 (TFS: ID# 
s33640). S6K1 #1 siRNA (TFS: ID# s12282). S6K1 #2 siRNA (TFS: ID# s12283). S6K2 
#1 siRNA (TFS: ID # s12287). S6K2 #2 siRNA (TFS: ID # s12286). Control siRNA (TFS: 
cat# 4390843). Plasmids were purchased from Addgene. HA-S6K2 plasmid: pcDNA3-
S6K2-WT was a gift from John Blenis (Addgene plasmid # 17729).  
 
Immunofluorescence 
Deparaffinization and rehydration steps were as follows: xylene for 10 minutes, 
100% ethanol for 5 minutes , 95% ethanol for 5 minutes, 70% ethanol for 5 minutes, 
Milli Q water for 10 minutes, and 1x PBST for 10 minutes. Antigen retrieval steps were 
as follows: slides were placed in the slide holder to pressure cooker immersed in 10 mM 
citric acid (pH 6.0). Then, slides were placed in the microwave and cooked at full power 
for 12.5 minutes, finishing when pressure valve has been up for 1 min. Pressurized 
steam was exhausted from the pressure cooker. The pressure cooker and slides were 
cooled under running water for 15 minutes. Slides were washed with 1x PBS for 10 
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minutes. Slides were permeabilized for 10 minutes with 1x PBS with 0.4%Triton-X. 
Slides were blocked with 2.5% bovine serum albumin and 1% Tween20 in 1x TBS. 
Slides were incubated overnight at 4˚C with primary antibody. Next, slides were washed 
with PBS and incubated in secondary antibodies for 1 hour at room temperature. Slides 
were washed with PBS with DAPI for 10 minutes. Prolong Gold Antifade with DAPI was 
used to mount slides (Fisher cat# P36935). Nikon Ti Eclipse Confocal Microscope (60x 
with oil magnification) was used to capture images. Images were captured with or 
without 3x digital zoom, 1/32 frames per second, 1024x1024 image capture, 1.2 Airy 
Units, 2x line averaging, appropriate voltage and power settings optimized per antibody. 
No image modification was performed, except image sizing reduction for figure 
preparation. Quantitative analyses were completed via Nikon Analysis Software, with 
the data analysis and images representing the average of 3 fields of view and more 
than 50% of the tissue core. NSCLC tissue microarray used for protein level detection of 
mEAK-7 and p-S6 was purchased from US Biomax (cat# HLug-Squ090Lym-01). 
Healthy lymph tissue microarray used for protein level detection of mEAK-7 and p-S6 
was purchased from US Biomax (cat# LN802A). NSCLC tissue microarray used for 
patient survival was purchased from US Biomax (cat# HLug-Squ150Sur-02). Primary 
antibodies for immunofluorescence were as follows: mEAK-7 (Santa Cruz 
Biotechnology (SCB) cat# sc-247321) and (Ser240/244) p-S6 ribosomal protein (D68F8) 
XP® (Cell Signaling Technologies (CST): cat#5364S). All antibodies were used at 
1:1,000 with a working volume of 1.5 mL in 5% BSA in PBS, unless noted otherwise. 
Secondary antibodies for immunofluorescence were as follows: Donkey anti-Goat IgG 
Alexa Fluor® 647 (TFS: cat# A-21447), Anti-rabbit IgG (H+L), and F(ab')2 Fragment 
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Alexa Fluor® 488 Conjugate (CST: cat# 4412S). All antibodies were used at a 
concentration of 1:1,000, with a working volume of 1.5 mL in 5% BSA in PBS. DAPI 
stain was used for DNA staining. 
 
Immunoblot analysis 
Cells were lysed in cold NP40 lysis buffer (50 mM Tris, 150 mM NaCl, and 1.0% 
NP-40 at pH 8.0). 50 μg of protein lysate was separated with Novex® Tris-Glycine SDS 
Running Buffer 10X (TFS: cat# LC2675-4) and Novex™ WedgeWell™ 4-20% Tris-
Glycine Gels (TFS; cat# XP04205BOX), NuPAGE™ 3-8% Tris-Acetate Protein Gels 
(TFS; cat# EA03785BOX). Proteins were transferred to PVDF membranes. 4-20% gels 
were used for proteins 100 kDa and below, while 3-8% gels were used for proteins 100 
kDa and above. Primary antibodies were incubated with membranes overnight at 4°C, 
and secondary antibodies were incubated with membranes at room temperature for 1 
hour. Membranes were incubated with SuperSignal™ West Pico Chemiluminescent 
Substrate (TFS; cat# 34078) or Femto (TFS; cat# 34095) for film capture on HyBlot CL 
autoradiography film (Denville Scientific: cat# e3018). Primary antibodies were as 
follows: α-mEAK-7 (KIAA1609) mouse monoclonal antibody clone OTI12B1 (formerly 
12B1) was obtained from Origene Technologies (OT; cat# TA501037, lot A01). All 
antibodies from Cell Signaling Technologies (CST) are rabbit: α-glyceraldehyde-3-
phosphate dehydrogenase (CST: cat# 2118S), α-phospho-S6 ribosomal protein 
(Ser240/244) (CST: cat# 2215S), α-phospho-S6 ribosomal protein (Ser235/236) (CST: cat# 
2211S), α-S6 ribosomal protein (CST: cat# 2217S), α-phospho-p70 S6 kinase (Thr389) 
(CST: cat# 9234S), α-S6K1 (CST: cat# 2708S), α-S6K2 (CST: cat# 14130S), α-mTOR 
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(CST: cat# 2983S), α-HA-tag mouse (CST: cat# 2367S), α-HA-tag rabbit (CST: cat# 
3724S), α-(Ser65) p-4E-BP1 (CST: cat# 9451S), α-(Thr37/46) p-4E-BP1 (CST: cat# 
9459S), α-(Thr70) p-4E-BP1 (CST: cat# 13396S), α-4E-BP1 (CST: cat# 9452S), α-N-
cadherin (CST: cat# 13116S), α-noxa (CST: cat# 14766S), α-Cleaved PARP (CST: 
5625S), α-(Thr68) p-Chk2 (CST: cat# 2197S), α-Chk2 (CST: cat# 3440S), α-(Ser2448) p-
mTOR (CST: cat# 2971S). Concentration of antibodies: p-S6, S6, and 4E-BP1 used at 
1:3,000 dilution and remainder at 1:1,000 dilution in 5% BSA in 1X TBST buffer with 
0.04% sodium azide. Secondary antibodies for immunoblot analysis: 1:4,000 dilution for 
α-mouse IgG (Promega; cat# W4021). 1:7,500 dilution for α-rabbit (Promega; cat# 
W4011), and 1:2,000 dilution for α-rabbit light chain specific antibody (Abcam: cat# 
ab99697) only for S6K2 IP experiments.  
 
Chemical Inhibitors 
All chemical were resuspended in DMSO, according to manufacturer 
recommendations. Rapamycin (CST; cat# 9904S), LY293002 (CST; cat# 9901S), 
NU7441 (Tocris Biotechne; cat# 3712). All inhibitors were applied to cells for at least 2 
hours, unless stated otherwise in the manuscript. 
 
Immunoprecipitation (IP) analysis and mass spectrometry 
After siRNA and/or plasmid transfection, cells were harvested in 1% NP40 lysis 
buffer or CHAPS lysis buffer (FIVEphoton Biochemicals (FB): cat# CIB-1) supplemented 
with protease inhibitors (FB: cat# PI-1) and phosphatase inhibitors (FB: cat# PIC1). For 
antibody-bead conjugation, 1 to 2 μg of antibodies and 50 μL of mixed Protein A/G 
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PLUS-Agarose (SCB; Cat # sc-2003) were incubated for 1 hour on vertical shaker at 
4°C. Afterwards, the antibody-bead mix was washed 3 times with 1x PBS. Next, 250 μg 
of protein in CHAPS buffer were incubated with the antibody-bead mix for 1.5 hours on 
vertical shaker at 4°C. After incubation, the antibody-bead conjugates were washed 3 
times with 1x PBS. Beads were washed 3 times with 1x PBS, and 3x loading buffer with 
SDS was added to the bead mix, boiled, spun down, and utilized for immunoblot 
analysis. Immunoprecipitation-mass spectrometry: Samples were processed by the 
University of Michigan Proteomics core for IP/MS analysis and protocols can be found 
on their webpage. Samples submitted to the core were pooled from 3x reactions of HA-
mEAK-7 in H1299 cells, as described above. Full excel sheet supplied as Table S1. 
Antibodies used for immunoprecipitation reactions were as follows: Anti-HA epitope tag 
polyclonal goat IgG Antibody (Novus Biologicals: cat# NB600-362), polyclonal goat IgG 
antibody (SCB: cat# sc-2028), α-S6K2 (CST: cat# 14130S), α-mTOR (CST: cat# 
2983S), mEAK-7 (SCB, cat# sc-247321). 
 
Cell Invasion assay 
After siRNA transfection and X-ray irradiation, cells were trypsinized and 50,000 
cells were seeded onto Corning® Matrigel® Invasion Chamber 24-Well Plate 8.0 Micron 
(Corning: cat# 354480), with 1 mL of DMEM-AAs without FBS within the top chamber, 
and 1 mL of 10% FBS-containing DMEM medium on the bottom of the plate. After 24 
hours, we processed the samples with Hema 3™Stat Pack (Fisher: cat# 123-869), 
according to manufacturer specifications. Images were captured with a stereoscope, 
attached to a digital camera. Brightness and contrast were adjusted, as needed. 
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Analysis was conducted via student’s t-test. % invasion was counted on 6 individual 
experiments per condition as: # cells adhered to the bottom chamber divided by # cells 
seeded total.   
 
Comet Assay 
Lysis Buffer, Alkaline Solution, and Eletrophoresis Running Solution were 
prepared according to manufacturer’s instructions. Solutions were stored at 4°C. 
Oxiselect Comet Agarose (Cell Bio Labs (CBL): #235002) was heated to 95°C for 20 
minutes, then placed in 37°C water bath until use. Cells were grown according to 
experimental procedures for siRNA treatment. Two days post siRNA treatment, cells 
were subjected to no treatment, 2 gy, and 6 gy X-ray irradiation. Cells were trypsinized 
and resuspended at a concentration of 1x105 cells/mL in cold PBS. Then, 10 μL of cell 
suspension was mixed with 90 μL of comet agarose. After mixing thoroughly, 75 μL of 
this mixture was transferred to the OxiSelect Comet Slide (CBL: #STA-352). Slides 
were placed in the dark at 4°C for 15 minutes. Slides were transferred to a small basin 
containing pre-chilled Lysis buffer and placed at 4°C for 60 minutes in the dark. Lysis 
solution was aspirated from the basin, replaced with pre-chilled Alkaline solution, and 
placed at 4°C in the dark for 30 minutes. Then, Alkaline solution was aspirated and 
replaced with pre-chilled TBE Electrophoresis solution. After 5 minutes, TBE 
Electrophoresis solution was aspirated and replaced with new TBE Electrophoresis 
solution. Slides were transferred to a horizontal electrophoresis chamber and the well 
was filled with enough TBE Electrophoresis solution to fully cover the slides. Voltage 
was applied for 45 minutes at 20 volts. After electrophoresis, slides were transferred to 
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a small basin containing pre-chilled DI H2O, and the slides were fully immersed. After 2 
minutes, the DI H2O was aspirated and replaced. This rinse was repeated twice. After 
the third rinse, slides were immersed in cold 70% ethanol for 5 minutes, then removed 
from the basin and allowed to air dry. Once the agarose was dried fully, 100 μL of 
diluted Vista Green DNA dye (CBL: cat# 235003, diluted 1:10,000 in TE buffer) was 
added to each well and allowed to incubate at room temperature for 15 minutes. Slides 
were imaged with Nikon Ti Eclipse Confocal Microscope at 10x magnification lens to 
capture images. Images were captured at 1/8 frames per second, 1024x1024 image 
capture, 1.2 Airy Units, 2x line averaging, appropriate voltage and power settings for 
FITC (488 nm). No image modification was performed, except image sizing reduction 
for figure preparation. 
 
Cancer Stem Cell sorting 
Cells were trypsinized and resuspended in DMEM medium with 10% FBS and 
counted on Luna cell counter (Logos Biosystems (LB): cat# L10001) using Acridine 
Orange/Propidium Iodide dye (LB: cat# F23001) for viability. 1x107 cells were filtered 
into each of 5 labeled 50 mL falcon tubes, through a 40 μm filter. 1x107 cells were 
filtered into each of 5 labeled 5 mL round bottom tubes (Falcon: cat# 352235) to be 
used as single-color controls. Tubes were centrifuged at 1,000 rpm for 4 minutes at 4°C 
and supernatant was discarded. One 5 mL single color control tube was resuspended 
with 200 µL PBS with 10% FBS to be used as a negative control. Three of the other 
single-color control tubes were resuspended with 200 μL PBS with 10% FBS, and single 
color dyes were added as detailed: 2 μL DAPI (Thermo Fisher: cat# D1306), 25 μL 
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CD90 (Biolegend: cat# 328107), and 10 μL CD44 (BD Biosciences: cat# 559942). The 
final single-color tube was used for Isotype control. This pellet was resuspended with 
191 μL PBS with 10% FBS and 2 μL DAPI, 2 μL APC Isotype (BD Biosciences: cat# 
340442), and 5 μL FITC Isotype (BD Bioscience: cat# 555909) were added. Cells in the 
50 mL tubes were resuspended with 10 mL PBS with 10% FBS. The stain master mix 
was added to each tube to be sorted. Tubes were placed on a rack and incubated at 
37°C for 30 minutes. Cells were rinsed with 1x PBS and resuspended 1x PBS 
containing 3% FBS.  Place all tubes on ice until samples will be run on Flow Cytometer 
(Sony: Cat# SH800).  
 
Clonogenicity Assay 
Cells were grown according to experimental procedures for siRNA treatment. 
Two days post siRNA treatment, cells were subjected to no treatment, 2 gy, and 6 gy X-
ray irradiation. 10,000 H1975 cells or 2,500 H1299 cells were plated into 60 mm dishes 
with 2 mL DMEM with 10% FBS. Cells were cultured in the incubator for 10 days (until 
control colonies contained >50 cells), and new media and new siRNA were added every 
4 days. Cells were fixed with 2 mL of fixation mix (glacial acetic acid (Sigma-Aldrich 
537020) and methanol (Sigma-Aldrich 67-56-1), at a 1:7 ratio) for 2-3 minutes at room 
temperature and incubated with 2 mL Crystal Violet (Sigma-Aldrich C6158-50G, diluted 
to 0.5% in Milli-Q water) for 2 hours at room temperature. After 2 hours, the Crystal 
Violet was removed and the dishes were rinsed with 2 mL of media (no FBS added), 
pipetting vigorously to dislodge cells. Dishes were rinsed carefully in DI water and 
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placed on paper towel to dry for 2-3 days. Once plates were dry, colonies were counted 
and recorded.  
 
Spheroid Formation Assay 
Cells were grown according to normal experimental procedures for siRNA 
treatment (n=6). Two days post siRNA treatment, cells were subjected to no treatment, 
2 gy and 6 gy X-ray irradiation. 10,000 H1975 cells or 5,000 H1299 cells were plated 
into ultralow attachment plates (Costar: cat# 3471). 2 mL of Serum Free Medium (435 
mL MEBM Medium (Lonza: cat# CC-3151), 10 mL B27 (Gibco: cat# 17504-044), 5 mL 
Pen/Strep (Gibco: cat# 15070), 5 mL Lipid Concentrate (Gibco: cat# 11905-031), 2.5 
mL Insulin (Sigma-Aldrich: cat# I6634), 10 μg EGF (BD Biosciences: cat# 354052), 10 
μg bFGF (BD Bioscience: cat# 354060), 500 μg Hydrocortisone (Sigma-Aldrich: cat# 
H4001), 500 μL 100 mM ß-mercaptoethanol (Sigma-Aldrich: cat# M3148), 2 mg 
Cholesterol (Sigma-Aldrich: cat# C4951)) were added to each well. Cells were grown for 
2 weeks, adding 500 μL of Serum Free Medium every 4 days to ensure cells have 
adequate nutrients. After 2 weeks, the number of spheres growing in each well (spheres 
must have defined, circular edges and be made of at least 10 cells) was counted, and 
representative images of spheres from each treatment group were taken. 
 
Statistical analysis and reproducibility  
 GTEx data acquisition, processing, and statistical analysis information can be 
found on “gtexportal.org”. cBioportal was accessed by searching for “MEAK7” or 
“MEAK7: gain amp”. Patient derived data from Oncomine were analyzed via unpaired 
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student’s t-test. Patient derived tissue microarray data were analyzed via paired Mann-
Whitney’s U-test. 2D/3D clonogenicity assay, comet assay, cell proliferation, cell 
migration, and cell size were analyzed via paired student’s t-test. Immunoblot and 
immunoprecipitation assays were repeated at least thrice in all cell lines. 
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Figure 3.1. MEAK7 gene expression is detected in normal human cells and upregulated in 
select human cancer types. (A) Genotype-Tissue Expression (GTEx) database analysis of 
MEAK7 expression in normal human tissues. (B) The Cancer Genome Atlas cBioPortal analysis 
MEAK7 for all genomic alterations or (C) for only gain of mRNA expression or amplification of 
gene copy number. The results shown here are based upon data generated by TCGA Research 
Network: http://cancergenome.nih.gov/. (D, E) Oncomine analysis of MEAK7 gene expression of 
patients with normal lung and lung cancer via two different studies: (D) Garber Lung Study 
analysis by student’s t-test 2-sample equal variance, (E) Hou Lung Study analysis by Mann 













Figure 3.2. mEAK-7 protein levels are highly detected in nearby lymph nodes of the tumor mass 
in NSCLC patients. (A) 3 representative human patient tissue sections stained for (Ser240/244) 
p-S6 and mEAK-7. White bar denotes 250 µm. (B) Statistical analysis of 30 paired NSCLC 
patients with the normal lung, primary tumor, and metastasized lymph node for (Ser240/244) p-
S6 staining. Mann-Whitney U-test was utilized. (C) Statistical analysis of 30 paired NSCLC 
patients with the normal lung, primary tumor, and metastasized lymph node for mEAK-7 
staining. Mann-Whitney U-test was utilized. (D) NSCLC tissue microarray analysis of Kaplan-
Meier survival curve. Log rank test was utilized. (E) H1975 cells were treated with control or 
mEAK-7 siRNA for 48 hours. 50,000 cells were seeded into in vitro matrigel-based invasion 
chambers and allowed to grow for 24 hours. Analyzed by student’s t-test (n=6). *P<0.01, 


















Figure 3.3. mEAK-7 is found in CD44+/CD90+ group and required for clonogenic potential and 
radiation resistance. (A) Flow sort diagram depicting the CD44+/CD90+ cell population in 
H1299 cells. (B) Immunoblot analysis of CD44-/CD90- and CD44+/CD90+ H1299 cells for 
mEAK-7 and mTOR signaling. (C) H1299 cells were treated with control or mEAK-7 siRNA for 
48 hours, X-irradiated at 2 or 6 gy, and 2,500 cells were seeded into 60 mm TCPs and grown 
for 10 days. (D) H1975 cells were treated with control or mEAK-7 siRNA for 48 hours, subjected 
to no treatment, 2 gy, and 6 gy X-ray irradiation, and 5,000 cells were seeded into 60 mm TCPs 
and grown for 10 days. White bars denote 2.5 mm. (E) H1299 surviving fraction analysis for (C). 
(F) H1975 surviving fraction analysis for (D). (G) H1299 colony number graphs for (C). (H) 
H1975 colony number graphs for (D). Analysis of clonogenic analysis via student’s t-test. 
*P<0.01, **P<0.001, ***P<0.0001, ‡P<0.00001, §P<0.000001. All experiments were repeated at 







Figure 3.4. mEAK-7 is required for spheroid formation and is necessary for an effective DNA 
damage response. (A) Images of spheroid. H1975 cells were treated with control or mEAK-7 
siRNA, X-irradiated at 2 gy or 6 gy, and 10,000 cells were seeded into 60 mm ultra-low 
attachment plates and grown for 10 days. White bar denotes 125 μm. (B) Quantification of 
spheroid formation and analysis via student’s t-test (n=6) of (a). *P<0.01, **P<0.001. (C) H1299 
cells were treated with control or mEAK-7 siRNA, and treated with DMSO or 10 μM cisplatin for 
4 or 8 hours and mTOR signaling was analyzed. (D) H1975 cells were treated with control or 
mEAK-7 siRNA and X-irradiated at 20 gy for 30 minutes, 1 hour, or 2 hours and analyzed for 
noxa expression by DNA damage response. (E, F) H1299 and H1975 cells were treated with 
control or mEAK-7 siRNA and X-irradiated at 2 or 6 gy for 30 minutes and assessed via the 
comet assay to detect damaged DNA. (G, H) Statistical analysis via student’s t-test (n=15) of 
(e,f) represented as box plots. White bar denotes 250 μm. *P<0.01, **P<0.001, ***P<0.0001, 
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Figure 3.5. mEAK-7 interacts with DNA-PK in response to X-ray irradiation to activate S6K2. 
(A) H1299 cells stably expressing HA-mEAK-7 were lysed in CHAPS buffer and HA-mEAK-7 
was immunoprecipitated and co-immunoprecipitated proteins were analyzed for mass 
spectrometry quantitative profiling. This figure only contains the top 10 proteins listed. (B) 
H1299 cells stably expressing HA-mEAK-7 were lysed in NP40 lysis buffer and HA-mEAK-7 
was immunoprecipitated to check DNA-PK interaction. (C) H1299 cells stably expressing HA-
mEAK-7 were X-irradiated at 10 gy for 30 minutes and 1 hour and lysed in NP40 lysis buffer. 
HA-mEAK-7 was immunoprecipitated to check DNA-PK interaction. (D) H1299 cells were 
transiently transfected with pcDNA3-HA-S6K2, then X-irradiated at 10 gy for 1 hour. HA-S6K2 
was immunoprecipitated to check DNA-PK or mTOR interaction. (E) H1975 cells were 
transiently transfected with control or mTOR #1 or mTOR #2 siRNA for 48 hours. Cells were 
collected in CHAPS and endogenous mEAK-7 was immunoprecipitated to check DNA-PK 
interaction. (F) H1299 and H1975 cells were transiently transfected with control or mEAK-7 
siRNA for 48 hours. Cells were subsequently starved of nutrients for 1 hour and replenished 
with DMEM+AAs and 10 μM insulin for 30 minutes or cultured normally and treated with 10 gy 
X-ray irradiation for 30 minutes. Immunoblot analysis was conducted on mTOR signaling. (G) 
H1975 cells were transiently transfected with control or mEAK-7 siRNA for 48 hours. Next, cells 
were treated with 10 gy X-ray irradiation, followed by IP of endogenous S6K2. (H) H1299 and 
H1975 cells were treated with either DMSO or NU7441 (DNA-PK inhibitor) at 5 µM for 2 hours. 
Cells were collected in CHAPS and S6K2 was immunoprecipitated and immunoblots were 
utilized to assess mTOR signaling. GAPDH was used for loading controls. All experiments were 





Figure 3.6. mEAK-7 and DNA-PK are required for X-ray irradiation-mediated mTOR signaling. 
(A) H1299 and H1975 cells were treated with control or mEAK-7 siRNA for 48 hours, X-
irradiated at 10 gy for 30 minutes, 2 hours, and 8 hours, and analyzed for mTOR signaling. (B) 
H1299 cells were subjected to the same protocol in (a) and analyzed for PARP cleavage. (C) 
H1975 cells were treated with control, mEAK-7, S6K1, and S6K2 siRNA for 48 hours and X-
irradiated at 10 gy for 30 minutes and 1 hour, and analyzed for mTOR signaling. (D) H1975 cells 
were treated with DMSO, DNA-PK inhibitor (5 μM NU7441 IC50 = 14 nM), mTOR inhibitor (100 
nM rapamycin, IC50 = 1 nM), and PI3K inhibitor (50 μM LY249002, IC50 = 2.3 μM) for 1 hour 
before treated with X-ray irradiation at 10 gy for 30 minutes and 1 hour, and analyzed for mTOR 
signaling. (E) Working model for a mEAK-7-mTOR-DNA-PK complex. All experiments were 























Figure 3.7. MEAK7 is expressed at basal levels in many normal human tissues, but significantly 
overexpressed in human cancer patients with mortality. (A) BioGPS analysis of MEAK7 in 
human tissues and cells. (B, C) Oncomine analysis of MEAK7 gene expression of patients with 
(B) ductal breast carcinoma (P=2.72x10-6, Fold Change: 2.136) and (C) acute myeloid 
























Figure 3.8. Normal lymph tissue analysis of mEAK-7 and p-S6 and clonogenicity assay in 
H1299 and H1975 cells at differing cell densities after X-ray irradiation. (A) 6 representative 
sections of US Biomax tissue microarray LN802a was analyzed using the antibodies against 
mEAK-7 and p-S6. (B) H1299 and H1975 cells were treated with control or mEAK-7 siRNA, X-
irradiated at 2 or 6 gy, and 10,000 or 25,000 cells were seeded into 60 mm TCPs and grown for 








Figure 3.9. Spheroid assay at a lower cell density. H1975 cells were treated with control or 
mEAK-7 siRNA, X-irradiated at 2 or 6 gy, and 5,000 cells were seeded into 60 mm ultra-low 
attachment plates and grown for 10 days. *P<0.01, **P<0.001. This experiment was repeated at 













Figure 3.10. Analysis of S6K1 and S6K2 on IR-mediated mTOR signaling. H1975 cells were 
treated with control, 2 unique S6K1, or 2 unique S6K2 siRNAs, then treated with 10 gy IR for 30 
minutes or 1 hour. Immunoblot analysis on mTOR signaling. This experiment was completed at 















Figure 3.11. mEAK-7 is required for X-ray irradiation-mediated mTOR signaling in MDA-MB-
231 cells. MDA-MB-231 cells were treated with control or mEAK-7 siRNA for 48 hours, X-
irradiated at 10 gy for 30 minutes, 2 hours, and 8 hours and processed for mTOR signaling. This 













Figure 3.12. Dose-dependent analysis of NU7441 on IR-mediated mTOR signaling and 
inhibition of DNA-PK, mTOR, and PI3K significantly decreased IR-mediated mTOR signaling in 
H1299 cells. (A) H1299 and H1975 cells were treated with DMSO or 0.5 μM, 1 μM, 5 μM 
NU7441 for 2 hours before treated with X-ray irradiation at 10 gy for 30 minutes and 1 hour. 
Immunoblot analysis on mTOR signaling. All experiments were repeated at least 3 times. 4E-
BP1 was utilized as a loading control. (B) H1299 cells were treated with inhibitors of DNA-PK (5 
μM NU7441, IC50 = 14 nM), mTOR (100 nM rapamycin, IC50 = 1 nM), and PI3K (50 μM 
LY249002, IC50 = 2.3 μM) for 1 hour before treated with X-ray irradiation at 10 gy for 30 
minutes and 1 hour. Immunoblot analysis on mTOR signaling. We observed that inhibition of 
DNA-PK, mTOR, or PI3K significantly decreased IR-mediated mTOR signaling. All experiments 
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 Chapter 4 – Conclusions and future directions 
 
A third mTOR complex 3 (mTORC3)?  
Strong evidence supports a role for mTOR in the regulation of essential cell 
processes and its dysregulation is involved in the pathogenesis of several human 
diseases. Aberrant activation of mTOR signaling contributes to malignant behavior of 
cancer cells by controlling proliferation, invasion, and metastasis. In Chapter 1, we 
provide an overview of mTOR signaling in relation to development and disease. This is 
not an exhaustive review as mTOR signaling research has influenced many facets of 
biology. Thus, we chose to focus on relevant growth processes of interest and human 
cancers that upregulate mTOR signaling. In Chapter 2, we demonstrate the function a 
novel regulator of mTOR signaling in human cells, which we have named mammalian 
EAK-7 (MTOR associated protein eak-7 homolog, mEAK-7). Preliminary data suggests 
that mEAK-7 forms a novel mTOR complex, independent of mTORC1/2, to regulate cell 
invasion in vitro and correlates to high levels of mEAK-7 protein detected in the 
metastasized lymph nodes of patients. This finding was most intriguing because this 
new signaling complex regulated S6K2 signaling rather than S6K1. In canonical 
mTORC1 signaling, conventional targeting was done via S6K1 phosphorylation. Thus, 
identifying molecules that suppressed S6K1 phosphorylation was not sufficient to 
specify the downstream targets specific to S6K2. This leads us and others (1, 2) to 
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reveal that novel mTOR complexes could exist. In Chapter 3, immunoprecipitation 
(IP)/mass spectrometry (MS) experiments provide evidence to suggest that DNA-PK 
can bind mEAK-7 and that this binding is increased with DNA damage induced by X-ray 
irradiation. This is intriguing because DNA-PK has been primarily demonstrated as a 
protein kinase essential for DNA damage repair by non-homologous end joining 
(NHEJ). Based on these data, we hypothesize that a new mTOR complex, mTORC3, 
composed minimally of mTOR, mLST8, mEAK-7 and DNA-PK may be more abundant 
in response to stress/DNA damage in certain cancer cells. In our final chapter, we will 
outline the lingering controversies, how our work will impact the mTOR community as a 
whole, and the research that will likely impact the future of mTOR signaling, in relation 
to mEAK-7. 
 
Lingering controversies and poor efficacy of mTOR inhibitors in clinical settings 
The findings outlined in this thesis will advance the field of mTOR signaling 
because it brings about a novel way to think about mTOR complexes in health and 
disease. Many rapamycin analogues or mTOR kinase catalytic site inhibitors 
demonstrate little efficacy for patients, suggesting that alternative mTOR signaling may 
be occurring in select patients. Additionally, the reason that patients who fail standard 
therapy of surgery, chemotherapeutics, or radiation therapy, is likely due to mechanisms 
that can alter cancer-specific signaling. Investigating the role of mTOR signaling in 
response to DNA damage will elucidate the nature by which chemo- or radio- resistant 
tumor cells alter mTOR signaling. mEAK-7 was never identified as a component of 
mTOR complexes in the past, likely due to the limited cell types, e.g. HEK293T or Hela, 
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that were used in the experiments. Since we have demonstrated that mEAK-7 is a bona 
fide interacting molecule of mTOR in human cancer cells, we posit that a third mTOR 
complex containing mEAK-7 plays an important role in cancer biology.  
While numerous research groups around the world demonstrate that inhibition of 
mTOR signaling can lead to significant reductions in tumor size and progression, this is 
not the case for mTOR inhibitors in the clinic. Since the discovery of rapamycin on 
Easter Island, scientists discovered the valuable role of rapamycin as an 
immunosuppressant (3, 4). Years after this discovery, mTOR inhibitors were reverse 
engineered and the first class of drugs created included rapamycin analogs or 
“rapalogs”. The first rapalog known as Temsirolimus was developed by Pfizer and was 
used for the treatment of renal cell carcinoma in 2007 (5). Patients who received 
temsirolimus alone had longer overall survival and progression-free survival than 
patients who received interferon alone (5). This was the first proof-of-principal study that 
demonstrated the effectiveness of mTOR inhibition of cancer. These findings were 
quickly followed by another rapalog, Everolimus, developed by Novartis in 2009 (6). 
Everolimus demonstrated encouraging antitumor activity against metastatic renal cell 
carcinoma (6). Curiously, mTOR signaling has been implicated in numerous cancer 
types in patients, but rapamycin analogs that target mTORC1 are not sufficient to 
induce cytotoxic effects, and rather yield cytostatic results. While there have been a 
small number of extraordinary responders when given mTOR inhibitors, predictive 
modeling to specify which patients would be required to yield the best results. This is a 
significant issue for patients on mTOR inhibitors since the majority of mTOR inhibitors in 
clinical trials have not fared well. One possible strategy is to pair genomic analyses with 
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different disease states to confirm that patients have upregulated mTOR signaling within 
key pathways. These ideas have been around for decades, as we have built a massive 
amount of data from -omics approaches. Thus, pharmacogenomics will allow us to 
investigate drug targets against specific scenarios based on a whole systems approach 
and the patients genome (7).  
With the amount of big data being generated for patient responses, health 
records, and genetic information, the most rational path forward is to incorporate 
advanced artificial intelligence paired with deep learning and machine learning to enable 
novel therapeutics to be developed (8). This will enable clinicians to determine which 
patients would benefit from specific mTORC1, mTORC2, or mTORC3 inhibitors. One 
issue with rapalogs is that, while in vitro and in vivo pre-clinical models demonstrate 
large efficacy, rapalogs do not fully suppress the downstream signaling and targets of 
other mTORC1 substrates (4, 9-11). Additionally, it is known that as mTORC1 inhibition 
releases the negative feedback on insulin/PI3K/Akt signaling, patients taking rapalogs 
have resulted in upregulated Akt signaling, leading to cancer cell survival (12). 
Therefore, one strategy that has been deployed is the use of second generation mTOR 
inhibitors that target the ATP-competitive catalytic site of mTOR. By targeting mTOR 
itself, we are able to block the downstream substrate specificities of mTORC1, 
mTORC2, and likely, mTORC3 and undiscovered mTOR complexes can be blocked. 
However, even with these advances in second generation mTOR inhibitors, their ability 
to block Akt signaling is transient and Insulin/PI3K is capable of overcoming the 
negative feedback loop with long-term treatment of mTOR specific inhibitors. Curiously, 
mTORC3 also involves another PIKK family member, DNA-PK. DNA-PK is also known 
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to be the physiological kinase that targets Akt under specific requirements, in 
conjunction with mTORC2 (13). Since mEAK-7 is required for DNA-PK/mTOR/S6K2 
signaling, it is likely that an alternative mTOR pathway functions in some biologic 
contexts. Finally, newly described “third-generation” mTOR inhibitors called “RapaLink” 
blocks ATP sites as well as mTORC1 via rapamycin, suggesting that prohibiting the 
binding of other substrates to mTOR substantially decreases both Akt and 4E-BP1 (14). 
Thus, developing novel ways to block mTOR binding to downstream substrate targets is 
the most effective way to inhibit aberrant mTOR signaling in human cancer and other 
diseases. 
There are three long-term goals of understanding mEAK-7 in the context of 
cancer in this thesis. First, is identifying mTORC3 downstream targets by 
phosphoproteomics before/after DNA damage. Second, is defining mTORC3 binding 
partners before and after DNA damage as these protein-protein interactors will provide 
insight to radioresistance mechanisms. Third, is determining the topographical structure 
of novel mTOR complexes, like mTORC3, and identifying essential protein-partner 
binding sites. Thus, while the field of mEAK-7 and its role in mTOR signaling is nascent, 
much work needs to be done before we can understand and assess the role of 
mTORC3 in response to DNA damage. These findings will be pivotal in creating create 
tools to study mTORC3 as a therapeutic target in human cancer.   
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Unexplored mTOR complexes in human cancer 
The mTOR signaling field made dramatic advances when raptor (mTORC1) and 
rictor (mTORC2) were identified. After these initial discoveries, more proteins that are 
essential components of mTORC1 and mTORC2 have been identified. Within the field 
of mTOR signaling, there is a growing awareness of cell-type or tissue-type specific 
mTOR complexes that are essential for regulation of metabolism. Although complex, the 
molecular constituents of novel mTOR complexes will continue to be discovered as new 
technologies are introduced and developed in protein biology. Since mTOR is the major 
component of a larger multimeric protein complex, it’s still unclear how all of the proteins 
interact and in what contexts. A single point mutation, R628C, is sufficient to change the 
binding affinity and kinase activity of mTOR (15), suggesting a decrease in binding of 
essential interacting proteins. Since aberrant mTOR signaling contributes to human 
cancer, many groups hoped to treat mTOR related cancers with mTOR direct or indirect 
inhibitors (16). However, widespread expression of mTOR kinase in normal human 
tissues has limited the effectiveness of single agent use of mTOR inhibitors for mTOR-
related malignancies (17). An alternative strategy for treatment of mTOR malignancies 
is to pair it with other inhibitors, since those protein targets may be required for residual 
mTOR activity. mEAK-7 would be one such protein target which could yield positive 
benefits for patents, 
Aberrant mTOR signaling has been observed in many types of cancers (16). 
Interestingly, mEAK-7 exhibits a preferential expression pattern in human cancer cell 
lines (18). However, prior to our manuscript, no other group has rigorously identified the 
molecular role for mEAK-7 in human cells. While EAK regulates dauer formation and 
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lifespan in nematodes (19), the molecular mechanism remains unknown and 
unexplored in mammals. S6K2 signaling has not been adequately distinguished from 
that of S6K1 due to their perceived redundancies (20), but the realization that mEAK-7 
utilizes the S6K2/4E-BP1 axis to regulate mTOR signaling (18) had challenged those 
notions. However, in breast cancer cells, loss-of-function studies demonstrate that S6K1 
and S6K2 have several different protein targets (21). Additionally, canonical models of 
mTORC1 and mTORC2, the traditional S6K regulators, may not exist in all cells, or 
function similarly in them. Expanding our knowledge of mTOR complexes in human 
disease may allow for the development of novel therapeutic agents to target aberrant 
mTOR signaling. Recently, a novel mTOR complex—other than mTORC1 and 
mTORC2—involving GIT1 in astrocytes was identified (2). Additionally, another mTOR 
complex was discovered, where a novel rapamycin insensitive molecule, ETV7, binds to 
mTOR in  B cell neoplasms to regulate its kinase activity, even in the presence of 
rapamycin (1). Most recently, research labs around the world have identified novel 
mTOR complexes in different tissue types and disease states. These findings have 
modified how we think about mTOR and have led us to hypothesize the possibility of a 
new set of mTOR complexes forming under different tissue types or disease states. 
While it is largely believed that mTOR signaling is suppressed under genotoxic 
stress via AMPK regulation of TSC2 (22), some studies have demonstrated aberrant 
activation of mTOR signaling in response to these same conditions. For example, 
mTORC1 signaling can inhibit DNA damage response mechanisms in vitro and in vivo 
through RNF168 (23). S6K2 knockdown induces a strong reduction of mTOR signaling  
and leads to chemoresistance in cancer cells (24). CHK1 function requires mTORC1 
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signaling in response to DNA damage, providing further evidence in support of a role for 
mTOR signaling in DNA damage responses (25). Sustained radiation treatment of mice 
activates mTOR signaling and oxidative stress in the intestine (26). There is a rationale 
to treat patients with chemotherapeutics and rapamycin since the combination results in 
an additive cytotoxic effect in breast carcinoma cell lines (27). Normal tissues 
undergoing radiation stress exhibit activated mTOR signaling, suggesting a role for DNA 
damage responses (28). These studies suggest that mTOR signaling and DNA damage 
responses are intertwined, but complex, and therefore require further study. Proposed 
mechanisms include the downregulation of p53 via S6K-mediated activation of MDM2 
(29), and/or 4E-BP1 phosphorylation in response to DNA damage (30).  
Given reports that genotoxic stress is capable of regulating mTOR signaling, we 
propose that mEAK-7 may contribute to these stress responses through an mTORC1/2 
independent mechanism. Future directions or study of mEAK-7 could include: (1) to 
identify mTORC3 downstream targets before and after DNA damage, (2) to identify 
proteins that form a complex with mEAK-7, but not Raptor or Rictor, and (3) to 
determine how they bind. 
 
The role for mEAK-7 and mTORC3 in human cancers 
mTOR signaling has been demonstrated to be an essential controller of 
metastasis-related genes in prostate cancer (31). In a screen of human squamous cell 
carcinomas, we found that the UM-SCC-17A cell line, derived from a primary laryngeal 
cancer, did not express detectable levels of mEAK-7 protein. Interestingly, the UM-
SCC-17B cell line, derived from a metastatic site in the same patient, did express 
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mEAK-7 (18). These findings suggest that the increased expression of mEAK-7 may be 
associated with tumor metastasis (32). To test this hypothesis in patients with cancer, 
we utilized mEAK-7 and activated mTOR specific antibodies against a patient tissue 
microarray that pairs normal tissue, primary lung cancer, and metastasized lymph node 
tissues. In our analyses, we determined that mEAK-7 and activated mTOR signaling 
were significantly increased in primary tumors and more so in the metastasized lymph 
nodes (Figure 3.2.,A-C). Thus, mEAK-7 protein is highly expressed in metastatic 
cancer, implying that it might be a new target for intervention (Figure 3.2). Furthermore, 
it could also be utilized as an essential marker for metastatic tumors, since normal 
lymph nodes do not express mEAK-7 or activated mTOR signaling. 
Several research labs have demonstrated that novel mTOR complexes exist in 
the absence of raptor (mTORC1) or rictor (mTORC2). We hypothesized that mEAK-7 
may be part of a novel mTOR complex and we sought to identify additional interacting 
partners of mEAK-7 (Figure 4.2). We determined by immunoprecipitation (IP) and mass 
spectrometry analyses that DNA-dependent protein kinase catalytic subunit isoform 1 
(DNA-PKcs) was significantly pulled down with HA-mEAK-7 (Figure 3.5.A), suggesting a 
role for regulation of mTOR signaling. To validate the IP-mass spectrometry results, we 
demonstrated that exogenous mEAK-7 interacts with endogenous DNA-PK (Figure 
3.5.B). Additionally, mEAK-7 increased its interaction with DNA-PK over time in 
response to DNA damage (Figure 3.5.C). These data suggest that mEAK-7 associates 
with DNA-PK in response to DNA damage. Other groups have demonstrated that 
mTOR and DNA-PK may interact after DNA damage, and that interaction regulates 
mTORC2 signaling in epithelial skin keratinocytes (33). Furthermore, nuclear DNA-PK 
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has been found to localize to the cytosol in response to DNA damage (33). These 
findings are intriguing because proteins with canonical roles in the nucleus may well be 
essential for other signaling pathways or cell processes in the cytosol. One example of 
this is NUF1P1, which has conserved nuclear functions to regulate snoRNPs, but in 
response to nutrient starvation it acts as a ribosome receptor for ribophagy (34). 
We demonstrated that mEAK-7 regulates mTOR signaling through an alternative 
mTOR complex (18). To determine if both mEAK-7 and DNA-PK are part of a complex 
that helps regulate mTOR signaling, we hypothesized that DNA-PK was capable of 
interacting with S6K2, as mEAK-7 is required for the mTOR-S6K2 axis (18). We 
discovered that HA-S6K2 is capable of binding to DNA-PK, and that interaction strongly 
increased after DNA damage, but mTOR and HA-S6K2 interaction did not increase 
(Figure 3.5.D). Thus, DNA-PK is capable of interacting with S6K2 to regulate its function 
in response to DNA damage.  
In conclusion, there is substantive evidence that a third mTOR complex exists in 
human cancer cells. In addition, it is plausible that cell-type and tissue-type and 
disease-specific mTOR complexes exist. The findings outlined in this thesis will be the 
catalyst for research groups to explore novel ideas with regard to mTOR signaling.   
 
Phosphoproteomics of mTORC3 downstream targets by DNA damage 
Transgenic mice with constitutive reductions of mTOR lose feedback inhibition of 
Akt signaling (35), thereby activating Akt; this phenotype also suggests that an 
alternative complex may regulate mTOR signaling. One of the challenges of mTOR 
signaling research is the lack of tissue-specific tools, since mTOR null mice are 
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embryonic lethal (36). Future work will require better tools to investigate novel mTOR 
complexes in different tissue types to specify the role of mTOR signaling in different 
cells. To understand the role of mTORC3 in human cancers, novel technologies such as 
clustered, regularly interspaced, short palindromic repeat (CRISPR) loci along with 
CRISPR-associated (cas) genes can create specific genetic lesions to delete mEAK-7. 
CRISPR knockout cells targeting Raptor (mTORC1), Rictor (mTORC2), and mEAK-7 
(mTORC3) would enable us to determine the essential effects of different mTOR 
complexes on mTOR signaling. Additionally, pursuing comparative phosphoproteomic 
analyses before/after DNA damage or differing nutrient conditions by stable isotope 
labeling with amino acids in cell culture (SILAC), would further support the likelihood of 
novel mTORC3 downstream targets. This will allow us to determine the extent to which 
mTORC3 downstream targets are similar to mTORC1/2 before/after DNA damage. 
mTOR is a promiscuous kinase and targets several proteins depending on the 
nature of the stimuli, cell type, and environment (16). One single amino acid change 
(R628C) is sufficient to reduce mTOR kinase activity (15). These results suggest that an 
alternative mTOR complex may take the reins of mTOR signaling when canonical 
signaling is diminished. While there have been many approaches to understanding the 
phosphoproteome, there is still much that we do not know when it comes to novel 
mTOR complexes. The mTOR phosphoproteome has revealed novel downstream 
targets, such as Grb10 (37, 38). Thus, proteomics analysis is capable of revealing new 
signaling networks originally hidden from view. Preliminary mass-spec data reveals that 
mEAK-7 interacts with mTOR and DNA-PK (Figure 3.5.A). These findings are 
surprising, given that DNA-PK functions primarily in the DNA damage repair response, 
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via non-homologous end joining. There is evidence that DNA-PK is essential for 
regulating animal metabolism and insulin signaling, but the rationale or mechanism 
remains unknown (39, 40). Thus, understanding the role of mEAK-7 and DNA-PK in 
alternative mTOR signaling will be an essential quest for the future. 
 
mTORC3 phosphoproteome overlap between mTORC1 and mTORC2.  
There are likely to be common and unique protein targets of mTORC1/2/3 
before/after DNA damage. To tease these out, CRISPR-Cas9 knockout (Rictor, Raptor 
or mEAK-7) constructs against cancer and normal cell lines may allow us to identify the 
key targets lost as a result of sequential knockout of mTORC1, mTORC2, or mTORC3. 
One strategy is to evaluate the phosphoproteomes of control versus knock-out using 
stable isotope labeling with amino acids in cell culture (SILAC), an approach for in vivo 
incorporation of a label into proteins for mass spectrometry-based quantitative 
proteomics. Thus, in the future we hope to identify shared and unique targets of 
mTORC1/2/3 to identify and validate the signaling networks associated with DNA 
damage responses. We hypothesize that there will be differential utilization of mTORC3 
during DNA damage by the allelic variants of mTOR.  
 
Novel mTORC3 binding partners before/after DNA damage  
Immunoprecipitation (IP) and mass spectrometry (MS) analysis of mEAK-7 
demonstrated that DNA-PK, a DNA damage sensor, is an interacting molecule and its 
binding increases after DNA damage (Figure 3.5.A). Further, the mEAK-7/DNA-PK 
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interaction required mTOR to promote the DNA damage response. Point mutations in 
the mTOR (R628C) HEAT domain are sufficient to reduce mTOR kinase activity (15) 
and may be involved in regulating the sensitivity to total body radiation (data not 
shown); preliminary IP-MS data indicates that DNA-PK binds to WT and mutant alleles 
of mTOR, with differential affinity. Therefore, it is essential to identify the novel binding 
partners of mTORC3 before/after DNA damage via quantitative mass spectrometry, and 
map the mEAK-7, mTOR, and DNA-PK domains required for mTORC3 formation. 
 
DNA-PK co-localizes and interacts with mEAK-7 and mTOR.  
Since the discovery that mEAK-7 regulates an alternative mTOR signaling 
pathway, we have placed a great deal of effort to identify the novel complex that 
governs this signaling complex. mEAK-7 interacts with mTOR (18) and DNA-PK (Figure 
3.5). DNA-PK and mEAK-7 interact strongly and their interaction increases in the 
presence of DNA damage (Figure 3.5., B and C). To link S6K2 to mEAK-7 and mTOR, 
we demonstrated that DNA-PK interacts with S6K2 in response to DNA damage, 
suggesting cross-talk signaling with mTOR. DNA-PK is capable of localizing to the 
cytoplasm in response to DNA damage (41), but the extent to which it may co-localize 
with mTOR at the lysosome is unknown. To test this hypothesis, it will be essential to 
apply DNA damage to cancer cells and determine the extent to which DNA-PK 
colocalizes with mTOR and mEAK-7 at the lysosome. Additionally, examining this 
binding under different modalities of DNA damage, like chemotherapeutics or gamma 
ray irradiation will be helpful to undertand this phenomenon. Given that mEAK-7 and 
DNA-PK interact with mTOR to form a novel complex in the absence of Raptor or 
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Rictor, it will be essential to determine which domains of mEAK-7, mTOR, and DNA-PK 
are required for mTORC3 formation at the lysosome.  
 
Topographical structure of mTORC3  
Advances in Cryo-EM technologies, computational power, and direct-electron-
detectors (DEDs) have revolutionized our ability to obtain structural information of lipid-
bound proteins and large multimeric complexes. Additionally, Cryo-EM technologies 
have enhanced our capacity to obtain 3D structural information of the most difficult 
multimeric complexes. Therefore, Cryo-EM is rapidly becoming the powerful tool of 
choice to study atomic resolution protein-protein, DNA-protein, and RNA-protein 
interactions to further the goals of basic research and drug discovery (42).  One 
challenge of traditional structural biology studies, e.g. X-ray crystallography, has been 
the limitation of growing well-diffracting crystals of large and multimeric complexes. The 
main advantage of Cryo-EM being that single molecules in solution are used rather than 
crystals. The mTOR community has been stymied without the ability to visualize how 
the mTOR complexes are formed. Now, we have high-quality resolution structures 
available for mTORC1 (43) and mTORC2 (44), and we can visualize how all of the 
components interact (Figure 4.1). These structural insights are essential for 
understanding the basic mechanics of the protein-protein interactions. Based on our 
preliminary data, we hypothesize that mTORC3 comprises mEAK-7, mTOR, mLST8, 
and DNA-PK and we will be interested in elucidating the structure of this complex to 
determine how these proposed subunits interact and how they function as a complex to 
target other proteins. 
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mTORC3 protein interactors on lipid membranes  
One crucial challenge towards our efforts in understanding lipid-bound protein 
complexes is the lack of lipid-membranes and their interactions to activate mTOR 
complexes. Numerous strategies have been employed to do so, one being the 
generation of lipid nanodiscs and the incorporation of proteins that are known to be lipid 
bound membrane proteins, as their folding integrity is dictated by their interaction with 
lipid membrane proteins (45). This method was recently employed to understand the 
mechanistic action of TRPV1, an ion channel embedded in plasma membranes, to 
reveal the specific mechanism of action and ligand binding through recreated movies 
(46). However, we recognize that a method that works for one particular protein may not 
be suitable for another, since stabilization of any membrane protein is purely an 
empirical trial-and-error process. Since mEAK-7 is a lipid-bound protein, we hypothesize 
that it will require lipid nanodiscs to demonstrate proper structural expression. Thus, it 
will be essential to test this purification strategy to exogenously tagged mEAK-7, mTOR, 
mLST8, and DNA-PK to test their binding. Additionally, we will determine the extent to 
which mEAK-7 binds to mTORC3 after treatment with rapamycin in a dose-dependent 
and time-dependent fashion. 
 
A curious and broad role for mEAK-7 in early mammalian development  
Throughout the development of this thesis project, it has been challenging to 
develop the necessary tools to observe mEAK-7 in relevant in vivo. After screening 10 
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commercially available antibodies, we identified a human mEAK-7 specific antibody 
capable of IF staining. Thus, we were interested in investigating the potential role of 
mEAK-7 during development, since we saw minimal mEAK-7 staining in adult tissues, 
when compared to metastatic tissues. Another challenge is that the antibodies we have 
screened to date do not work across species, limiting the utility of these tools. In 
collaboration with Dr. Isabelle Lombaert, we obtained human fetal tissues to determine 
the extent that mEAK-7 was expressed during early development. We discovered that 
mEAK-7 and activated mTOR signaling was strongly expressed in human fetal eyes 
(Figure 4.3.A). mTOR has been demonstrated as an essential metabolic program for 
the development of mammalian eyes. mTORC1 inhibition via rapamycin inhibits retinal 
progenitor cell cycle and retinal development (47). Finally, other eukaryotes, such as 
Drosophila or zebrafish require functional mTOR signaling for proper retinal 
development (48, 49). mEAK-7 is expressed in the epithelial layer, where retinal 
progenitor cells are located, in human fetal eye tissues, which is overlapped with 
activated mTOR signaling. This suggests that mEAK-7 could play an important role in 
eye development.  
In addition, we discovered that mEAK-7 and activated mTOR signaling was 
strongly expressed human fetal salivary glands (Figure 4.3.B). Curiously, PI3K signaling 
was implicated in the development of salivary glands, where EGF-stimulation is 
necessary for branching morphogenesis in fetal mouse submandibular glands (SMG) 
(50). Additionally, another group demonstrated via a genetic mouse model approach 
that SMG and SLG development was delayed in mTOR conditional KO (Wnt1-cre: NCC 
specific) mice, where the SMG and SLG were smaller in size and resulted in fewer 
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epithelial branching of the SMG and SLG (51). Surprisingly, mTORC1 disruption 
through Raptor conditional KO mice (Wnt1-cre: NCC specific) mirrored similar results to 
mTOR conditional KO mice, but Rictor conditional KO mice (Wnt1-cre: NCC specific) 
only resulted in a mild defect (51). Since this group only focused on mTORC1 and 
mTORC2, it will be essential to identify the role of mTORC3 (mEAK-7 specific) in these 
organ systems and the extent to which mEAK-7 is required for embryonic development 
of craniofacial organs and structures. 
Another important organ, as a dentist-scientist, is the human tongue. We 
identified mEAK-7 to be robustly found at the basilar epithelium and suprabasal 
epithelium of the human fetal tongue, as marked by K19 staining (Figure 4.3.C) 
Interestingly, it is also located in the developing taste bud, suggesting that mEAK-7 
could play a role in taste sensation or noxious stimuli (Figure 4.3.C). PI3K inhibition 
resulted in a decrease of cell proliferation of ex vivo culture of tongue organs (52). The 
tongue epithelium of newborn mice with mTOR conditional KO (epithelium) resulted in a 
lack of cell stratification when compared to wild-type mice (53). Further investigation of 
mEAK-7 in the human tongue is important in understanding its role in epithelial 
development of the tongue and how aberrant mEAK-7/mTOR signaling can result in 
cancer.  
Our understanding of mEAK-7 during organismal development and disease is at 
its earliest stages and much more work will be required to understand mEAK-7 function. 
We have demonstrated mEAK-7 is a crucial regulator of mTOR signaling in humans, but 
there is a high likelihood that mEAK-7 will play an essential role in other eukaryotes. 
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Conclusions and future directions 
mTOR’s classical role in metabolism ranges from controlling protein synthesis, 
nucleotide synthesis, lipid synthesis, and autophagy (54). Aberrant mTOR signaling is 
found in most cancers since mTOR signaling is a critical regulator of cancer initiation 
and metastasis (31). These processes require eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1), a critical downstream target of mTORC1, for the specific 
expression of invasion sensitive genes (31). mTORC1 controls cell proliferation, but not 
cell size, through 4E-BP1 in mammalian cells (55). Furthermore, double-knockout 
mouse models of 4E-BP1 and 4E-BP2 result in increases tumorigenesis and causes 
tumor progression to occur significantly faster in p53 loss-of-function mice. This 
suggests that without the endogenous function of 4E-BP1 to inhibit eukaryotic 
translation initiation factor 4E (eIF4E), rampant tumor formation ensues. While loss-of-
function 4E-BPs contribute to tumorigenesis, overexpression of a gain-of-function 4E-
BP1 significantly reduces the tumor formation in PI3K and KRAS overexpressed mice. 
Thus, mTOR signaling plays a significant role in tumorigenesis. 
The long-term goal of this thesis is to further our understanding of the 
mechanisms that regulate mEAK-7 and, in turn, the mechanisms that are regulated by 
mEAK-7. In this context, we discovered a role for mEAK-7 as a key component of 
mTORC3, and understanding how mTORC3 behaves in human cancer will yield novel 
insights into mTOR signaling and cancer biology. Rapamycin analogues or mTOR 
kinase catalytic site inhibitors demonstrate limited efficacy for patients, suggesting that 
alternative mTOR signaling is occurring. Patients who fail standard therapies (e.g. 
surgery, chemotherapeutics, radiation therapy), may do so through mechanisms that 
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commandeer cancer specific signaling. Investigating the role of novel mTOR complexes 
in response to DNA damage will provide insights into how chemo- or radio-resistant 
tumor cells hijack mTOR signaling. This will give us insight to develop targeted 
therapeutics against mEAK-7 for the specific treatment of cancer. Developing 
therapeutics will depend on demonstrating that mTORC3 has a critical, positive 
biological role in cancer. Further, since mEAK-7 is required for sustained mTOR 
signaling in response to IR, we hypothesize that mEAK-7 may promote radioresistance 
in cancer. However, the elucidation of all complex binding partners of mTORC3 or if 
mTORC3 plays a role in other human diseases will take more time to investigate. These 
studies will set the stage to identify new mTOR complexes which may form under 
different conditions and which may be cell-type specific (Figure 4.2). 
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Figures 
Figure 4.1. Experimental plan for investigating novel mTOR complexes in human cells. (A) 
mTORC1 structure: mTOR, mLST8, and Raptor (1) (reproduced with permission from Elsevier). 
(B) mTORC2 structure: mTOR, mLST8, mSin1, Rictor (187) (reproduced with permission from 





Figure 4.2. Diagram of mTOR signaling. The classical mTORC1 and mTORC2 signaling 
pathways have well established protein targets. mTORC1 targets S6K1 and 4E-BP1, while 
mTORC2 targets Akt. However, the newest member, mTORC3, which is comprised of mLST8, 






Figure 4.3. Human fetal tissue staining of mEAK-7 and activated mTOR signaling. (A) Section 
of epithelial layer of human fetal eye. (Ser240/244) p-S6 (Cell Signaling Technologies # 5364), 
mEAK-7 (Santa Cruz Biotechnology (SCB) # sc-18822), Cell Signaling Technologies #  (B) 
Section of human fetal salivary gland. (Ser240/244) p-S6 (Cell Signaling Technologies # 5364), 
mEAK-7 (Santa Cruz Biotechnology # sc-247321). (C) Section of human fetal tongue 
(Ser240/244) p-S6 (Cell Signaling Technologies # 5364), (Santa Cruz Biotechnology # sc-
247321). K19 (Cell Signaling Technologies # 12434). DAPI for nuclear stain. Tissues were a gift 
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